Identification of MurT-GatD enzymatic complex and insights into the biological role of this secondary modification by Figueiredo, Teresa Carla de Almeida
 
 
 
 
 
Amidation of peptidoglycan 
in Staphylococcus aureus 
 
Identification of MurT-GatD enzymatic complex 
and insights into the biological role of this 
secondary modification 
 
 
Teresa de Almeida Figueiredo 
 
Dissertation presented to obtain the Ph.D. degree in Biology  
 
Instituto de Tecnologia Química e Biológica António Xavier 
Universidade Nova de Lisboa 
 
Oeiras, December, 2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Apoio financeiro da FCT BD nº: SFRH/BD/36843/2007 
 
Teresa de Almeida Figueiredo 
ISBN: 978-989-20-5060                     
iii 
 
 
 
 
       
 
 
     Supervisors: 
     Dr. Hermínia de Lencastre, 
     Dr. Alexander Tomasz, 
     Dr. Ana Madalena Ludovice, 
     Dr. Rita Sobral. 
       
     Chairman of examiners: 
     Dr. Cecília Arraiano. 
       
     Examiners: 
     Dr. Arsénio Fialho, 
     Dr. Carlos São José, 
     Dr. Hermínia de Lencastre, 
     Dr. Adriano Henriques, 
     Dr. Rita Sobral. 
 
Dissertation presented to obtain a Ph.D. degree in Biology by Universidade 
Nova de Lisboa, Instituto de Tecnologia Química e Biológica António 
Xavier. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
Acknowledgments 
The work presented in this Thesis would not have been possible without 
the contribution and support of a group of extraordinary people and 
institutions. I would like to take this opportunity to acknowledge them and 
apologize to whom I may have forgotten to mention. 
First, I would like to express my gratitude to Professor Hermínia de 
Lencastre, my supervisor, Head of the Laboratory of Molecular Genetics at 
Instituto de Tecnologia Química e Biológica (ITQB) for accepting me in her 
laboratory to do my PhD. For her supervision, striking criticism and rigor on 
the work, that made me also more conscientious and decisive in my 
scientific life. For the trust deposited on me, so important in the difficult and 
stressful periods of this work. For providing all the opportunities and 
conditions, without which the work presented here would not have been 
possible. I will always be grateful to Professor Hermínia for her help, 
understanding, patience and concern in a very difficult period of my 
personal life.  
To my co-supervisor, Professor Alexander Tomasz, Professor and Head of 
the Laboratory of Microbiology at the Rockefeller University, for his support 
and supervision during my PhD. For the stimulating discussions and for all 
the help in writing manuscripts and reports. I am grateful for his attention, 
concern and care in some specific stressful periods of this PhD work. For 
sharing with me his enthusiasm for science, his remarkable knowledge and 
his fantastic sense of humor. 
To my co-supervisor, Assistant Professor Ana Madalena Ludovice, who 
accepted, unhesitatingly, to guide and supervise my PhD. I am grateful to 
her for all help, guidance, patience, and encouragement since the 
beginning of this long trip. For her scientific and non-scientific advices. Her 
vi 
 
encouragement, advice, and friendship were very important and decisive to 
me to proceed in science and begin the PhD. Thus, probably, without her 
help this PhD Thesis would not have been possible.  
To my co-supervisor, Auxiliary Researcher Dr. Rita Sobral, for believing 
and trusting in me since day one. For offering me the opportunity to work in 
a very interesting topic and for sharing with me her enthusiasm for science. 
For accompanying me in the good and in the stressful moments during this 
long trip. For her perceptiveness and capacity to view ahead of the practical 
results. For her endless patience in reviewing my reports and making them 
more concise and interesting, and for finding always something interesting 
in my results. For always being available with scientific and non-scientific 
advice. For her concern and friendship in a very difficult time of my 
personal life. I will always keep in my heart her support and friendship in 
this period. 
To Professor Waldemar Vollmer, Professor in Centre for Bacterial Cell 
Biology (CBCB), Newcastle University, for welcoming me in his laboratory 
and offering all the conditions to perform a great part of the work presented 
in this Thesis. For all the helpful discussions and for sharing with me his 
wide knowledge regarding cell walls.  
To Dr. José Trincão, Investigator in Research Complex at Harwell, for 
welcoming me in his laboratory and offering me all the conditions to 
perform part of my PhD work. For introducing to me to the “world of 
crystallography”. For all the help and support during my stay in Harwell.  
To the members of my PhD Thesis committee, Professor Waldemar 
Vollmer and Professor Adriano Henriques for the helpful discussions and 
for their constructive criticism in the PhD Thesis committee meetings, which 
contributed to enrich this work. 
vii 
 
To all the members of the Laboratory of Molecular Genetics at ITQB for 
their friendship and support:  
To Dr. Maria Miragaia, for all the care, warmth, kindness and friendship 
during all these years. For the scientific and non scientific conversations. 
For being always available to listen to my complains. For sharing with me 
her calm and tranquility, so useful in my scientific dramas. For the good 
moments shared together in New York, that made those weeks so much 
more enjoyable.  
To D. Isilda Gueifão for her care, technical support, and for being always 
there when something was missing in the bench. 
To D. Manuela Nogueira for all the friendship, care and total availability, 
and to make the paperwork so much easier.  
To all other friends and colleagues at the Laboratory of Molecular Genetics 
at ITQB: Raquel Sá-Leão, Nuno Faria, Teresa Conceição, Catarina 
Milheiriço, Ons Bouchami, Ana Tavares, Joana Rolo, Inês Grilo, Diana 
Espadinha, Celine Coelho, Ana Cristina Paulo, Nelson Frazão, Alexandra 
Simões, Sónia Nunes, Carina Valente, Débora Tavares, Sónia Almeida, 
Sofia Félix, Sara Handem for all the friendship and cheerful environment 
during all these years.  
To all the members of the Centre of Bacterial Cell Biology (CBCB) for the 
friendship and for contributing to the good work atmosphere of CBCB:  
To all members of the second floor of CBCB for the friendship, technical 
support and for the pleasant moments shared inside and outside the 
laboratory.   
viii 
 
To my friends and colleagues from Vollmer laboratory, specially to Khai 
Bui, Jacob Biboy and Christine Aldridge for always being available to help 
me, for the friendship and care, for the scientific and non scientific 
conversations, for the pleasant “coffee and tea times”, for the good 
moments shared together inside and outside the laboratory, for being my 
support in the really bad moments, giving me strength to carry on. Thank 
you for just being there in the very difficult times.   
To the Instituto de Tecnologia Química e Biológica António Xavier, for 
accepting me as a PhD student and for providing all the conditions and 
facilities required to carry out this work. 
To the Rockefeller University for accepting me as a visiting student and for 
providing such wonderful scientific environment.  
To the Centre for Bacterial Cell Biology, Newcastle University, for accepting 
me as a visiting student for such a long period, and for providing so 
outstanding scientific conditions, necessary to accomplish a large part of 
the work presented in this Thesis. 
To the Research Complex at Harwell, for accepting as a visiting student 
and for providing all the conditions required to carry on part of the work 
presented in this Thesis. 
To Fundação para a Ciência e Tecnologia for the financial support through 
fellowships SFRH/BD/36843/2007,132/BI-BI/2011, 112/BI-BI/2012 and 
102/BI-BI/2013. 
To Fundação Calouste Gulbenkian for the financial support through the 
fellowship 057/BI-BI/2012. 
ix 
 
To European Molecular Biology Organization for the financial support 
through the short term fellowship ASTF 345-2011.  
To my friend Raquel Portela, for her friendship and help during all these 
years. For being with me when I needed to stay longer in the laboratory. 
For always being available to listen to me. For the good moments shared 
together inside and outside work.  
To my friends at CBCB, Aurelie Guyet, for her friendship and kindness, for 
the “cinema time” on Tuesdays, for the fantastic cakes and quiches, and 
Patricia Dominguez-Cuevas, for her friendship and for all the good 
moments that made the time spent in Newcastle so much enjoyable and 
unforgettable.  
To my Portuguese friends in Newcastle, Daniela Pinto and Ana Roque for 
their friendship, support and for the wonderful moments spent in Newcastle. 
To Richard, Ling, Alexander and Philippe Daniel family, for warmly 
welcoming me in their place, in their family, during my two stays in 
Newcastle. I think that all the words in the world are not enough to express 
my gratitude. For sure that they turned the time away from my home much 
easier and pleasant. For making me feel like home in Newcastle. I could 
not have found a better place to stay.  
To an extraordinary person that became one of my best friends, Susanne 
Pohl. For the person she is. For having shown me the truly meaning of 
friendship. For being always available for me. For warmly welcoming in her 
place. For the long, long conversations. For her character and values. For 
everything… 
Aos meus Pais, a quem eu dedico esta tese, por me terem dado todas as 
condições de forma a eu poder fazer o que realmente gosto, pela 
x 
 
educação e pelos valores que me transmitiram, por me terem sempre 
apoiado nas minhas escolhas e por me transmitirem ânimo e confiança, 
num desejo comum de atingir a meta desejada. Sem a vossa ajuda, eu não 
teria chegado até aqui… Um muito obrigado por tudo! 
Um especial obrigado à minha Mãe, por me ter acompanhado sozinha 
nestes últimos anos. Pela sua força, coragem, amor, compreensão, 
dedicação, e por ter suportado tão bem as minhas longas ausências 
durante o período em que decorreu este Doutoramento.   
Ao meu Pai que de certeza se está a sentir muito feliz e orgulhoso por esta 
meta alcançada….   
 
 
 
 
 
 
 
 
 
 
 
 
 
xi 
 
Abstract 
Staphylococcus aureus is one of the most important contemporary human 
pathogens. The evolutionary “success” of this species is closely related to 
its remarkably capacity to acquire antibiotic resistance traits. In this 
perspective, it is important to extend our knowledge concerning the 
mechanisms of antibiotic resistance in S. aureus and to identify new 
antimicrobials targets.  
Peptidoglycan is a unique and essential structure of the bacterial cell wall; 
its biosynthetic pathway is the target of powerful antibiotics such as β-
lactams and glycopeptides. The biosynthesis of this heteropolymer, which 
consists of alternating disaccharide units composed of N-acetyl-
glucosamine (GlcNAc) and N-acetyl-muramic acid (MurNAc) crosslinked by 
short peptides, is a complex process that takes part in three different 
cellular compartments. The biosynthesis begins in the cytoplasm with the 
formation of the UDP-MurNAc-pentapeptide precursor. Then, in the inner 
face of the cell membrane, the pentapeptide precursor is linked to a 
membrane associated lipid carrier, which results in the formation of lipid I 
that, with the subsequent addition of the GlcNAc, form the lipid II structure. 
The last stage of peptidoglycan biosynthesis includes polymerization of the 
disaccharide pentapetide units at the outside surface of the cytoplasmic 
membrane, through the coordinated action of transpeptidases and 
transglycosylases. During its synthesis and assembly, S. aureus 
peptidoglycan undergoes several modifications in its structure, namely the 
O-acetylation of MurNAc; the association of structures covalently linked, 
including teichoic acids, proteins and capsules; and the D-alanine 
esterification of wall teichoic acids. Furthermore, the peptidoglycan of S. 
aureus is virtually free of carboxyl groups, as the second aminoacid of the 
stem peptide, D-glutamic acid, is modified by amidation of its α-carboxyl 
group, which results in the formation of D-iso-glutamine. Although 
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peptidoglycan amidation is commonly present among gram-positive 
bacteria, its biological role is not completely clear, and the genes 
responsible for this modification were not identified, until now.  
The first part of this Thesis describes identification of two hitherto unknown 
genes, murT and gatD, in the genome of the methicillin resistant S. aureus 
(MRSA) strain COL. The protein products of these two genes are 
responsible for the amidation of D-glutamate into D-iso-glutamine, in the 
peptidoglycan of S. aureus. 
Due to their sequence similarities, the open reading frames corresponding 
to the murT and gatD genes were automatically annotated as a Mur ligase 
family-like protein and a glutamine amidotransferase, respectively. The 
DNA sequence analysis raised the hypothesis that murT and gatD genes 
are co-transcribed, since both genes are next to each other in the 
chromosome; they are transcribed in the same direction, and there is no 
promoter region upstream of the gatD gene. The results from reverse 
transcription-PCR and Northern blotting assays allowed us to conclude that 
murT and gatD are co-transcribed from the same promoter, forming a small 
operon. It is also interesting to note that and the murT-gatD are merged in 
several Gram-positive bacteria, and exist as a single gene. 
In order to explore the role of these uncharacterized genes the murT-gatD 
operon was placed under the control of an inducible promoter in the 
background of the MRSA strain COL. In the absence of inducer, the murT-
gatD conditional mutant produced a peptidoglycan of abnormal 
composition, with an increase in the amount of muropeptides containing D-
glutamate instead of D-iso-glutamine in the stem peptide. This provided 
direct evidence for the involvement of murT-gatD in the amidation of S. 
aureus peptidoglycan. The previously characterized glnRA transposition 
mutant RUSA208, in which the transcription of glutamine synthetase (glnA) 
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is affected, has already shown a similar - abnormal - muropeptide 
composition of its cell wall. In the present work, the peptidoglycan 
composition of the double mutant, in which expression of both murT-gatD 
and glnRA are inhibited, showed absence of amidated muropeptides, 
strongly suggesting that their protein products are the sole determinants for 
the amidation of the D-glutamate residues of S. aureus peptidoglycan. 
Analysis of the cell wall precursor pool composition, in the parental and in 
murT-gatD depleted cells, revealed the presence of D-glutamate in 
peptidoglycam precursors of both strains, which indicated that the 
amidation reaction occurs in a later stage of peptidoglycan biosynthesis, 
most likely in the membrane phase. Further, in vivo complementation 
assays of the murT-gatD depleted phenotype allowed us to infer that 
peptidoglycan amidation requires specifically expression of murT, (which 
appears to be essential and highly specific for the recognition of the 
peptidoglycan precursor), and at least a basal level of gatD, suggesting that 
S. aureus contains other glutamine amidotransferases able to partially 
replace GatD activity.  
The experimental data together with the analysis of aminoacid sequence, 
and the mechanism of action of the glutamine amidotransferases allowed 
us to propose that MurT and GatD together contain the domains and motifs 
required for the amidation of S. aureus peptidoglycan to occur. MurT, with 
its central domain similar to Mur ligases with motifs for ATP binding seems 
to represent the synthetase domain, responsible for the recognition of the 
acceptor substrate and for ATP binding, while GatD contains the 
glutaminase domain, catalyzing the hydrolysis of glutamine and the transfer 
of the resultant amino group to the acceptor substrate, the peptidoglycan 
precursor. 
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The inhibition of murT-gatD transcription caused impairment in growth rate, 
which demonstrated that peptidoglycan amidation has an important role in 
bacterial growth. Nevertheless, the murT-gatD depleted cells showed 
normal morphology, by electron microscopy analysis, indicating that the 
murT-gatD operon is not required for cell division and the involvement of 
peptidoglycan amidation in bacterial growth is completely independent of 
cell division. Consistent with the previous results from the glnRA 
transposition mutant RUSA208, the murT-gatD depleted mutant showed 
decreased methicillin resistance, confirming that peptidoglycan amidation is 
associated with the mechanism of resistance to β-lactams. Furthermore, it 
was found that lack of murT-gatD transcription caused decrease of 
lysozyme resistance both in cells and also in purified peptidoglycan, 
indicating that the reaction catalyzed by MurT and GatD proteins is directly 
involved in the mechanisms of resistance to lysozyme.       
The second part of this Thesis provides direct experimental evidence that 
the MurT and GatD proteins interact physically, forming a stable enzymatic 
complex, and that this interaction is essential for peptidoglycan amidation to 
occur.   
The co-transcription of murT and gatD genes and the requirement of both 
proteins for full in vivo complementation of the murT-gatD depletion 
phenotype, (as demonstrated in the first part of the Thesis), strongly 
suggested the existence of an interaction between MurT and GatD 
proteins. In the second part of the Thesis, the co-purification of MurT and 
GatD recombinant proteins, (from a vector expressing both murT and gatD 
genes), clearly showed that these proteins interact physically and form a 
stable enzymatic complex, needed for the amidation of S. aureus 
peptidoglycan. Additionally, several important findings were obtained 
through the in vitro analysis of lipid II amidation, using MurT-GatD and 
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GatD purified proteins. These findings included demonstration that: i) lipid II 
is a substrate for MurT-GatD catalyzed reaction; ii) that the in vitro 
amidation reaction requires the presence of both proteins; and iii) that 
amidation is dependent on ATP and glutamine.   
The third part of this Thesis describes that peptidoglycan amidation has 
different impacts in the expression of methicillin and lysozyme resistance, 
in representative strains of the most widespread clones of MRSA.  
Despite mecA being considered the main genetic determinant of methicillin 
resistance, several genes from the core genome and some related with cell 
wall biosynthesis, including murT-gatD operon, are required for the optimal 
expression of methicillin resistance in S. aureus. In the present work, 
different degrees of decrease in the original methicillin resistance were 
observed when murT-gatD transcription was inhibited in various MRSA 
genetic backgrounds, with a more pronounced effect on community 
acquired (CA-MRSA) related backgrounds, when compared with hospital 
acquired strains (HA-MRSA).  
It is also interesting that these different phenotypes may be related to the 
capacity of the strains’ genetic background to acquire and maintain the 
mecA gene, since the genetic backgrounds, previously described to be 
more prone to receiving mecA, were the ones less dependent of murT-gatD 
to express methicillin resistance. Inhibition of murT-gatD transcription, in a 
mecA-independent resistant strain, caused a decrease in methicillin 
resistance, suggesting that peptidoglycan amidation also contributes to the 
methicillin resistance by a mecA-independent pathway. Further, more two 
CA-MRSA genetic lineages showed a more pronounced effect on the 
decrease of methicillin resistance, when murT-gatD transcription was 
inhibited, as compared to inhibition of expression of MurF, an essential S. 
aureus Mur ligase. These findings highlight the proposition that MRSA can 
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follow different strategies, by recruitment of different housekeeping genes, 
for the optimal expression of methicillin resistance.  
Peptidoglycan amidation appears to be more significant for lysozyme 
resistance in cells of CA-MRSA backgrounds, as compared with cells of 
HA-MRSA. The absence of significant differences in the level of lysozyme 
resistance of peptidoglycan, indicated that lysozyme resistance in the CA-
MRSA analyzed may involve others factors that are triggered by 
peptidoglycan amidation. 
 
 
 
 
xvii 
 
Resumo 
Staphylococcus aureus é um dos mais importantes agentes patogénicos 
humanos, cujo sucesso evolutivo está intimamente relacionado com a sua 
capacidade de adquirir resistência aos antibióticos. Por esta razão é 
criticamente importante alargar os nossos conhecimentos relativamente 
aos mecanismos de resistência aos antibióticos em S. aureus e identificar 
novos alvos antimicrobianos.  
O peptidoglicano é o principal constituinte da parede celular bacteriana; as 
enzimas envolvidas na sua síntese são utilizadas como alvo para 
importantes antibióticos, como é o caso dos β-lactâmicos e dos 
glicopéptidos. A biossíntese deste heteropolímero, que consiste em 
unidades alternadas de dissacáridos compostas por N-acetilglucosamina 
(GlcNAc) e por ácido N-acetilmurâmico (MurNAc) ligadas por pequenas 
cadeias peptídicas, é um processo complexo que ocorre em três 
compartimentos celulares distintos. A biossíntese inicia-se no citoplasma 
com a formação do precursor muropeptídico, o pentapéptido-MurNAc. De 
seguida, na face interna da membrana celular, este precursor liga-se a um 
transportador lipídico membranar, originando o lípido I, que por sua vez ao 
associar-se com uma molécula de GlcNAc, origina o lípido II. A última fase 
da biossíntese do peptidoglicano inclui a polimerização das unidades do 
dissacarído pentapetídico, na face externa da membrana citoplasmática, 
através da ação coordenada das transpeptidases e transglicosilases. 
Durante a sua síntese, o peptidoglicano de S. aureus adquire várias 
modificações estruturais: é alvo de O-acetilação do MurNAc, de 
associação de estruturas covalentemente ligadas, como é o caso dos 
ácidos teicóicos, proteínas e cápsula, e de esterificação da D-alanina dos 
ácidos teicóicos. Para além disso, o peptidoglicano de S. aureus não 
contém grupos carboxilo, uma vez que o segundo aminoácido da cadeia 
peptídica, o D-glutamato, é modificado através da amidação do seu grupo 
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α-carboxilo em D-iso-glutamina. Apesar da amidação do peptidoglicano ser 
frequente em bactérias Gram-positivas, o seu papel biológico não é 
conhecido, e os genes responsáveis por esta modificação não estavam 
identificados até à realização desta Tese. 
A primeira parte desta Tese descreve a identificação de dois genes, até 
agora desconhecidos, murT e gatD, no genoma da estirpe COL, uma 
estirpe MRSA (de “Methicillin Resistant Staphylococcus aureus). Os 
produtos proteicos destes dois genes são responsáveis pela amidação do 
D-glutamato em D-iso-glutamina, no peptidoglicano de S. aureus. 
Devido a semelhanças de sequência, as ORFs (de “Open Reading 
Frames”) correspondentes aos genes murT e gatD, foram 
automaticamente anotadas nas bases de dados como codificando uma 
proteína pertencente à classe das Mur ligases e uma glutamina 
amidotransferase, respectivamente. A análise da sequência de DNA 
sugeriu que os genes murT e gatD são co-transcritos, uma vez que o 
codão stop do murT e o codão de iniciação do gatD apenas estão 
separados por 4 nucleótidos, ambos os genes são transcritos na mesma 
direção, e não existe nenhuma região promotora antes do início do gatD. 
Os resultados de PCR por transcriptase reversa e a análise por “Northern 
blotting” permitiram-nos concluir que murT-gatD é co-transcrito a partir do 
mesmo promotor, confirmando que se trata de um pequeno operão. É 
curioso também notar que em algumas bactérias Gram-positivas estes dois 
genes existem como uma única região codificante, o que sugere uma 
interação ou complementaridade de funções entre os respectivos produtos 
proteicos. 
Com o objetivo de investigar o papel destes genes construiu-se um 
plasmídeo em que o operão murT-gatD foi colocado sob o controlo de um 
promotor indutível na estirpe COL. Na ausência de indutor, este mutante 
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condicional do murT-gatD originou um peptidoglicano com uma 
composição alterada, nomeadamente, um aumento da quantidade de 
muropéptidos contendo D-glutamato em vez de D-iso-glutamina, na cadeia 
peptídica. Estes resultados constituíram evidências diretas para o 
envolvimento do murT-gatD na reação de amidação do peptidoglicano de 
S. aureus. O mutante de transposição RUSA208, no qual a transcrição da 
sintetase da glutamina (glnA) está afetada, também apresenta alterações 
idênticas na composição dos muropéptidos da sua parede celular. No 
presente trabalho, observou-se a ausência de precursores muropeptídicos 
amidados no duplo mutante, no qual a transcrição de murT-gatD e de glnA 
foi inibida, sugerindo que as respectivas proteínas são os únicos 
determinantes da amidação do D-glutamato do peptidoglicano de S. 
aureus. A análise da composição dos precursores citoplasmáticos da 
parede celular, na estirpe parental e na estirpe na qual murT-gatD não é 
transcrito, revelou a presença de D-glutamato em ambas, indicando que a 
reação de amidação ocorre numa fase posterior da biossíntese do 
peptidoglicano, muito provavelmente na fase lipídica. Os ensaios in vivo de 
complementação do fenótipo mutante, permitiram-nos inferir que a 
amidação do peptidoglicano requer a expressão de MurT, (que parece ser 
essencial e altamente específica para o reconhecimento do precursor do 
peptidoglicano), e uma expressão residual de GatD, sugerindo que em S. 
aureus existem outras glutamino amidotransferases, capazes de substituir 
parcialmente a atividade da proteína GatD. Os resultados experimentais, 
juntamente com a análise da sequência de aminoácidos, e o mecanismo 
de ação das glutamino amidotransferases permitiram-nos propor que as 
proteínas MurT e GatD, em conjunto, contêm os domínios e motivos 
necessários para que a amidação do peptidoglicano em S. aureus possa 
ocorrer. MurT, com o seu domínio central semelhante ao das Mur ligases e 
motivos para a ligação ao ATP, parece representar o domínio de sintetase, 
sendo responsável pelo reconhecimento do substrato recetor e pela 
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ligação ao ATP, enquanto a GatD contém o domínio da glutaminase, 
catalisando a hidrólise da glutamina e a subsequente transferência do 
grupo amino para o substrato recetor, o precursor do peptidoglicano. 
Na ausência de indutor, observou-se a diminuição da taxa de crescimento 
do mutante condicional do murT-gatD, o que demonstrou que a amidação 
do peptidoglicano é importante para o crescimento bacteriano. No entanto, 
sob as mesmas condições, as células do mutante não apresentaram 
diferenças significativas de morfologia, quando foram analisadas por 
microscopia eletrónica, indicando que o murT-gatD não é necessário para 
a divisão celular, mas que é importante para o crescimento bacteriano, 
através de um mecanismo independente do processo da divisão celular. 
Tal como já tinha sido observado com o mutante de transposição do gene 
glnA, RUSA208, a inibição da transcrição de murT-gatD causou diminuição 
na resistência à meticilina, confirmando que a amidação do peptidoglicano 
está associada ao mecanismo de resistência aos β-lactâmicos. Foi 
também demonstrado que a reação catalisada pelas proteínas MurT e 
GatD está diretamente envolvida nos mecanismos de resistência à 
lisozima, uma vez que tanto as culturas celulares como o peptidoglicano 
purificado mostraram-se mais sensíveis à lisozima, quando a expressão de 
murT-gatD se encontra afetada.  
A segunda parte desta Tese apresenta evidências experimentais para a 
existência de uma interação física entre as proteínas MurT e GatD, 
formando-se desta forma um complexo enzimático estável, sendo esta 
interação essencial para a ocorrência da amidação do peptidoglicano. 
A co-transcrição dos genes murT e gatD e a necessidade da expressão 
das duas proteínas para a total complementação do fenótipo mutante, 
(como demonstrado na primeira parte desta Tese), sugeriram a existência 
de uma interação entre as proteínas MurT e GatD. A co-purificação das 
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proteínas recombinantes MurT e GatD, (através de um plasmídeo que 
expressa simultaneamente os dois genes), mostrou claramente que estas 
proteínas interagem e formam um complexo enzimático estável, 
necessário para a amidação do peptidoglicano de S. aureus. 
Adicionalmente, a análise da reação de amidação, in vitro, do lípido II, 
usando as proteínas MurT-GatD e GatD purificadas, permitiu demonstrar 
que: i) o lípido II é um substrato para a reação catalisada pelo complexo 
MurT-GatD; ii) que a reação da amidação, in vitro, necessita da presença 
de ambas as proteínas, e iii) que a amidação é dependente da presença 
de ATP e glutamina. 
A terceira parte desta Tese descreve o impacto da falta de amidação do 
peptidoglicano na expressão da resistência à meticilina e à lisozima, em 
estirpes representativas dos clones mais disseminados de MRSA. 
Apesar do gene mecA ser o principal determinante genético da resistência 
à meticilina, existem outros genes, localizados no cromossoma e alguns 
relacionados com a biossíntese da parede celular, como é o caso do 
operão murT-gatD, necessários à expressão ótima da resistência à 
meticilina em S. aureus. No presente trabalho, foi observado um impacto 
diferente no decréscimo da resistência original à meticilina, quando a 
transcrição do murT-gatD era inibida em vários clones MRSA, havendo um 
impacto maior nos clones CA-MRSA (de ”Community Acquired-MRSA”), do 
que nos clones HA-MRSA (de “Hospital Acquired-MRSA”). 
É também interessante notar que estes diferentes fenótipos de resistência 
podem estar relacionados com a capacidade de cada estirpe de adquirir e 
manter o gene mecA, uma vez que os clones, anteriormente descritos 
como sendo mais eficientes na aquisição do gene mecA, foram os que 
apresentaram menor dependência do operão murT-gatD para expressar a 
resistência à meticilina. A inibição da transcrição dos genes murT-gatD 
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provocou um decréscimo de resistência numa estirpe resistente que não 
contém mecA, sugerindo que este operão está também envolvido na 
resistência à meticilina, através de um mecanismo que não necessita da 
presença do gene mecA para ser expresso. Curiosamente, duas linhagens 
genéticas de CA-MRSA apresentaram um efeito mais drástico na 
diminuição da resistência à meticilina, quando a transcrição de murT-gatD 
foi inibida, do que na ausência de expressão de uma Mur ligase essencial 
de S. aureus, a proteína MurF. Estas observações sugerem que MRSA 
pode desenvolver diferentes estratégias, através da utilização de diferentes 
genes essenciais de S. aureus, de forma a expressar resistência à 
meticilina. 
A amidação do peptidoglicano também parece ser mais importante para a 
expressão da resistência à lisozima em clones CA-MRSA, do que em HA-
MRSA. No entanto, não se observaram diferenças significativas 
relativamente ao nível de resistência à lisozima do peptidoglicano 
purificado, o que parece sugerir que a resistência à lisozima, nos clones de 
CA-MRSA analisados, é determinada por fatores que estão sob o controlo 
de murT-gatD. 
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Thesis Outline 
Staphylococcus aureus is an important human pathogen whose clinical 
relevance is mainly due to its remarkable capacity to develop mechanisms 
of resistance to antibiotics that are being introduced into the therapeutic 
arsenal. In this context, it is urgent and extremely important to extend our 
knowledge regarding the mechanisms of antibiotic resistance in S. aureus, 
and to discover new targets for the development of alternative 
antimicrobials agents. Peptidoglycan, a major component of the Gram-
positive bacteria cell wall, is essential for cell survival and unique to 
bacteria which makes the enzymatic steps of its biosynthetic pathway 
excellent candidates for the design of new antibiotics. Furthermore, the fact 
that most of the genes associated with β-lactam antibiotic resistance in S. 
aureus are important players in the biosynthesis of peptidoglycan, highlight 
their potential as targets for antimicrobial therapy. Despite the fact that the 
peptidoglycan biosynthetic pathway has been extensively studied, some 
features have remained unknown. The main finding of this Thesis is the 
identification of the so far uncharacterized murT and gatD genes, 
responsible for the amidation of the glutamic acid residue of the stem 
peptide of S. aureus peptidoglycan.  
Chapter I provides a general introduction to some of the important aspects 
of the cell wall of S. aureus, namely its structure is described and all the 
enzymatic steps of the peptidoglycan biosynthesis pathway are mentioned 
in detail. The relevant findings about peptidoglycan hydrolases, which 
includes the N-acetylmuramidase lysozyme, are also reviewed and a 
current understanding of cell wall modifications is summarized. As the 
structure of peptidoglycan is the primary target of β-lactam antibiotics, the 
mode of action and the mechanisms of resistance against this class of 
antibiotics are also described in some detail. Finally, some relevant aspects 
of the molecular epidemiology of S. aureus are also briefly reviewed.   
xxviii 
 
Chapter II entitled “Identification of Genetic Determinants and Enzymes 
Involved with the Amidation of Glutamic Acid Residues in the Peptidoglycan 
of Staphylococcus aureus” describes the genetic and biochemical studies 
performed that allowed identification of the murT-gatD operon as 
responsible for the amidation of the glutamic acid residue in the stem 
peptide of S. aureus peptidoglycan. In this chapter, evidence is described 
that suggests that MurT and GatD proteins have a coordinated action in 
order to amidate glutamic acid. The availability of a murT-gatD conditional 
mutant enabled us to conclude that amidation of S. aureus peptidoglycan is 
involved in the mechanisms of resistance to β-lactam antibiotics and to 
lysozyme and is important for bacterial growth. 
Chapter III entitled “MurT-GatD is an enzyme complex responsible for the 
amidation of glutamic acid residues in the peptidoglycan precursor lipid II of 
Staphylococcus aureus” describes co-purification of MurT and GatD 
recombinant proteins from a vector expressing both murT and gatD genes, 
which allowed us to conclude that these proteins interact physically, 
forming a stable enzymatic complex. In this chapter, the in vitro lipid II 
amidation demonstrated that both proteins, MurT and GatD, as well as ATP 
and glutamine are required for the reaction to occur, and lipid II is a 
substrate of MurT-GatD complex. 
Chapter IV entitled “Contribution of Peptidoglycan Amidation to β-Lactam 
and Lysozyme Resistance in Different Genetic Lineages of Staphylococcus 
aureus” shows that peptidoglycan amidation has different impacts in the 
level of β-lactam and lysozyme resistance, according to the genetic 
background of the strain. The transcription of murT-gatD seems to be more 
important for the expression of methicillin resistance in the community 
acquired methicillin resistant S. aureus (CA-MRSA), than in hospital 
acquired strains (HA-MRSA). On the other hand, it is also shown in this 
chapter that inhibition of glutamic acid amidation produces a higher impact 
xxix 
 
on lysozyme resistance in cells of CA-MRSA than in HA-MRSA, suggesting 
the existence of specific factors in CA-MRSA, associated with lysozyme 
resistance, that are triggered by murT-gatD expression.   
Chapter V includes a general discussion of the main findings of my doctoral 
Thesis work. Strategies to follow up of the observations produced in this 
work, are also described in some detail.   
Appendix I is entitled “Purification, crystallization and preliminary X-ray 
diffraction analysis of GatD, a glutamine amidotransferase-like protein from 
Staphylococcus aureus peptidoglycan” and it reports the crystallization of 
native and the selenomethionine-derivative of GatD protein. 
 
Chapters II, IV and Appendix I describe findings that appear in the following 
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Peptidoglycan of Staphylococcus aureus.  PLoS Path. 8: e1002508. - 
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GatD, a glutamine amidotransferase-like protein from Staphylococcus 
aureus peptidoglycan. Acta Cryst. F70: 632–35. - Appendix I. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter I 
 
 
General Introduction   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
                                                                                                                  General Introduction  
3 
 
1. Staphylococcus aureus 
1.1. General description 
Staphylococci are Gram-positive cocci and were first described in 1881 by 
Alexander Ogston, who designated the clustered micrococci as 
“staphylococci” from the Greek staphyle, meaning bunch of grapes (247). In 
1884, Rosenbach, a German surgeon, proposed the first taxonomic 
description of the genus Staphylococcus after the isolation of two types of 
pigmented colonies: Staphylococcus aureus, from the Latin aurum for gold 
colonies, and Staphylococcus albus (later named Staphylococcus 
epidermidis) from the Latin albus for white colonies (173).  
All members genus Staphylococcus share several features: they are Gram-
positive bacteria of low DNA G+C content, facultative anaerobes, glucose 
fermenting, and positive for catalase activity converting hydrogen peroxide 
to water; also, they have the capacity to grow at temperatures ranging from 
15 to 45 degrees Celsius and at high saline concentrations. 
Among staphylococci, S. aureus and S. epidermidis are the most important 
for their capacity to interact with humans. S. aureus can be differentiated 
from S. epidermidis by the secretion of coagulase, which converts 
fibrinogen to fibrin, promoting the coagulation of plasma, and also by its 
ability to ferment mannitol aerobic and anaerobically. S. aureus is the best 
characterized staphylococcal species. In the past decades, it has been 
extensively studied, mainly due to its high prevalence, virulence, and 
capacity to acquire mechanisms of resistance to many antibiotics. 
 
1.2. S. aureus importance as a pathogen 
S. aureus are mostly mutualist or commensal organisms that are frequently 
found colonizing the skin and mucosas of human and several animal 
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species. It is estimated that 20 to 25% of the healthy human population are 
persistent carriers and about 60% are intermittent carriers of S. aureus (40, 
262). Despite the fact that the relationship between S. aureus and the host 
is frequently asymptomatic, the rupture of the cutaneous barrier allows 
bacteria to penetrate, causing disease. As a pathogen, S. aureus is 
considered an extraordinary versatile bacteria, as it can cause a wide 
spectrum of infections in humans ranging from skin and soft tissue 
infections (e.g., cellulitis, folliculitis, mastitis, impetigo, furuncles, superficial 
and deep skin abscesses, wound infections), to severe life-threatening 
diseases (e.g., pneumonia, meningitis, bacteremia, endocarditis, 
osteomyelitis) and toxin-mediated diseases (e.g., toxic shock syndrome, 
scalded skin syndrome and food poisoning) (280). 
S. aureus is considered an important human pathogen not only for its 
capacity to easily acquire and accumulate resistance to several 
antimicrobials (see section 4), but also for containing a large number of 
virulence factors. These virulence factors can be grouped according to their 
role during infection: i) virulence factors that cause the attachment to the 
host’s cells or extracellular matrix, as fibrinogen-binding proteins, 
coagulase, clumping factor, adhesins and biofilm related polysaccharides; 
ii) virulence factors that allows the bacterial evasion from host’s defense, 
including enterotoxins, protein A and leukocidins; and iii) virulence factors 
involved in invasion and tissue penetration, which attack the host’s cell and 
degrade components of extracellular matrices, such as hemolysins, α-toxin 
and phospholipase C (280). 
The expression of the virulence factors is controlled by a complex 
regulatory circuit, throughout the S. aureus life cycle (208) and at least 
three major operons are involved: the agr (accessory gene regulator) (285, 
337); the sar (staphylococcal accessory regulator) (43) and the sae 
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(staphylococcal accessory element) loci (3). Additionally, other regulatory 
systems also have an impact on virulence gene expression and these 
include arlR and arlS (autolysis-related locus sensor) (96) and rot 
(repressor of toxins) (303).  
 
2. Cell wall 
The bacteria cell wall envelope is a semi-rigid layer essential for the cell’s 
structural integrity and for the maintenance of cellular shape, as it provides 
protection against mechanical stress or damage from osmotic pressure; the 
cell wall also represents a functional interface between the bacteria and the 
outside environment. In the last decades, this organelle has been 
recognized as a highly complex and dynamic structure, which is in a 
constant state assembly and degradation, in order to allow a variety of 
cellular processes, such as: cell growth and division, cellular 
morphogenesis, chromosome segregation, competence and virulence. The 
cell wall of Gram-positive bacteria is structurally different from the one of 
Gram-negative microbes. Since S. aureus is a Gram-positive bacterium, we 
will focus on the description of this type of wall in the next section of this 
Thesis. 
 
2.1. Gram-positive cell wall 
The cell wall of Gram-positive bacteria is mostly composed of 
peptidoglycan, consisting of up to 50% of its mass, in contrast to Gram-
negative cell wall, whose peptidoglycan layer is thinner, contributing only 
with 10% of its mass (108). Importantly, unlike Gram-negative bacteria, 
Gram-positive are not protected by an outer membrane. In addition to 
peptidoglycan, the structure and synthesis of which is described in section 
2.2 and 2.3, the Gram-positive cell wall also includes several other 
chemically distinct molecules such as linear polymers of polysaccharides 
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and proteins, most of them covalently attached to the peptidoglycan mesh. 
Due to their importance for S. aureus physiology, the teichoic acids and the 
penicillin binding proteins (PBPs) will be a major focus of this Thesis. 
Teichoic acids (TAs). These phosphate-rich glycopolymers are present in 
the cell wall in roughly equal proportions to peptidoglycan, constituting 
about 50% of its total mass. TAs are anionic polymers with long chains, 
composed of alternating phosphate and alditol groups, and can be divided 
in two groups: i) wall teichoic acids (WTAs), long chains of ribitolphosphate 
units covalently attached to the peptidoglycan muramic acid, by 
phosphodiester bonds (277); and ii) lipoteichoic acids (LTAs), long chains 
of 1,3-linked glycerolphosphate residues, which are linked to the 
cytoplasmic membrane by a glycolipid (89). Importantly, the chemical 
structure of WTAs is modified in Gram-positive bacteria, namely WTAs of 
S. aureus are D-alanylated, which has implications in the bacteria 
mechanism of clearance by the host immune system during the infection 
process (see section 3).   
Recent studies have indicated that TAs have a critical role in cell division 
and morphogenesis by controlling the biosynthesis of peptidoglycan. On 
the one hand, LTAs are involved in the control of autolysis rates (268) and 
in other important cellular processes, namely in bacterial growth, 
physiology and during development (for a review see reference 287). On 
the other hand, in Bacillus subtilis, the transcription of several genes from 
peptidoglycan biosynthesis can be induced by alterations in WTAs 
production (57).  
In S. aureus, several functional roles have been attributed to WTAs, 
namely: i) host colonization; involvement of WTAs in bacterial adhesion to 
endothelial cells (363); ii) coordination of peptidoglycan synthesis; WTAs 
control the level of secondary cross-linking by temporally and spatially 
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regulating the recruitment of PBP4 to the site of cell-wall synthesis, the 
division septum (14); iii) β-lactam resistance mechanism; the impairment of 
tarO, which encodes a glycosyl transferase responsible for the first 
enzymatic step in WTAs biosynthesis (319), caused a decrease in β-lactam 
resistance level (39, 209); and iv) autolysis regulation; WTAs are important 
for the proper localization of Atl, the major staphylococcal autolysin, at the 
cross-wall where it performs the last step of cell division, namely the 
separation of daughter cells (305).   
The recent discoveries regarding the role of TAs in essential cellular 
processes in S. aureus, have made the biosynthesis of these polymers as a 
promising antibacterial target. Actually, early results in targeting TAs 
biosynthesis are encouraging, and both synthetic and modifying enzymes 
are validated antibiotic targets in a variety of animal models (for a review 
see reference 260).  
 
2.2. S. aureus peptidoglycan structure 
The peptidoglycan (murein) sacculus is a unique and essential structural 
macromolecule that encompasses the entire bacterial cell, providing 
strength to resist the high internal osmotic pressure and maintaining cell 
shape (226, 241, 353). Also, it functions as a scaffold for anchoring other 
cell envelope components such as proteins (77) and teichoic acids (243), 
as was mentioned in section 2.1. This polymer consists of alternating 
disaccharide units, composed of N-acetyl-glucosamine (GlcNAc) and N-
acetyl-muramic acid (MurNAc) linked by β-1,4 glycosidic bonds, to which 
pentapeptide chains are attached (L-Ala-γ-D-Glu-L-Lys-D-Ala-D-Ala) 
through the lactyl moiety of MurNAc. In S. aureus, most of the pentapeptide 
chains of the adjacent macromolecules are interlinked by pentaglycine 
bridges between the penultimate D-alanine of one peptide chain and the 
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free amino group of the L-lysine residue of an adjacent chain, accompanied 
by the release of the last D-alanine (Figure 1). It has been estimated that 
only about 20% of the terminal D-alanyl-D-alanine residues remain intact 
(356).  
 
Figure 1. Structure of S. aureus peptidoglycan. (A) Schematic representation of the 
mesh-like structure of S. aureus peptidoglycan (adapted from reference 335); (B) Structure 
of a disaccharide composed of N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid 
(MurNAc) attached to a pentapeptide, which is cross-linked to a second peptidoglycan 
molecule by a pentaglycine bridge (adapted from reference 170). 
A
B
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The peptidoglycan of Gram-positive and Gram-negative bacteria shows 
some diversity, regarding chemical structure. The most common variations 
are the presence of unmodified D-glutamate amino acid in the position 2 
and meso-diaminopimelate residue in the position 3 of the pentapeptide 
structure of Gram-negative bacteria, while Gram-positive bacteria have D-
iso-glutamine and L-lysine in the positions 2 and 3, respectively.  Another 
important feature of the peptidoglycan of Gram-positive bacteria is the 
presence of an interpeptide bridge that is used in the cross-linking reaction, 
which is commonly absent in Gram-negative bacteria where the 
pentapeptides are directly crosslinked. The structure of this interpeptide 
bridge is extremely diverse in size and sequence of amino acids among 
bacterial species. In S. aureus, the interpeptide bridge is composed of five 
glycine residues that are added at the third amino acid (L-lysine) of the 
stem peptide (352).  
Identification of the chemical structure of S. aureus peptidoglycan were 
performed through the analysis of the muropeptide profile by reverse-phase 
high performance liquid chromatography (RP-HPLC), combined with mass 
spectrometric analysis. About 21 distinct peaks and a “hump” of unresolved 
material, corresponding to oligomers with high degree of cross-linking, were 
identified when S. aureus peptidoglycan was digested with a muramidase 
(62) (Figure 2). The mass spectrometry analysis of these peaks revealed 
the existence of monomers (disaccharide pentapeptides that represent 
13% of S. aureus muropeptides), dimers (two monomeric structures cross-
linked that correspond to 20%), trimers to enneamers (40%) and even 
higher oligomers account for an additional 15% of the muropeptides units.  
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Figure 2. S. aureus peptidoglycan composition. Separation of S. aureus cell wall 
muropeptides by reverse-phase HPLC. Peptidoglycan of methicillin resistant S. aureus 
strain COL was isolated, digested with muramidase and the resulting muropeptides were 
separated by reverse-phase HPLC (adapted from reference 62).   
 
2.3. S. aureus peptidoglycan biosynthesis pathway 
In the last half century, the peptidoglycan biosynthesis pathway has been 
extensively studied, partly for its role as an antimicrobial target. The 
resolution of this pathway started with the pioneering work of Park and 
Johnson, who first reported the impact of penicillin on cell wall (259), 
followed by the description of specific steps of the peptidoglycan 
biosynthesis pathway by Strominger and collaborators (146-150). 
Peptidoglycan biosynthesis is a complex process that takes place in three 
stages at three different cellular compartments. The biosynthesis begins in 
the cytoplasm where the soluble nucleotide precursors, the UDP-MurNAc-
pentapeptide precursor and the UDP-GlcNAc are synthesized. The second 
stage takes place at the cytoplasmic membrane, and consists in the 
transfer of the UDP-N-acetylmuramyl-pentapeptide to the membrane 
acceptor bactoprenol, leading to the synthesis of lipid I. The subsequent 
addition of GlcNAc from UDP-GlcNAc produces lipid II. The stage II also 
includes synthesis of the interpeptide crossbridge, which constitutes a 
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distinctive structure of S. aureus peptidoglycan. The lipid II is then 
translocated from the cytoplasmic face to the external face of the 
membrane, where it is incorporated into nascent peptidoglycan by 
penicillin-binding proteins (PBPs). In the stage III, the last steps of 
biosynthesis take place, which include the assembly of peptidoglycan 
through transglycosylation and transpeptidation reactions catalyzed by 
PBPs (Figure 3).   
 
Figure 3. The peptidoglycan biosynthesis occurs in three different locations in the 
cell. In a first stage, which occurs in the cytoplasm, the peptidoglycan monomer is 
produced. The second stage takes place at the cytoplasmic membrane, where the UDP-
MurNAc-pentapeptide precursor is linked to a membrane associated lipid carrier resulting in 
the formation of lipid I, which is subsequently added to GlcNAc forming lipid II. The stage 
three includes the translocation of Lipid II from the cytoplasmic face to the external face of 
the membrane, where it is incorporated into nascent peptidoglycan by transglycosylation 
and transpeptidation reactions (adapted from reference 275).  
 
2.3.1. Stage I: synthesis of the cytoplasmic precursor 
The cytoplasmic steps that result in the formation of the peptidoglycan 
monomer include the following reactions: formation of UDP-GlcNAc, 
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conversion of UDP-GlcNAc into UDP-MurNAc, assembly of the stem 
peptide leading to UDP-MurNAc-pentapeptide (15). 
Formation of UDP-N-acetyl-glucosamine (UDP-GlcNAc). UDP-GlcNAc 
biosynthesis from fructose-6-phosphate requires four successive enzyme 
activities. The first reaction, the conversion of D-fructose-6-phosphate into 
glucosamine-6-phosphate is catalyzed by the glucosamine-6-phosphate 
amidotransferase, GlmS. Then, GlmM, a phosphoglucosamine mutase, 
catalyses the isomerization of glucosamine-6-phosphate to glucosamine-1-
P (Glc-1-P), which is modified sequentially to UDP-N-acetylglucosamine by 
acetylation and uridylation through the action of a bifunctional enzyme, 
GlmU. The C-terminal domain of GlmU acts as an acetyltransferase, 
transferring an acetyl group from acetyl-CoA to Glc-1-P yielding N-acetyl-
glucosamine-1-phosphate (GlcNAc-1-P), and the N-terminal domain works 
as an uridyltransferase, catalyzing the transfer of an uridyl group from UTP 
to GlcNAc-1-P, which results in the formation of UDP-GlcNAc (Figure 4). 
 
Figure 4. Formation of UDP-GlcNAc. Formation of UDP-GlcNAc from a fructose-6-P 
molecule, through the sequential catalytic action of GlmS, GlmM and GlmU enzymes.  
GlmS GlmM
GlmU
GlmU
Frutose-6-P                                Glucosamine-6-P                               Glucosamine-1-P
L-Gln L-Glu
Acetyl-CoA
N-acetylglucosamine-1-P 
UDP-GlcNAc
UTP
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Formation of UDP-N-acetyl-muramic acid (UDP-MurNAc). The formation 
of UDP-MurNAc from UDP-GlcNAc occurs in a two-step process. First, 
MurA catalyses the transfer of the enolpyruvyl moiety from 
phosphoenolpyruvate to the 3’-hydroxyl of UDP-GlcNAc, resulting in the 
formation of UDP-GlcNAc-enolenol. Then, the enolpyruvyl moiety 
undergoes a reduction catalysed by MurB, yielding UDP-MurNAc. These 
two reactions are the first ones that occur specifically for the peptidoglycan 
synthesis.   
Formation of the UDP-MurNAc-pentapeptide. The UDP-MurNAc-
pentapeptide is formed through the stepwise assembly of five amino acids 
to the UDP-MurNAc. These successive reactions are ensured by four 
specific and essential enzymes, known as the Mur ligases enzymes (MurC, 
D, E and F) (316). These proteins catalyse the addition of L-alanine (MurC), 
D-glutamic acid (MurD), L-lysine (MurE) and dipeptide D-alanyl-D-alanine 
(MurF) onto the D-lactoyl group of UDP-MurNAc (Figure 5).  
Biochemical studies regarding the mechanism of action of the Mur ligases 
have revealed that these enzymes share some characteristics: i) they share 
the same type of enzymatic reaction, consisting in the activation of the 
carboxyl group of the UDP precursor by ATP, generating an acyl phosphate 
intermediate and ADP, and in the nucleophilic attack by the amino group of 
the condensing amino acid or dipeptide, which removes the phosphate and 
forms a new amide bond (5); ii) they show a series of six invariant amino 
acid residues in addition to an ATP-binding consensus sequence, a 
characteristics that led to the definition of the Mur ligases as a new family of 
enzymes (32, 85); iii) they also share a similar three-dimensional structure 
based on the occurrence of three domains, a N-terminal domain primarily 
responsible for binding the UDP-MurNAc substrate, a central domain 
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involved in the binding of ATP and a C-terminal domain, associated with 
binding of the incoming amino acid (26, 310).  
 
Figure 5. Formation of UDP-MurNAc-pentapeptide. Formation of UDP-MurNAc-
pentapeptide by a series of consecutive peptidoglycan synthesis committed steps, which 
occurs in the cytoplasm.  
Formation of D-alanyl-D-alanine. To synthesize the D-alanyl-D-alanine 
dipeptide, L-alanine is converted to D-alanine by the alanine racemase Alr. 
Then, the two D-alanine residues are dimerized through the action of DdlA 
ligase with the consumption of an ATP molecule. 
 
2.3.2. Stage II: synthesis of peptidoglycan lipid-linked 
intermediates 
Formation of the lipid intermediates. Once completely synthesized, the 
pentapeptide precursor has to be translocated across the cytoplasmic 
membrane in order to reach the cell wall, where the polymerization of the 
peptidoglycan occurs. This process begins with the transfer of the muramyl-
pentapeptide from UDP-MurNAc-pentapeptide to the undecaprenyl-
phosphate (or bactoprenol), a lipid carrier molecule embedded within the 
membrane, resulting in the synthesis of the MurNac(pentapeptide)-
UDP-GlcNAc
UDP-MurNAc
UDP-GlcNAc-enoylpyruvate
UDP-MurNAc-L-Ala
UDP-MurNAc-dipeptide
MurA
MurB
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MurE
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NADPH
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phosphate-undecaprenol, also designated lipid I (124). This transfer is 
catalysed by the UDP-MurNAc-pentapeptide phosphotransferase, MraY 
(33, 143). Then, the GlcNac, from the UDP-GlcNac precursor, is transfered 
to lipid I to form a β-1,4 glycosidic bond, through the activity of a N-
acetylglucosaminyltransferase, MurG, yielding the second lipid 
intermediate, lipid II.  
Formation of the glycine bridge. As mentioned before, in the particular 
case of S. aureus, a peptide crossbridge composed of five glycines, 
connects the L-lysine of the stem peptide of one peptidoglycan strand to 
the D-alanine in position 4 of the adjacent strand. This bridge is formed in a 
sequential order by the activity of specific peptidyltransferases: FemX, adds 
the first glycine (296), FemA adds the glycines at the position 2 and 3 (206, 
323), and FemB is responsible for the addition of the last two glycines 
(Figure 6). Since these enzymes require glycyl-tRNAs as glycine donors 
(216), which are only present in the cytoplasm membrane, the synthesis of 
the pentaglycine bridge must occur in the inner side of the cytoplasmic 
membrane, after the formation of Lipid II, the glycines acceptor structure 
(306). This pentaglycine structure is of great importance for S. aureus; 
besides conferring a high degree of cross-linking to peptidoglycan, it also 
plays a crucial role in the cell division and level of expression of methicillin 
resistance (127, 206).  
Amidation of D-glutamate. Siewert and collaborators concluded that the 
D-glutamate at position 2, of the S. aureus stem peptide, is modified by 
amidation of its α-carboxyl group at the stage of the lipid-linked 
intermediate (313). The same study showed that L-glutamine or NH3 is 
required as an amino donor and that the reaction requires ATP. Later, the 
analysis of Tn551 insertion mutants (see section 5.3) allowed to conclude 
that the amidation of D-glutamate is important for the optimal expression of 
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methicillin resistance (252) and that the reaction requires the expression of 
glutamine synthetase (120).  
The identification of the genes responsible for the D-glutamate amidation, 
and its impact on important biological processes in S. aureus are 
addressed in this Thesis.  
 
Figure 6. Three enzymes, FemX, FemA and FemB catalyse the addition of specific 
residues to form the S. aureus pentaglycine interpeptide. M: N-acetyl-Muramic acid; N: 
N-acetyl-Glucosamine (reproduced from reference 306). 
Translocation of lipid II. The translocation of the peptidoglycan monomer 
to the external surface of the cytoplasmic membrane does not occur 
spontaneously (36, 345). In Escherichia coli, lipid II is translocated from the 
inner to the outer side of the cytoplasmic membrane by the lipid II flippase 
FtsW localized in the septum (231, 359). This integral membrane protein 
forms a size-restricted pore-like structure, which accommodates lipid II 
during transport across the cytoplasmic membrane, indicating that FtsW is 
specific for the catalysis of lipid II translocation (230). Although in S. 
aureus, the protein responsible for this process is not identified, it is likely 
that lipid II is translocated at the septum by a similar mechanism, as two 
homologues of FtsW were identified in this species.  
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2.3.3. Stage III: polymerization of peptidoglycan 
The last stage of peptidoglycan synthesis consists of the polymerization of 
the monomer unit at the outside surface of the cytoplasmic membrane, 
through the concerted action of peptidoglycan synthetases and hydrolases. 
 
2.3.3.1. Penicillin binding proteins (PBPs) 
The PBPs catalyze the polymerization of the glycan strands 
(transglycosylation) and the cross-linking between peptide chains 
(transpeptidation). These enzymes can also hydrolyze the last D-alanine of 
stem pentapeptides (DD-carboxypeptidation) or cleave the cross-bridge 
connecting two glycan strands (endopeptidation). PBPs have been divided 
into two main categories: the high molecular mass (HMM) and the low 
molecular mass PBPs (LMM) (113).  
The group of HMM PBPs is composed of multimodular proteins, and 
includes the major enzymes responsible for peptidoglycan polymerization 
and insertion into pre-existing cell envelope. Their topology consists of a 
cytoplasmic tail, a transmembrane anchor and two specific domains: a C-
terminal penicillin-binding domain and a N-terminal domain (113). 
Accordingly to the structure and the catalytic function of the N-terminal 
domain, the HMM belong either to class A or to class B PBPs. Both classes 
have a C-terminal penicillin-binding domain, responsible for the 
transpeptidase reaction and for β-lactam binding. However, in class A 
HMM-PBPs, the N-terminal domain is responsible for their 
glycosyltransferase activity, catalyzing the elongation of uncross-linked 
glycan chains, whereas in class B the N-terminal is presumably associated 
with cell morphogenesis by interacting with other proteins involved in the 
cell cycle (69, 135, 376). Surprisingly, in some Gram-positive bacteria 
including B. subtilis (222), Enterococcus faecalis (10), and Enterococcus 
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faecium (290), it appears that these bifunctional PBPs are not essential, 
since strains lacking all class A PBPs are viable and have only minor 
differences in peptidoglycan composition. However, in Streptococcus 
pneumoniae, the deletion of class A PBP1a and class A PBP2a was lethal 
(139). In S. aureus, the PBP2 that is the only PBP of class A, is essential 
for viability in methicillin-susceptible strains but not to methicillin-resistant 
strains (273, 276).  
The LMM PBPs are single-domain proteins that can catalyse both DD-
carboxypeptidase and transpeptidase reactions (107). 
Multiple PBPs are present in all peptidoglycan-containing bacteria, whose 
number varies regarding bacterial species. It seems that the number of 
PBPs is related with the morphology and complexity of the life cycle of the 
respective organism. The rod-shaped bacteria E. coli and B. subtilis have 
12 (three class A, two class B and seven LMM PBPs) and 16 PBPs (four 
class A, six class B and six LMM PBPs), respectively; while coccoid 
bacteria S. pneumoniae and S. aureus have six (three class A, two class B 
and one LMW PBPs) and four PBPs (one class A, two class B and one 
LMW PBPs), respectively.  
DD-transpeptidation reaction. This reaction is responsible for the cross-
linking between stem peptides of different glycan strands. This process 
begins with the disruption of D-alanyl-D-alanine bond of the pentapeptide 
unit due to the nucleophilic attack of the hydroxyl group of the active serine, 
present in the penicillin binding domain, on D-alanyl-D-alanine bond, 
resulting in the formation of a serine ester-linked peptidyl enzyme 
intermediate. This intermediate structure is resolved by transferring the 
peptidyl moiety to the side chain amino group of the L-lysine residue of 
another peptide (107).  
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DD-carboxypeptidation reaction.  This reaction cleaves the terminal D-
alanyl-D-alanine of the peptidoglycan unit, preventing in this way that 
transpeptidation occurs with that particular peptide molecule. The 
carboxypeptidases are responsible for the control of the cross-linking 
degree of peptidoglycan and of the cell division process (17). The reaction 
mechanism is very similar to the one described for transpeptidation. It also 
involves the acylation of the serine residue of the catalytic domain, resulting 
in the cleavage of the D-alanyl-D-alanine bond and the formation of an 
ester-linked acyl-enzyme complex. The difference lies on the resolution of 
this intermediate structure, which involves in this case the transfer of the 
peptidyl to a water molecule, instead of the L-lysine residue of the second 
stem peptide (107). 
DD-endopeptidation reaction. Transpeptidation and endopeptidation can 
be considered reverse activities, since DD-endopeptidation cleaves cross-
bridges between two glycan strands.   
Transglycosylation reaction. Transglycosylation consists in the 
elongation of the linear glycan chains. The resolution of the crystal structure 
of PBP2 in complex with moenomycin (structural analog of 
transglycosylase substrate lipid II) was crucial for the clarification of the 
transglycosylation mechanism. It was proposed that transglycosylase 
interacts both with the growing chain (donor) and lipid II (acceptor) (202). 
The growing glycan chain attached to the membrane lipid carrier (PP-
undecaprenyl) acts as glycosyl donor and is transferred to the GlcNAc 
moiety of lipid II with the formation of a new β-1,4 glycosidic bond (375). 
 
2.3.3.2. Monofunctional glycosyltransferases (Mgts) 
Besides the transglycosylase activity provided by the class A PBPs, 
bacteria may also express membrane-bound enzymes composed by a 
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single transglycosylase domain, capable of catalyzing only the formation of 
uncross-linked peptidoglycan, known as monofunctional 
glycosyltransferases (Mgts) (53, 71, 321, 360).  Interestingly, in B. subtilis 
and Enterococcus spp., no Mgts were identified so far (10, 182, 290), which 
suggest that in both species, transglycosylases are not required for survival 
or that additional enzymes with transglycosylase activity are yet to be 
identified. Regarding S. aureus, significant advances have been made in 
order to determine the exact role of Mgts in transglycosylase activity and in 
expression of -lactam resistance in this organism. In fact, in vitro 
transglycosylase activity of two Mgts was reported in S. aureus, MGT and 
SgtA (286, 332, 360). Although MGT and SgtA do not seem essential, in 
the absence of PBP2, the transglycosylase activity of MGT is crucial for cell 
viability. This indicated that either PBP2 or MGT is the sole peptidoglycan 
transglycosylase in S. aureus (286).  
 
2.3.3.3. PBPs in S. aureus 
As mentioned before, S. aureus has four native PBPs, including one 
bifunctional class A HMM PBP (PBP2), two class B HMM PBPs (PBP1 and 
PBP3) and one LMM PBP (PBP4) (106). PBP1 and PBP2 are both 
essential in MSSA, while PBP3 and PBP4 are not (274, 276, 355). MRSA 
strains have acquired an extra class B HMM PBP (PBP2A) which has low 
affinity to β-lactams antibiotics, being primarly responsible for the 
expression of β-lactam resistance (see section 5.2.4 and 5.3).  
PBP2 is the major peptidoglycan transpeptidase and also the most 
abundant among the native PBPs, being the unique bifunctional PBP 
present in S. aureus (105). PBP2 is only essential in MSSA, since in MRSA 
the transpeptidase activity of PBP2 is complemented by PBP2A (276). 
Nevertheless, the PBP2 transglycosylase domain, although not essential, is 
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required for the expression of β-lactam resistance, as it cooperates with the 
transpeptidase domain of PBP2A to sustain cell wall biosynthesis, in the 
presence of a β-lactam (273) (see section 5.2.4 and 5.3).     
PBP1 was shown to be essential in MSSA and MRSA strains  (263, 355), 
and to be intimately related with the mechanism of cell division, playing an 
important role in septum’s formation (263). Interestingly, in contrast to 
PBP2 (276), the essential function of PBP1 could be not replaced by 
PBP2A (263), suggesting that the essential role of PBP1 in cell division is 
not dependent of its transpeptidase activity. PBP1 was proposed to have a 
dual role in cell cycle of S. aureus: it is an essential protein in the initiation 
of the septation and also it acts as a transpeptidase to generate a critical 
signal for cell separation at the end of cell division (264).  
PBP3 is the less studied staphylococcal PBP and although it was 
suggested to be involved in septation (249), its exact role remains to be 
determined.  
PBP4, the only LMM-PBP, was characterized to have both DD-
carboxipeptidase and transpeptidase activities in vitro (180). Later, PBP4 
was described as being directly involved in secondary cross-linking of the 
peptidoglycan (128, 373). It seems that PBP2 and PBP4 cooperate in order 
to produce the high cross-linking level that characterizes S. aureus. This 
process starts with the primary cross-linking, catalysed by PBP2, which 
results in the formation of dimeric, trimeric, and tetrameric muropeptides. 
Then, these muropeptides constitute the substrate of PBP4, with the 
subsequent formation of more complex oligomers. On the other hand, it 
was also shown that PBP4 plays a crucial role the mechanism of β-lactam 
resistance in community-acquired MRSA (CA-MRSA) (225).    
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Regarding their cellular localization, PBP1, PBP2 and PBP4 localize at the 
septum (14, 263, 271), which is consistent with the fact that peptidoglycan 
synthesis occurs only at this site (271). So far, the localization of PBP3 
remains unknown. The recruitment of each PBP to the division site occurs 
by different mechanisms. Since PBP1 is essential for cell division through a 
mechanism that does not require its transpeptidase activity, it seems that 
this PBP is part of the divisome and, probably, is recruited to the division 
site by an unidentified divisome protein through a mechanism that does not 
require the PBP transpeptidase domain (263, 264). Regarding PBP2, the 
delocalization of this protein can be observed when its substrate (lipid II) is 
eliminated, suggesting that PBP2 is recruited to the division site after 
binding to lipid II (272). Interestingly, PBP2 becomes dispersed over the 
cell surface, if its transpeptidase active site is acylated. However, in the 
presence of PBP2A, the lack of transpeptidase activity does not result in 
delocalization of PBP2, indicating that acylated PBP2 can be maintained in 
place by functional PBP2A (272). The recruitment of PBP4 to the septum is 
regulated by an unidentified intermediate of WTAs synthesis (14). As WTAs 
are attached to peptidoglycan, its synthesis probably occurs at the division 
septum after peptidoglycan assembly has been initiated by PBP1 and 
PBP2. Thus, it most likely that PBP4 is recruited to the septum later than 
PBP1 and PBP2, in order to allow the incorporation of polysaccharides and 
proteins into the cell wall, which may be hampered if peptidoglycan were to 
become highly cross-linked at an earlier stage (14). 
 
2.3.3.4. Peptidoglycan hydrolases 
In order to allow the incorporation of new murein units and also to promote 
the separation of the two daughter cells, old peptidoglycan must be 
degraded and removed by the action of peptidoglycan hydrolases such as 
N-acetylglucosaminidases, N-acetylmuramidases, N-acetylmuramyl-L-
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alanine amidases, lytic transglycosylases and endopeptidases (Figure 7). 
Importantly, these enzymes are also associated with cell wall turnover, lysis 
induced by cell wall synthesis inhibitors, establishment of competence for 
genetic transformation and bacterial pathogenicity processes (for a review 
see reference 136).  
 
Figure 7. Murein hydrolase targets within S. aureus peptidoglycan. The peptidoglycan 
is composed of interlinked glycan chains containing alternating subunits of N-
acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc). Pentapeptide chains, 
attached to MurNAc, are cross-linked to stem peptides from adjacent muropeptide strands 
as indicated. Different murein hydrolases that cleave the various bonds within peptidoglycan 
have been identified and include N-acetyl muramidase, N-acetyl-β-D-glucosaminidase 
(Lysozyme), N-acetylmuramoyl- L-alanine amidase, L-alanoyl-D-glutamate endopeptidases, 
and interpeptide bridge endopeptidases (adapted from reference 327). 
The analysis of the pattern of autolytic enzymes in S. aureus, obtained by 
zymograme assays revealed the presence of more than 20 bacteriolytic 
bands, suggesting that S. aureus produces several peptidoglycan 
hydrolases (324). Although at least 13 genes were identified as responsible 
for the expression of known or putative peptidoglycan hydrolases, only 
three genes, atl, sleI, and lytM, and their products have been characterized. 
Atl, the major staphylococcal autolysin, is a bifunctional protein initially 
synthesized as a 138 kDa protein that undergoes proteolytic cleavage to 
produce two independent hydrolases, a 62-kDa N-acetylmuramyl-L-alanine 
amidase and a 51-kDa N-acetylglucosaminidase (176, 254). Atl is important 
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for separation of daughter cells after cell division, cell wall recycling, and for 
biofilm formation (27, 31, 126, 328). Both amidase and glucosaminidase 
proteins localize at the equatorial ring on the staphylococcal cell surface 
that marks the future cell division site (374). Curiously, the mechanism by 
which Atl-hydrolases are targeted to the equatorial surface ring is based on 
an avoidance strategy by WTAs, which prevents binding of Atl. As WTAs 
are abundant in the old cell wall but not at the cross-wall region, Atl is able 
to bind to this region (305). Sle1 is a 32 kDa protein with N-acetylmuramyl-
L-alanine activity and is also involved in cell separation after division in S. 
aureus (126). In fact, Sle1 together with Atl were considered the main, if not 
the only, lytic enzymes responsible for cell separation after division in S. 
aureus (161). LytM is a 32 kDa protein with glycylglycine endopeptidase 
activity, being able to hydrolyze the glycyl-glycine bonds of S. aureus cross-
bridges. It appears that LytM plays a role in cell growth as it is distributed 
uniformly on the cell surface (282, 283). Other peptidoglycan hydrolases 
with N-acetyl-muramyl-L-alanine amidase activity were described in S. 
aureus including LytH (33 kDa), LytA (23 kDa) and LytN (46 kDa). 
Importantly, despite their role in cell separation, the inactivation of any of 
these genes and respective protein products, or even the deletion of both 
genes, is not lethal for the cell, suggesting that other genes with similar 
functions should exist (161). 
Since many of these enzymes are able to cause cell wall disruption, their 
activities and expression must be strongly regulated to avoid undesired 
lysis. In S. aureus, the regulation of autolytic activity involves several two-
component signal transduction systems and global regulators. The 
autolysis in S. aureus can be negatively controlled by MgrA (144, 205), 
ArlRS (195), LytSR (118), and SarA (100, 210). On the other hand, walkr 
(78), agr (100) and cidABC (289) are able to regulate positively the autolytic 
activity.  Additionally, it was shown that perturbations of S. aureus cell wall 
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synthesis resulted in a strong transcriptional repression of several 
peptidoglycan hydrolases, which provided evidence for close regulation 
between cell wall synthetic and hydrolytic enzymes (8). 
 
2.3.3.4.1. Lysozyme: the host N-acetylmuramidase 
Lysozyme, a powerful antibacterial protein, is among the most and best-
studied enzymes. It is present in a large number of organisms and various 
biological fluids such as tears, breast milk, respiratory and saliva 
secretions, as well as in cells of the innate immune system including 
neutrophils, monocytes, macrophages, and epithelial cells, being involved 
in the initial host defensive response against bacterial infection (191). 
The protective role of lysozyme for opportunistic pathogens was 
demonstrated in a study wherein killing of group B streptococci and 
Pseudomonas aeruginosa was enhanced by over- expression of lysozyme 
in the lungs of transgenic mice (4). On the other hand, deletion of both 
genes that encode two important lysozymes in mice resulted in a defective 
clearance of P. aeruginosa and Klebsiella pneumoniae from the mice lower 
airways (47).  
In fact, lysozyme is an important player in the host’s response against 
invading microorganisms, since it targets the bacterial cell wall and is 
associated with the removal of high molecular weight peptidoglycan 
fragments that remain after cell lysis. The persistence of these fragments, 
within the cell, may often cause physiological problems in the host, even 
after the majority of the viable bacteria have been destroyed (29; for a 
review see reference 353). Beside its antimicrobial activity, lysozyme has 
other important functions: it can be an enhancer of the phagocytic activity of 
polymorphonuclear leukocytes and macrophages (174, 333), and can 
stimulate proliferation and antitumor functions of monocytes (190).  
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The ability of lysozyme to cause bacterial lysis relies on its N-
acetylmuramidase activity since it hydrolyses the β-1,4 glycosidic bonds 
between MurNAc and GlcNAc residues of peptidoglycan, resulting in its 
degradation and consequently causes the lysis of bacterial cells (269, 304).      
Most pathogenic bacteria are resistant to lysozyme, such as S. 
pneumoniae, Streptococcus suis, Listeria monocytogenes, S. aureus, 
Neisseria gonorrhoeae, E. faecalis, and Helicobacter pylori. The 
mechanisms of resistance to lysozyme are mainly due to peptidoglycan 
modifications, which hamper recognition by the enzyme. In the particular 
case of Gram negative bacteria, they are generally resistant to lysozyme 
because their outer membrane prevents access of the secreted enzyme to 
the peptidoglycan. The modifications of cell wall associated with lysozyme 
resistance are described in section 3.  
Importantly, lysozyme has two different antimicrobial activities. Besides the 
muramidase activity, lysozyme can also act as a cationic antimicrobial 
peptide (CAMP), which results in its ability to cause disruption of the 
cytoplasmic membrane. The CAMP activity of lysozyme was demonstrated 
using catalytically inactivated lysozyme, peptides isolated from digested 
lysozyme, and synthetic lysozyme-derived peptides (79, 141, 142, 184). S. 
aureus has two different resistance mechanisms to lysozyme, which are 
related to the muramidase and CAMPs activities of lysozyme (129). Both 
mechanisms will be described in section 3. 
The CAMPs are present in mucous membranes and skin and are 
responsible for the killing capacity of phagocytic cells. They are small 
positively charged peptides with hydrophobic residues (189), which allow 
interactions with bacterial cytoplasmic membrane, that usually contains 
negatively charged phospholipids. In fact, membrane damage is probably 
the main CAMPs’ mechanism of action; it involves firstly the interaction 
                                                                                                                  General Introduction  
27 
 
between the cationic groups of the peptide with the anionic groups of the 
membrane lipids, and secondly the integration of the peptide into the 
hydrophobic core of the membrane. On the other hand, several authors 
assume that lysozyme as a CAMP is not only acting as a membrane 
permeabilization agent, but also it activates autolytic wall enzymes of 
Gram-positive bacteria thus causing cell lysis (110, 111, 362). It has been 
shown that the degree of D-alanylation of teichoic acids, modification that 
confers resistance to CAMPs action, affects the autolysis rate (46, 90, 243). 
In line with these findings, it was demonstrated in S. aureus that CAMPs 
activate autolytic enzymes (129).   
Bacteria have developed several strategies to resist to CAMPs  (for a 
review see reference 267). One of these mechanisms is based on 
modifications of their cell surfaces to reduce the net negative charge of the 
cell envelope and therefore reduce the affinity of CAMPs for the bacterial 
membrane (83, 265). The cell wall modifications involved in the resistance 
to CAMP activity of lysozyme will be described in the section 3. 
 
3. Cell wall modifications  
The normal glycan strands of bacterial peptidoglycan consist of alternating 
unmodified residues of β-1,4-linked MurNAc and GlcNAc. However, there 
are no known examples of bacterial species that contain exclusively 
unmodified peptidoglycan polymerized from lipid II, as mature glycan 
strands become modified or linked to other polymers after their insertion 
into the cell wall (for a review see reference 350). Several secondary 
modifications were described and although their functional roles are not 
completely understood, their presence affects the hydrolysis of 
peptidoglycan and its enlargement during cell growth. Furthermore, these 
alterations avoid the recognition of bacteria by host factors, which 
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contribute to the bacteria resistance to host defense factors such as 
lysozyme. Actually, the occurrence of modifications in cell wall components, 
which leads to lysozyme resistance, are not surprising since bacteria are 
likely to encounter host lysozymes during infection, thus the development of 
resistance to these and other defense mechanisms confers a selective 
advantage to bacteria, being crucial for maintaining bacterial viability. The 
more frequent variations are in the glycan strands, that include their N-
deacetylation and O-acetylation, the D-alanine esterification of teichoic 
acids, and the modification of membrane phospholipids with L-lysine.  
N-deacetylation. The presence of N-deacetylated glucosamine (GlcN) was 
first described in the peptidoglycan of Bacillus cereus (9), and soon after N-
deacetylated muramic acid residues (MurN) were identified in the Bacillus 
anthracis peptidoglycan (379). The existence of N-deacetylated GlcN was 
further extended to several other bacterial species including S. pneumoniae 
(248, 351), Lactobacillus fermentum (201) and L. monocytogenes (30), 
while N-deacetylated MurN was identified in small quantities only in S. 
pneumoniae (351) and Micrococcus lysodeiktikus (138). 
The gene which encodes a peptidoglycan GlcNAc deacetylase, pgdA, was 
first identified in S. pneumoniae (351); later, several pgdA homologues 
were identified in other pathogenic species including S. suis (91, 92), L. 
monocytogenes (30), and H. pylori (358). The deacetylation reaction most 
likely occurs on polymerized peptidoglycan, since deacylated precursors 
were not detected in bacteria with deacylated peptidoglycan and also the 
deacetylases have a predicted extracytoplasmic localization (351). 
The presence of deacetylated peptidoglycan strongly reduces the lysozyme 
activity, as interactions between the acetyl groups of glycan strands and 
amino acids of the lysozyme molecule are crucial for substrate binding (28, 
349). The impact of deacetylated peptidoglycan on lysozyme activity, and 
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consequently on virulence of important human pathogens, has been 
analyzed in mouse infectious models. In S. pneumoniae, a pgdA mutant 
exhibited significantly reduced virulence in an intraperitoneal mouse model, 
indicating that PgdA is a putative virulence factor (351). Interestingly, in S. 
suis the deletion of pgdA caused a severe impairment in the bacteria ability 
to persist in the blood. It was also observed an increase of pgdA expression 
upon interaction of the bacterium with neutrophils in vivo as well as in vitro 
(92), which suggests that deacetylation is an adaptative response to 
escape the immune clearance mechanisms.  
The inactivation of pgdA in L. monocytogenes revealed the key role of 
peptidoglycan deacetylation in virulence, as the mutant was very sensitive 
to the bacteriolytic activity of lysozyme and rapidly destroyed within 
macrophages (30). Similar findings were observed when pgdA homologue 
was inactivated in H. pylori (357). It seems that both lysozyme activities, the 
muramidase and the CAMP activities, are affected by the deacetylation of 
peptidoglycan, since a L. monocytogenes pgdA mutant was more 
susceptible not only to mutanolysin (a muramidase) but also to lysozyme as 
a CAMP (279). It was also evident that pgdA mutant was more prone to 
autolysis, suggesting that some of the peptidoglycan hydrolases 
(autolysins), in particular those cleaving in the glycan strands, have 
different functional activities against fully acetylated or deacetylated 
peptidoglycan. If the hydrolases’ activity is affected by the state of 
acetylation of the peptidoglycan, the separation of the daughter cells should 
also be altered. However, in S. pneumoniae the pgdA deletion did not affect 
cell separation (351). 
O-acetylation. The O-acetylation occurs specifically at the C-6 hydroxyl 
group of muramoyl residues of peptidoglycan. Recently, the O-acetylation 
of GlcNAc residues was described in B. anthracis and also in Lactococcus 
plantarum (25, 183). O-acetylated peptidoglycan was discovered more than 
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50 years ago in the cell walls of E. faecalis (2), and since then this 
modification has been found in 49 other species of bacteria, both Gram 
positive and Gram negative, including S. aureus, B. anthracis and H. pylori  
(19, 44). Similarly to N-deacetylation, peptidoglycan O-acetylation is known 
to be a maturation event, occurring within the peptidoglycan sacculus 
following its synthesis and assembly (44). oatA from S. aureus was the first 
peptidoglycan O-acetyltransferase gene identified (21). Meanwhile, 
homologues of oatA have been described in several other Gram positive 
bacteria including S. pneumoniae (56), B. cereus, B. anthracis (183), and 
Lactococcus lactis (347). 
O-acetylation turns the peptidoglycan resistant to the hydrolytic activity of 
lysozyme (38). As the binding of peptidoglycan to lysozyme involves a large 
H-bonding network between the C-6 hydroxyl moieties of three MurNAc 
residues and amino acids from the active site of the enzyme (28), the steric 
hindrance caused by the O-acetylation of the C-6 group results in a weaker 
affinity of the enzyme for the modified substrate (Figure 8).  
In fact, O-acetylation of peptidoglycan contributes to lysozyme resistance of 
pathogenic Gram-positive bacteria such as S. aureus and S. pneumoniae, 
as oatA mutants of both species showed more sensitivity to lysozyme (21, 
56). Additionally, a correlation was found between pathogenicity, lysozyme 
resistance and the occurrence of O-acetylation in the peptidoglycan of 
staphylococcal species (19).  
During infection, bacteria are normally lysed by the immune system, and 
the resulting peptidoglycan fragments rapidly degraded by hydrolytic 
enzymes. Since human lysozyme is unable to digest the O-acetylated 
peptidoglycan fragments, the persistence of these fragments in the host 
may lead to inflammation and eventually rheumatoid arthritis (94). Several 
studies demonstrated in vivo that the persistence of peptidoglycan in a host 
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is directly due to the high degree of O-acetylation (299). Therefore, it 
appears that, as in the case of N-deacetylation, O-acetylation prevents the 
recognition of peptidoglycan fragments by host factors such as 
peptidoglycan recognition proteins.  
 
Figure 8. Proposed interaction of the aminoacids of the binding groove of the egg-
white lysozyme and staphylococcal peptidoglycan, based on the structure of 
reference 28. The C6-OH group of muramic acid in staphylococci is modified by O-
acetylation and serves also as an anchor for wall teichoic acid (WTA). Five amino acid 
residues of lysozyme binding groove (Asp101, Gln57, Phe34, Asn37 and Arg114) interact 
with the C6-OH group of unmodified peptidoglycan. The high degree of O-acetylation of 
staphylococcal peptidoglycan inhibits the interaction with lysozyme, thus causing lysozyme 
resistance. LCS, lysozyme cleavage site. (reproduced from reference 21). 
 
Interestingly, the decrease of O-acetylation degree upon treatment with 
penicillin in S. aureus (312), suggested that O-acetylation should be related 
with the cross-linking reaction. Although the mechanism is not clarified, 
peptidoglycan containing pentapeptides was proposed to be a poor 
substrate for O-acetylation. It was also reported that the presence of 
teichoic acid and a high degree of peptide cross-linkage in the 
peptidoglycan may contribute to lysozyme resistance in S. aureus (20). 
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D-Alanylation of teichoic acids. In Gram-positive bacteria, resistance to 
CAMPs is explained by the increase of the positive surface charge due to 
D-alanylation of teichoic acids, catalysed by the dlt operon gene products 
and/or incorporation of L-lysine into phosphatidylglycerol, the major 
membrane lipid, mediated by the mprF gene product (364). Deletion of the 
dlt operon leads to the complete absence of D-alanyl esters of TAs in S. 
aureus and confers sensitivity to antimicrobial peptides (266). In S. aureus, 
its high levels of lysozyme resistance are not only based on resistance to 
its muramidase activity, due to the occurrence of O-acetylation, but also to 
its inherent CAMP resistance, which is related to D-alanylation (129). 
Several studies in animal models have demonstrated that alanylated 
teichoic acids contribute to an increased virulence of S. aureus, as this 
modification helps the bacteria to avoid rapid killing by CAMPs from the 
host immune system (51, 314, 365).   
 
4. Antibiotic resistance in S. aureus  
S. aureus has always been a challenge for antimicrobial chemotherapy, 
due to its remarkable capacity to acquire antibiotic resistance mechanisms, 
overcoming all therapeutic agents that have been developed in the last 70 
years.  
Before the antibiotic era, the mortality rate of patients with S. aureus 
invasive infections was extremely high, exceeding 80%, and over 70% 
developed in metastatic infections (315). In the early 1940s, the discovery 
of penicillin (93), the first cell wall targeting β-lactam antibiotic, significantly 
improved the prognosis of patients with staphylococcal infections, with over 
94% of strains exhibiting susceptibility (223). However, shortly after the 
introduction of penicillin into clinical use, penicillin-resistant S. aureus 
expressing and secreting a β-lactamase were isolated (1, 284 ). In the 
1960s, more than 80% of hospital and community-acquired staphylococcal 
                                                                                                                  General Introduction  
33 
 
isolates were resistant to penicillin (300) and currently, more than 90% of 
staphylococcal isolates produce β-lactamases (203). The pattern of 
resistance, consisting in the emergence of resistance in the hospitals that 
can then spread into the community, is presently a well-established pattern 
that occurs with each new antibacterial (42, 203). 
In 1960, in order to overcome the problem of penicillin-resistant S. aureus 
strains, the first semi-synthetic penicillin resistant to β-lactamases, 
methicillin, was introduced in clinical practice (297). However, two years 
later, S. aureus resistant to this antibiotic were isolated (156). These 
strains, designated as methicillin resistant S. aureus (MRSA), have 
acquired the mecA gene, which encodes PBP2A, an extra PBP with low 
affinity for β-lactam antibiotics (37, 123, 288). In contrast to penicillin 
resistant S. aureus, MRSA show resistance to the entire class of β-lactam 
antibiotics including penicillins, cephalosporins and carbapenems. 
Multidrug-resistant MRSA became a serious health problem in hospitals, 
frequently developing resistance to virtually all antibiotics and spreading 
worldwide (72). 
As a consequence of MRSA spread, vancomycin, a glycopeptide antibiotic 
that also targets the cell wall and to which MRSA were consistently 
susceptible, became the remaining most often therapeutic agent against 
this pathogen. However, the increased use of vancomycin led to the 
emergence, in 1996, of vancomycin resistant intermediate S. aureus strains 
(VISA)  and in the 2000s highly vancomycin resistant S. aureus strains 
(VRSA) also appear in the USA and very recently in Europe as well (41, 84, 
134).   
In the last decade, a huge effort has been made in order to develop 
alternative antibiotics to treat MRSA infections (200), including inhibitors of 
protein synthesis (quinupristin-dalfopristin, tigecycline and linezolid) and 
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inhibitors of the transmembrane electrical potential gradient (daptomycin); 
nevertheless, all of them show specific disadvantages and resistance has 
already been observed for most (122, 125, 131, 339). Currently, the 
development of compounds that inhibit PBP2A transpeptidase activity 
constitute a significant progress and seems to represent a good therapeutic 
choice against MRSA infections (200). 
Overall, the remarkable capacity of S. aureus to adapt and acquire 
resistance to the antibiotics that are being introduced into clinical use, turns 
this microorganism into a major public health concern, as staphylococcal 
infections may become untreatable in the future.  
The mode of action of β-lactam antibiotics will be discussed in detail in the 
next section, due to its importance for the work developed in this Thesis. 
 
5. β-lactam mode of action and resistance mechanisms 
β-lactam antibiotics are the most widely used class of antimicrobial agents, 
mainly due to their low toxicity to humans, high efficiency, low cost and 
general broad-spectrum of action. They include several compounds which 
are divided according to their chemical structure into penicillin derivatives, 
cephalosporins, monobactams, carbapenems and β-lactamases inhibitors 
(242). 
The β-lactams, which owe their name to the presence of the four member 
β-lactam ring in their chemical structure, are highly specific inhibitors of the 
PBP enzymes involved in the polymerization of cell wall, by acting as 
suicide substrates of the transpeptidase domain of these proteins. In fact, 
the bactericidal activity of these compounds depends on their structural 
similarly to the carboxy-terminal D-alanyl-D-alanine of the peptidoglycan 
precursor, the natural substrate of PBPs. Therefore, the β-lactam molecule 
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irreversibly binds to the serine residue of the PBPs’ active site, through an 
acylation reaction, which results in the formation of a covalent acyl 
complex. The resultant acyl enzyme species are irreversibly inactived, 
preventing the crosslinking (transpeptidation) of the nascent peptidoglycan, 
and cell wall synthesis (107). 
Several mechanisms have evolved in bacteria to resist β-lactam antibiotics, 
namely: i) degradation of the antibiotic molecule by β-lactamase enzyme 
(154); ii) production of low-affinity PBPs to β-lactams, which allow the 
transpeptidation reaction even in the presence of high concentrations of β-
lactam antibiotics (104); or iii) decrease of the production of outer 
membrane proteins, present only in Gram-negative bacteria, which leads to 
reduction of the outer membrane permeability, and consequently blocks the 
access of the antibiotic to their cellular target (198, 322).  
In S. aureus, resistance to β-lactams is known to occur by two 
mechanisms. One mechanism, conferring resistance only to penicillin, is 
based on the production of the β-lactamase enzyme encoded by the blaZ 
gene, which cleaves the β-lactam ring of penicillin (245, 292). The second 
one, conferring resistance to most β-lactams, is due to the acquisition of 
mecA gene, which encodes the low affinity PBP, PBP2A (37, 124, 288). 
 
5.1. β-lactamase resistance mechanism 
The β-lactamase resistance mechanism is the most predominant among S. 
aureus, as more than 95% of staphylococcal isolates produce β-lactamases 
(199, 203). The majority of β-lactamases are related to PBPs, being both 
considered active-site serine enzymes (98, 213). Therefore, these enzymes 
inactivate β-lactams by hydrolyzing the amide group of the β-lactam ring, 
through a mechanism similar to the one described for the inhibition of PBPs 
by β-lactams (98, 214, 215). However, in this resistance mechanism, β-
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lactamases are able to undergo deacylation, by the hydrolysis of the β-
lactam ring, inactivating in this way the antibiotic molecule and regenerating 
their own activity (107).    
The β-lactamase BlaZ is predominantly extracellular and its expression is 
normally induced by the presence of β-lactam antibiotics (45, 291). The 
gene blaZ, which can be plasmid or chromosome located, is under the 
control of two adjacent regulatory genes, the anti-repressor blaR1 and the 
repressor blaI (45). The signaling pathway responsible for the induction of 
β-lactamase synthesis is dependent of the sequential cleavage of the 
regulatory proteins BlaR1 and BlaI. In the absence of β-lactams, BlaI binds 
to the bla promoter region, which represses the RNA transcription from 
both blaZ and blaRI-blaI. In the presence of antibiotic, the β-lactam 
molecule binds to the extracellular part of transmembrane sensor 
transducer, BlaRI, which causes a conformational modification that 
activates its cytoplasmatic domain as a protease, and it cleaves itself. The 
repressor, BlaI, is then cleaved by the BlaRI protease, so that it no longer 
binds to the bla operator, thus allowing synthesis of blaZ mRNA and hence 
β-lactamase (117, 193, 378).  
 
5.2. mecA gene resistance mechanism 
5.2.1. mecA gene 
The MRSA strains show high level of resistance to β-lactams due to the 
presence of the exogeneous mecA gene (2.1kb in length), which encodes 
PBP2A, a PBP with low affinity to all β-lactam antibiotics, allowing cell wall 
biosynthesis when the native PBPs have been inactivated by β-lactam 
antibiotics (37, 124, 288, 343). In fact, a drastic reduction in methicillin 
resistance was observed in mutant strains with inactivated mecA, strongly 
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suggesting that this gene is crucial for the optimal expression of methicillin 
resistance in S. aureus (217, 236).  
Although mecA is undoubtedly the main genetic determinant for methicillin 
resistant in MRSA, very recently, a highly divergent mecA gene, designated 
mecC, was identified with relatively low prevalence rates (102, 311). 
The mecA gene is not native to S. aureus but was acquired from another 
species by an unknown mechanism (16). According to DNA and amino acid 
sequence alignments, it has been proposed that the mecA gene of S. 
aureus may have resulted from a fusion event between a β-lactamase gene 
and a PBP gene (320). On the other hand, efforts to track the evolutionary 
origin of mecA led to the identification of a close homologue of the S. 
aureus mecA gene, present in all strains of Staphylococcus sciuri as the 
pbpD gene. S. sciuri is a taxonomically primitive staphylococcal species 
recovered most frequently from rodents and mammals (54). The purification 
of the protein product of pbpD showed that it shares a number of 
biochemical properties with S. aureus PBP2A (99). In fact, several studies 
have supported the proposition that S. sciuri pbpD may be associated 
and/or be an evolutionary precursor of mecA gene in S. aureus: (i) the 
transpeptidase domain of S. sciuri pbpD has 88% similarity, at the amino 
acid level, with the mecA gene of MRSA (370); (ii) introduction of the pbpD 
from a methicillin-resistant strain of S. sciuri into a susceptible strain of S. 
aureus resulted in an increased of β-lactam resistance and allowed 
continued growth and cell wall synthesis of the bacteria in the presence of 
high concentrations of β-lactams (307, 372) and iii) reconstruction of the 
methicillin resistant phenotype in an highly homogeneously resistant MRSA 
(lacking the SCCmec), using a plasmid-borne copy of the heterologous 
upregulated S. sciuri pbpD gene (7). 
 
Chapter I 
 
38 
 
5.2.2. Regulation of mecA transcription  
Until recently, it was assumed that the expression of mecA was regulated 
by a two component system consisting of a sensor-transducer, MecR1, and 
a transcriptional repressor, MecI (309), which are located immediately 
upstream of mecA promoter and are transcribed divergently from mecA. 
The regulation of mecA expression is similar to the one of blaZ gene, since 
the mecR1-mecI-mecA element is homologous to the S. aureus β-
lactamase blaR1-blaI-blaZ genetic system (121, 309, 340). However, while 
MecI and BlaI repressors are almost identical and seem to be compatible in 
blocking transcription of both genes (117, 121, 192), MecR1 and BlaRI are 
specific for their own repressors (221). The MecR1/MecI system consists of 
two main proteolytic steps, as follows: first, the acylation of MecR1 
extracellular sensor domain, through the binding of the β-lactam, leads to a 
conformational change, which results in the activation of the intracellular 
proteolytic domain. Then, the active protease induces the cleavage of the 
MecI repressor that is bound to mecA promoter region, allowing for mecA 
to be transcribed (11, 378). This model was recently modified with the 
identification of a third gene responsible for the induction of mecA 
transcription, designated mecR2 gene. The cleavage of MecI, which is 
essential for mecA transcription, can be also promoted by MecR2 (12) 
(Figure 9).   
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Figure 9. Regulation of mecA transcription. In the presence of a -lactam antibiotic, 
MecR1 is activated and rapidly induces the expression of mecA and mecR1-mecI-mecR2. 
The anti-repressor activity of MecR2 is essential to sustain the mecA induction since it 
promotes the inactivation of MecI by proteolytic cleavage (reproduced from reference 12). 
 
5.2.3. Staphylococcal Cassette Chromosome mec (SCCmec) 
The mecA gene is located on a large mobile genetic element (21-67 Kb) 
named staphylococcal cassette chromosome mec (SCCmec) (153, 167). 
This element integrates in the genome of susceptible strains at a specific 
site at the 3’ end of orfX, which is located near the origin of replication 
(167), and encodes a staphylococcal ribosomal methyltransferase (34). The 
SCCmec element is composed of two essential genetic complexes: (i) the 
mec gene complex containing mecA, its regulatory elements and insertion 
sequences upstream or downstream of mecA; and (ii) the cassette 
chromosome recombinase (ccr) gene complex, containing ccrAB or ccrC 
genes that encode site-specific recombinases, namely 
invertases/resolvases, responsible for the excision/integration of SCCmec 
from/into the chromosome (145). Also, the basic structure of SCCmec 
element includes three genetic regions called the “joining” (J) regions: i) the 
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J1 region, located between the chromosomal right junction and the ccr 
genes; ii) the J2 region that comprises the region between ccr genes and 
the mec complex; and iii) the J3 region that includes the genetic region 
between the mec complex and orfX (132). Some SCCmec type variants are 
defined by differences in the J regions (227, 228). 
Up to now, eleven different types of SCCmec elements (SCCmec I to XI) 
and several variants have been identified and characterized, each type 
being defined according to the binary combination of the class of mec 
complex and the type of ccr gene complex (133, 145).  
Currently, five different classes of mec complex were described: mec 
complex A, B, C, which is divided in C1 and C2, and mec complex E (145). 
Regarding ccr gene complex variability, three distinct ccr genes were 
described: ccrA, ccrB and ccrC, the latter representing a ccr complex 
classified in two main structures: one carrying two adjacent genes, ccrA 
and ccrB, and the other carrying only one gene, ccrC. So far, seven ccr 
gene complex types were described in S. aureus: types 1 to 4, carrying 
ccrA and ccrB with four allotypes (ccrA1B1, ccrA2B2, ccrA3B3, ccrA4B4); 
type 5 carrying a single allotype, ccrC; type 7 carrying the combination of 
ccrA1B6 and type 8 carrying the combination ccrA1B3 
(http://www.sccmec.org).  
 
5.2.4. PBP2A and the mechanism of methicillin resistance in S. 
aureus 
PBP2A is a 78 KDa HMW PBP located in the extracellular surface of the 
cytoplasmic membrane, where it can catalyze the final steps of cell wall 
assembly (113). The crystal structure of PBP2A revealed the presence of 
three domains: i) a N-terminal domain, which corresponds to the anchor 
characteristic of the HMW PBPs; ii) a central non-penicillin binding domain 
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of unknown function; and iii) a C-terminal penicillin binding domain with the 
typical folding pattern of the PBP transpeptidases and the serine β-
lactamases (196). PBP2A has the particularity of the nucleophilic serine 
active site being sequestrated within an extended narrow groove, which 
results in a substantial decrease in the affinity for β-lactams, when 
compared to the native PBPs (124, 196, 288).  
Initially, the model of β-lactam resistance mechanism mediated by PBP2A 
was based on the fact that, in the presence of β-lactams, the only functional 
PBP, able to catalyze the final reactions of the cell wall biosynthesis, is the 
low-affinity PBP2A, as the four native PBPs are fully acylated and 
consequently inactivated (124, 288). However, it was later described that 
PBP2A is a poor substitute of the native PBPs, as it shows a weak 
transpeptidase activity. The peptidoglycan of a MRSA strain, challenged 
with β-lactams, is weakly cross-linked, being composed mainly by 
monomeric, dimeric and trimeric structures, in contrast to the highly cross-
linked peptidoglycan produced by the same MRSA strain, grown without 
antibiotic (61). Subsequently, several observations indicated that this model 
required revision. 
 
5.3. Role of auxiliary genes in β-lactam resistance 
Despite being the main player in the mechanism of resistance to methicillin, 
the production of PBP2A is not sufficient for the optimal expression of 
methicillin resistance. The first evidence that pointed in that direction came 
from the study wherein no correlation between the levels of resistance and 
the respective PBP2A cellular amounts was observed, suggesting that 
other factors, besides mecA, were involved in the expression of resistance 
to methicillin (123, 236). Additionally, introduction of mecA gene, from 
homogeneous MRSA strains, into MSSA, produced transformants with low 
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resistance or heterogeneous resistance to methicillin, independently of the 
mecA donor, which indicated that additional genes, belonging to the strains’ 
genetic background, determine the levels of methicillin resistance (236).   
The identification of these additional factors was initially addressed by two 
independent laboratories, that screened Tn551 mutants of a homogeneous 
MRSA strain for reduced levels of methicillin resistance (22, 65, 67, 179). 
The location of the transposon insertion site in those mutants led to the 
identification of several genes, described as necessary for the full 
expression of methicillin resistance and designated as factors essential for 
methicillin resistance (fem) or auxiliary (aux) genes.  
Initially, only the mutants that showed a drastic decrease in methicillin 
resistance were selected, allowing the identification of femAB (22, 24), 
femX, femC and femD (23, 66). The femAB operon, the first genetic locus 
identified as an additional player in the methicillin resistance mechanism, 
encodes two proteins, FemA and FemB (22, 24). This operon is 
responsible for the formation of the branched-peptide structure 
characteristic of S. aureus peptidoglycan, the pentaglycine bridge, namely 
FemA is essential for the addition of glycine residues 2 and 3, while FemB 
is specific for the attachment of glycine residues 4 and 5 (80). The first 
glycine is added independently of FemA and FemB, through the action of 
femX (178, 296). Characterization of the femC mutant revealed that the 
transposon inserted in the glutamine synthetase repressor (glnR), which 
has a polar effect on the transcription of the glutamine synthetase 
transcription (glnA) (120). The inhibition of the glnRA operon produced a 
decrease in glutamine synthetase activity and therefore, a reduction in the 
glutamine availability in the cells. Importantly, the analysis of the 
peptidoglycan composition of the femC mutant, by HPLC, revealed a 
decrease in the proportion of cross-linked peptides and the existence of 
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new muropeptides structures containing glutamic acid units with free α-
carboxyl group instead of the normal isoglutamine residues (253). The 
femD (glmM) gene encodes GlmM, a phosphoglucosamine mutase, which 
catalyses the conversion of phosphoglucosamine-6-phosphate into 
glucosamine-1-phosphate, leading to the production of UDP-N-
acetylglucosamine (158). The inhibition of GlmM production results in the 
decrease of the synthesis of the peptidoglycan precursor, which is revealed 
by a complete disappearance of the unsubstituted disaccharide monomer 
from the peptidoglycan (63). Importantly, all these mutants were unaffected 
regarding mecA expression and most of them showed a heterogeneous 
resistance to methicillin (179) (see section 5.4). 
On the other hand, the analysis of the Tn551 mutants that showed a less 
severe decrease in methicillin resistance led to the identification of 20 to 30 
auxiliary genes, most of them associated with cell wall biosynthesis (65, 
67).  
The murE gene, which encodes the Mur ligase responsible for the addition 
of the L-lysine residue to the UDP-muramyl-dipeptide cell wall precursor, 
was also identified as an auxiliary gene by the characterization of a Tn551 
transposon mutant (204). Contrary to previously studied auxiliary genes, 
the inhibition of murE transcription affected the amount of PBP2A, 
suggesting that the expression of this PBP can be directly or indirectly 
under the control of the murE gene (103).  
The analysis of an insertion mutant for murF gene, which encodes the 
UDP-N-acetylmuramyl-pentapeptide synthetase, allowed identification of 
this gene as being important for methicillin resistance. The inactivation of 
murF caused both a decrease in methicillin resistance and a reduction in 
mecA transcription, suggesting that the expression of mecA and murF 
seems to be correlated (317). Later, the analysis of a murF conditional 
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mutant demonstrated that MurF is also important for cell division, being 
essential for cell viability (318).   
It was surprising to find that pbpB was an auxiliary gene, since it was 
assumed that PBP2 was inactivated in the presence of β-lactams (270). 
The inactivation of the transglycosylase domain, but not the transpeptidase 
domain, of PBP2 results in a decrease of β-lactam resistance, even in the 
presence of PBP2A (273). This suggested that, in the presence of 
antibiotic, MRSA peptidoglycan biosynthesis depends on the functional 
cooperation between the transglycosylase domain of the native PBP2 and 
the transpeptidase domain of PBP2A (273, 276). Also, in the presence of β-
lactams, PBP2A complements the essential peptidoglycan transpeptidase 
function of PBP2, confirming that PBP2A has transpeptidase activity (276) 
(Figure 10). 
 
Figure 10. Model for the cooperative functioning of the transglycosylase (TGase) 
domain of PBP2 and the transpeptidase (TPase) domain of PBP2A in methicillin-
resistant S. aureus. (left) In the absence of antibiotic, both the TPase and TGase domains 
of PBP2 participate in the biosynthesis of staphylococcal peptidoglycan. (Right) When 
antibiotic is present, the TPase domain of PBP2 is acylated and is unable to perform its 
peptide crosslinking activity. However, the penicillin-insensitive TGase domain of PBP2 
remains functional and cooperates with the TPase activity of PBP2A (adapted from 
reference 273). 
Also, while pbpA gene, which encodes for PBP1, was involved in methicillin 
resistance (263), impairment of pbpD did not affect the β-lactam resistance 
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level of MRSA, being not classified as an auxiliary gene (166). Later, pbpD 
was shown to be an auxiliary gene only in the community acquired MRSA 
(CA-MRSA), playing a key role in the resistance mechanism of these 
strains (225). Within the four staphylococcal PBPs, only PBP3 is not 
consider a auxiliary gene for β-lactam resistance, as the inactivation of 
pbpC gene had no significant impact on the methicillin resistance profile 
(274). 
Besides the genes described above, other cell wall related genes were 
linked to the optimal expression of methicillin resistance (for a review see 
reference 295): i) fmtA gene, which encodes a methionyl- tRNA 
formyltransferase, affects both methicillin resistance and autolysis in the 
presence of Triton X-100 (175, 176); ii) mrp (or fmtB), which protein product 
was annotated as a sortase A-dependant cell surface protein (371); iii) tarO 
gene, which is involved in the first enzymatic step in WTAs biosynthesis 
(319), has an impact on both methicillin resistance and autolysis rate (209). 
The genetic strategy, based on the screening of Tn551 insertion mutants, 
showed some limitations, as genes that are involved in essential reactions 
for cell survival and that simultaneously contribute to β-lactam resistance 
are not identified through this approach. Recently, in order to overcome this 
issue, a genome-wide antisense fragmentation approach was followed to 
identify essential genes (95). The genes targeted by antisense RNAs were 
identified in a community acquired and in a hospital acquired MRSA strains 
(187). The resulting mutants were then screened under inducing conditions 
to identify additional genes required for β-lactam resistance (187). In this 
way, more genes were recognized to contribute to β-lactam resistance, 
including essential factors of cell division (ftsZ and ftsA), protein secretion 
(spsB), wall teichoic acid biosynthesis (tarL) and signal transduction system 
(pknB) (187). 
Chapter I 
 
46 
 
The mechanism behind the contribution of auxiliary genes to the expression 
of methicillin resistance is far from being completely understood. It is 
proposed that the auxiliary genes, which are cell wall related, are implicated 
in β-lactam resistance by providing optimal peptidoglycan precursors 
substrates for PBPs to complete peptidoglycan synthesis. The inactivation 
of these genes leads to the production of abnormal muropeptides 
structures, which are inefficient substrates for PBP2A. Consequently, 
methicillin molecules may easily bind to the active site of PBP2A due to the 
lack of correct muropeptide competitors, which results in the decrease of 
methicillin resistance (65).  
Although the mechanism behind the contribution of auxiliary genes to the 
expression of an optimal methicillin resistance phenotype is not clarified, 
the identification of their role is a significant step and shows that β-lactam 
resistance requires the coordinated activity of a large network of 
interdependent biological processes. In fact, many other genes, not related 
with cell wall biosynthesis, were recognized as auxiliary genes. The large 
number of auxiliary genes described until now and the diversity of their 
cellular functions illustrates the complexity of the β-lactam resistance 
mechanism in S. aureus.  
 
5.4. Heterogeneity  
In most MRSA strains the level of antibiotic resistance, minimal  inhibitory 
concentration (MIC), varies widely from one strain to another and also 
within the progeny of a single MRSA isolate, which reveals a 
heterogeneous expression of methicillin resistance. Heterogeneous 
methicillin resistant strains are composed of a majority of cells with low-
resistance to methicillin, corresponding to the MIC of the strain, and one or 
more subpopulations of highly resistant cells present at variable low 
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frequencies (123, 325). In clinical settings, this heterogeneous phenotype 
can be easily misinterpreted as sensitive, which consequently, originates 
treatment failure of infections caused by these strains (123). The level of 
resistance of the subpopulations and their frequency within the culture, are 
reproducible and specific features of the MRSA strain (64). In fact, 
regarding the high resistance level phenotype, once expressed, it is stable 
and most of these highly resistant subpopulations, designated as 
“homostar” population, express highly homogeneous resistance and do not 
revert to the heterogeneous phenotype (88, 123). Therefore, it appears that 
the heterogeneous composition of MRSA cultures is genetically controlled, 
i.e., the highly resistant subpopulations of bacteria must carry mutations in 
some genes, not located in the SCCmec element (302). Some genes 
including hmrA, hmrB, lytA and the dlt operon were indicated as putative 
candidates to develop such mutations (101, 177, 240). Moreover, it was 
recently described that, within a heterogeneous population, the 
subpopulations that were able to express high-level resistance carried a 
single mutation in the relA gene, causing the accumulation of a small 
signaling molecule called (p)ppGpp, which in turn leads to persistent 
activation of the stringent response, an important bacterial stress response 
(238). Soon after, evidences were provided that support the model in which 
the ultimate controlling factor of the phenotypic expression of β-lactam 
resistance in MRSA is a RelA-mediated stringent response (76, 169). 
Although heterogeneity is mainly due to genomic differences, namely 
chromosome mutations, methicillin resistance in MRSA is dependent upon 
the growth medium and other factors such temperature, pH, osmolarity, 
trace metals, chelating agents, and anaerobiosis (218). 
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6. Molecular Epidemiology of Methicillin Resistant S. aureus (MRSA)  
In 1961, two years after the introduction of methicillin in clinical practice, the 
first MRSA was isolated in the United Kingdom (156). In the following 
years, MRSA became pandemic, spread worldwide and accumulated 
resistance to almost all antimicrobial classes (72, 203). During this time, 
MRSA isolates seemed to be confined mainly to hospitals and other 
healthcare facilities, being designated as hospital or healthcare acquired 
MRSA (HA-MRSA). However, in the last two decades, this scenario has 
changed and the emergence of community-acquired MRSA (CA-MRSA), 
causing infections among healthy individuals, has been the subject of a 
growing concern, as MRSA are no longer limited to the hospital 
environment (41, 42, 130, 235). Nevertheless, as the global epidemic of 
CA-MRSA continued, CA-MRSA begun to appear as a cause of hospital 
outbreaks, replacing the classic HA-MRSA clones in some hospitals (35, 
171, 255, 256, 261, 278, 308). The emergence of CA-MRSA as a cause of 
nosocomial infections is a serious threat for public health. First, it puts a 
wider group of hospitalized patients, healthcare workers and their 
community contacts potentially at risk of a MRSA infection. Second, the 
presence of CA-MRSA in hospital environment exposes them to the 
selective pressure of antibiotic use in hospitals, which can result in the 
increase of antibiotic resistance. On the other hand, the spread of strains, 
associated with the healthcare setting, into the community has also been 
described (137, 212, 219, 329), suggesting that the boundaries between 
the hospital and community are blurring. 
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6.1. Origin, evolution and global dissemination of hospital-acquired 
MRSA (HA-MRSA) clonal lineages  
HA-MRSA are the leading cause of the majority of nosocomial infections, 
including bacteremia, pneumonia, urinary tract, surgical wound infections, 
and catheter-related infections (116).  
Epidemiological studies, conducted by the SENTRY Antimicrobial 
Surveillance Program, between 1997 and 2003, revealed that the global 
MRSA prevalence in hospitals was 23% in Australia, 67% in Japan, 40% in 
South America, 36% in USA and 23% in Europe (18, 72, 119, 334). 
However, data from the European Antimicrobial Resistance Surveillance 
Network (EARSS), between 1999 and 2002, revealed that the prevalence 
of MRSA in Europe is not homogeneous. While in the Northern countries, 
the percentage of MRSA is approximately 1%, in the Southern countries it 
is as high as 45% (334). 
Another study was based on the genetic analysis of more than 3,000 
MRSA isolates from surveillance and outbreak studies in Southern and 
Eastern Europe, North and Latin America and Asia, through the CEM/NET 
initiative, between 1994 and 2000 (336), revealed that the majority of the 
cases of HA-MRSA infections are caused by a small group of epidemic 
MRSA (EMRSA) clones, which are highly disseminated worldwide (251). 
Each clonal lineage, designated as Iberian (ST247-IIA), Brazilian (ST239-
IIIA), Hungarian (ST239-III), New York/Japan (ST5-II), Pediatric (ST5-VI) 
and epidemic MRSA-16 (EMRSA-16) (ST36-II) clones, was defined as a 
result of its specific genetic background and to the geographic site of its 
first identification. Additionally, two other clones, the EMRSA-15 (ST22-IV) 
and Berlin (ST45-IV) showed epidemic potential, in the United Kingdom 
and Germany, respectively (157, 234, 361, 368). 
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Several studies have addressed the topic related to the origin and evolution 
of the major contemporary MRSA clones. The most widely accepted theory 
defends that SCCmec was introduced several times into different S. aureus 
lineages that subsequently disseminated (55, 82, 114, 237).  
In order to clarify the origin and evolution of MRSA strains, the genetic 
background of MSSA and early MRSA strains isolated in the 1950/60s, in 
Denmark and United Kingdom was characterized (55). The comparison of 
these genetic profiles with the ones of the MRSA contemporary epidemic 
clones revealed that MSSA strains had gradually acquired resistance traits, 
in parallel to the introduction of antimicrobials in therapy. Moreover, it was 
shown that a large group of early MSSA isolates were identical to all early 
MRSA, in phenotypic and genetic properties, suggesting that these MSSA, 
with the genotype sequence type 250 (ST250), are the progeny of an S. 
aureus strain, that was one of the first recipients of the mec element in the 
MRSA evolutionary history. This early MRSA, with SCCmec type I and 
ST250, designated as Archaic clone, (55, 251) was the sole MRSA clone, 
in Danish hospitals, for over 17 years, after its emergence in 1960s (114). 
Furthermore, the Iberian clone (ST247-I) was described as a single locus 
variant of ST250, indicating that it was a direct descendent of the Archaic 
clone (55), which was further confirmed by a similar study of S. aureus, 
isolated in the 1960s, from blood infections in Denmark (114). 
Soon after, an evolutionary model was proposed through the 
characterization, (by SCCmec typing and MLST), of a large collection of 
MRSA and MSSA, isolated in 20 countries between 1961 and 1999 (82). 
The major MRSA clones evolved from five different groups of related 
genotypes or clonal complexes (CC): CC5, CC8, CC22, CC30 and CC45, 
each arising from a distinct ancestral genotype. The presence of different 
SCCmec elements within the same sequence type (ST), suggested that 
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methicillin resistance had emerged on multiple occasions within a specific 
lineage. In fact, additional high-resolution genetic evolutionary studies 
revealed that it emerged due to at least 20 SCCmec acquisitions, and that 
the acquisition of this genetic element was four times more common than 
the replacement of one SCCmec between the MRSA clones (294), which 
emphasizes the role of this genetic element as a driving force for MRSA 
evolution. Furthermore, a more recent study, proposed that the SCCmec 
element was imported much more frequently than previously suggested, 
and that MRSA apparently emerged by temporal and geographically 
independent SCCmec acquisitions (246).  
Therefore, accordingly to both studies, the CC8 lineage includes the first 
MRSA, ST250-I (Archaic clone), that was derived through acquisition of 
SCCmec type I, by ST250 MSSA, which itself was derived from the lineage, 
ST8-MSSA. ST250 MSSA is also the ancestor of other nosocomial MRSA 
pandemic lineages such as ST247-I (Iberian clone) and ST239-III 
(Brazilian/Hungarian clone). CC8 also comprises one of the most 
widespread community acquired clones, the ST8-MRSA-IV (USA300 clone) 
(82, 294, 331). In the CC5 lineage, ST5-MSSA was the ancestor of three 
major contemporary clonal lineages: the ST5-MRSA-II (New York/Japan 
clone), the ST5-MRSA-IV (Pediatric clone) and ST228-MRSA-I (Southern 
German clone). The CC22 lineage includes ST22-MRSA-IVh, known as 
EMRSA-15 that originated through the SCCmec-IVh acquisition into ST22-
MSSA. On the other hand, in CC45, the ancestor ST45-MSSA precedes 
the ST45-MRSA-IV background of the Berlin clone. In CC30, ST30-MSSA 
diverged into two distinct clonal types, which are the hospital acquired 
ST36-MRSA-II (EMRSA-16) and the community acquired ST30-MRSA-IV 
Southwest Pacific clone (293, 294).  
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The evolutionary pathways of the five MRSA clonal lineages referred to 
above showed that worldwide disseminated EMRSA clones have originated 
through the acquisition of the methicillin resistance determinant, by 
successful MSSA lineages, frequently associated with disease (55, 82, 
114). In this way, the epidemicity of MRSA clones seems to depend on 
genetic determinants that control the ability to colonize and/or cause 
disease. The study performed by Katayama et al (165) demonstrated that 
MSSA strains from major MRSA lineages were easier to transform with a 
plasmid-expressed mecA and better able to express resistance, in 
comparison to MSSA from other lineages, indicating that not all S. aureus 
genetic backgrounds favored the presence of the mecA gene in an active 
form. However, a thorough analysis of selected sequenced genomes did 
not show evidence that there are specific genetic factors, differentiating 
epidemic from sporadic S. aureus clones (181). 
The putative presence in strains of intrinsic properties, that defined the 
capacity to acquire and maintain the SCCmec element is not well 
understood and is being explored in several laboratories.  Such studies 
should help understand the reasons for the limited number of MRSA clones 
detected in surveillance studies. 
6.2. The emergence and epidemiology of community-acquired MRSA 
(CA-MRSA)  
For a long time MRSA strains were exclusively isolated from nosocomial 
environment. However, in the mid and late 1990s, a change in the MRSA 
epidemiology occurred, with the emergence of CA-MRSA strains, which 
have the capacity to infect otherwise healthy individuals (41, 60, 115, 130).  
The epidemiological success of CA-MRSA is due to the combination of 
methicillin resistance at low fitness cost (59, 73, 188) with a high level of 
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aggressive virulence, which enables CA-MRSA to spread and cause 
severe infections in otherwise healthy people (68, 257). 
The range of diseases caused by CA-MRSA is similar to the ones caused 
by MSSA in the community, but are clearly distinct from infections caused 
by HA-MRSA. Commonly, CA-MRSA causes skin and soft-tissue 
infections, however, it can be also associated with more severe infections 
such as folliculitis, cellulites, impetigo, pyomyositis and myositis, septic 
arthritis, osteomyelitis, sepsis, endocarditis, and necrotizing pneumonia 
(229, 258). 
Regarding the global epidemiology of CA-MRSA, a huge difference in the 
CA-MRSA prevalence between USA and the rest of the world has been 
observed. While in the USA the percentage of CA-MRSA infections can 
reach 59% (235), and is associated with only a single clone (USA300 
clone), in Europe, the prevalence of CA-MRSA is lower, ranging from 1 to 
29% (185, 211, 212, 367) and these strains are genetically diverse (298). 
The impact of the fast epidemic spread of CA-MRSA in United States on 
public health is remarkable, and it contributed for an overall increase of 
MRSA in this country (164, 171). The annual death rate caused by MRSA 
the highest among all those caused by an infectious agent, even higher, for 
example, than the one due to the human immunodeficiency virus, HIV 
(171). 
Studies on the molecular epidemiology of CA-MRSA suggested that CA-
MRSA emerged through the acquisition of SCCmec elements, mainly 
SCCmec type IV, by community strains of MSSA (70, 250). The existence 
of MSSA strains in the community sharing the same genetic background as 
CA-MRSA supports this hypothesis (114). Additionally, it has been 
described that genetic lineages of CA-MRSA are clearly distinct from the 
predominant HA-MRSA clones within defined geographic regions, 
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demonstrating that CA-MRSA did not emerge from local HA-MRSA (346). 
On the other hand, the larger clonal diversity of CA-MRSA, when compared 
to HA-MRSA, indicates that more MSSA clones have the ability to become 
CA-MRSA than HA-MRSA (82, 250).   
The first case of CA-MRSA, identified as belonging to the Southwest Pacific 
(SWP) clone (ST30-IVc) (52), was recovered among Aboriginal patients in 
remote communities from Western Australia in 1993 (341). However, CA-
MRSA were considered a public health threat, only in 1998, when four 
healthy children died from sepsis and necrotizing pneumonia due to CA-
MRSA, belonging to USA400 clone (ST1-IVa), in Minnesota and North 
Dakota (41).  
Since then, several CA-MRSA genetic backgrounds emerged and spread 
differently in separate geographical areas. Until recently, the five major CA-
MRSA clones, not genetically related, could be associated to a continent 
specific geographic location (346). Therefore, the USA300 clone (ST8-Iva, 
CC8) and USA400 (ST1-Iva, CC1) were both epidemic in the United States 
(172, 330), the European clone (ST80-IVc, CC80) was detected in several 
European countries (87, 186), the Southwest Pacific clone (ST30-IVc, 
CC30) was prevalent in Asia and Oceania (348), and the ST59 (CC59) 
clone, circulated mainly in the Asian-Pacific area (140). In recent years, 
another clone that became important was ST398-V (CC398), which was 
first considered a livestock-clone associated with colonization in pigs. The 
first descriptions were reported in France (13) however, nowadays, the 
ST398 clone is disseminated worldwide, not only in animals but also in 
humans (86, 168, 342, 344). Currently, CA-MRSA clones are not restricted 
to a specific geographic region anymore and the five major CA-MRSA 
clones are disseminated worldwide: the USA 400 clone in Asia, Europe and 
the USA, the USA300 clone in the USA and Europe, the Southwest Pacific 
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clone in Australia, Europe and South America, the ST59-V clone in Asia 
and the USA and the European clone, ST80-IV in Europe, Asia and the 
Middle-East) (224, 233). 
Presently, more than 20 distinct genetic lineages of CA-MRSA are known 
(60, 68, 224, 366), however, their epidemicity varies. The USA300 is the 
most epidemic CA-MRSA clone, having been found in as many as 50 
different countries (244, 298). Moreover, USA300 is considered the cause 
of almost all CA-MRSA infections in USA (235), having quickly overcome 
the USA400 clone. In these last years, the pathogenic success of USA300 
in USA has been remarkable as it was able to spread rapidly within the 
community, to start severe outbreaks in terms of frequency and severity of 
infection and to emerge as the major cause of hospital associated 
infections in USA (97, 155, 220, 229, 235).  
 
7. CA-MRSA versus HA-MRSA strains - genotypic and phenotypic 
uniqueness  
Soon after its emergence, it was shown that CA-MRSA contain several 
interestingly features that distinguish them from HA-MRSA (346). 
CA-MRSA is generally considered more virulent than HA-MRSA (194, 354). 
The mechanisms underlying the high virulence of CA-MRSA are based on 
their efficient evasion of the host immune system (326). The capacity of 
CA-MRSA to evade or subvert host defenses is mainly due to the presence 
of mobile genetic elements, such as the phage-encoded Panton-Valentine 
leukocidin (PVL) (346), the arginine catabolic mobile element (ACME) (75, 
81, 112) and to the increased expression of virulence genes, carried by the 
accessory or adaptative genome, most importantly the ones coding for the 
phenol-soluble modulins (PSM) and the alpha-hemolysine (60, 194). 
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PVL is a S. aureus-specific exotoxin that forms pores in the cytoplasmic 
membrane of neutrophils, causing their lysis (197). This bi-component 
exotoxin is encoded by two co-transcribed genes, lukF-PV and lukS-PV 
(369), which are carried by staphylococcal temperate bacteriophages (162, 
163). PVL genes have been found in all CA-MRSA strains, namely in the 
ones associated with severe disease, in contrast to HA-MRSA, in which 
PVL is usually absent (109, 197, 229, 257, 346, 377). Therefore, PVL was 
initially considered to be the main cause of the increased virulence and - 
together with a specific genetic background and the presence of SCCmec 
types IV or V - a genetic marker for CA-MRSA (48, 58, 239, 338, 346).   
In addition to the pronounced virulence, common to all CA-MRSA, some 
particularly strains contain specific additional factors that contribute to their 
pathogenic success. For instance, the presence of the arginine catabolic 
mobile element (ACME) in the genome of the successful CA-MRSA 
USA300 clone is assumed to contribute to its growth, virulence and high 
capacity to spread. It contains two gene clusters, arc and opp-3, which 
encode for an arginine deiminase pathway and an oligopeptide permease 
system, respectively (75). While arc is responsible for the depletion of L-
arginine, which is involved in the production of nitric oxide, a molecule used 
in the innate and adaptive immune responses against bacterial infections 
(232), opp-3 belongs to the ABC transporter family, which members have a 
variety of biological functions such as quorum sensing, resistance to 
antimicrobial peptides, peptide nutrient uptake and chemotaxis (74).  
Regarding methicillin resistance, the structure of the SCCmec element 
differs in CA-MRSA and HA-MRSA strains. Commonly, CA-MRSA carry the 
smaller and potentially more mobile SCCmec types IV, V, VII (59, 151, 152, 
338, 346),  whereas HA-MRSA are typically associated with the largest 
chromosomal elements SCCmec type I-III (60). Consequently, CA-MRSA 
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strains are relatively susceptible to other antibiotics, and most are resistant 
only to β-lactams, since SCCmec types IV-VII do not carry ancillary 
resistance genes.  
On the other hand, as antibiotic resistance is associated to a fitness cost 
(6), which is easily attenuated by compensatory mutations in the bacterial 
genome (207), the different suitability caused by the diverse SCCmec types 
could influence the virulence of CA and HA-MRSA. In this context, it was 
recently demonstrated that SCCmec type II, but not the SCCmec type IV, 
has a significant cost for the bacteria, which results in a decrease in the 
growth rate, and in a reduction of the toxin production (49, 50). It appears 
that the balance between the costs of virulence and antibiotic resistance 
can explain why MRSA with attenuated virulence and SCCmec type II are 
found mainly in hospital environments where high antibiotic pressure, 
immunocompromised individuals and vector-mediated transmission are 
present. The low levels of antimicrobial agents used in the community 
favors the presence of MRSA harboring SCCmec type IV, which does not 
impose a high biological cost, allowing a more pronounced virulence.  
Additionally, the reduced virulence of HA-MRSA containing SCCmec type II 
can be explained by the high levels of mecA expression in HA-MRSA, in 
comparison to CA-MRSA with SCCmec type IV (301). It was previously 
observed that HA-MRSA with SCCmec type II tend to be more resistant to 
oxacillin than CA-MRSA containing SCCmec type IV (250), probably 
because they produce higher levels of PBP2A. In fact, it was later 
confirmed that the hospital-associated SCCmec type II strains are more 
resistant to oxacillin and produce higher concentrations of PBP2A than CA-
MRSA harboring SCCmec type IV (301). Consequently, the high levels of 
PBP2A production, by mecA gene on MRSA SCCmec type II, induce 
changes in cell wall that “disable” the strain to respond to the accessory 
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gene regulator (agr) auto-inducing peptide, reducing in this way the 
secretion of cytolytic toxins. In contrast, the same study showed that the 
toxicity CA-MRSA SCCmec type IV was not affected, probably due to their 
lower levels of PBP2A production. Therefore, the dual activity of mecA on 
antibiotic resistance and virulence regulation, has allowed CA-MRSA to 
maintain both virulence and antibiotic resistance and succeed where HA-
MRSA could not. 
Besides mecA, psm-mec, a cytolysin gene located in type-II and type-III 
SCCmec but not in type-IV SCCmec, connects virulence to methicillin 
resistance in MRSA (159, 281). It was shown that psm-mec RNA 
specifically binds agrA mRNA, a gene belonging to agr locus, inhibiting its 
translation (160). Since AgrA drives the transcription of RNAIII, the 
inhibition of its translation results in the suppression of virulence. Therefore, 
absence of psm-mec function in CA-MRSA, harboring SCCmec type IV, 
“explains” its high virulence property. 
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Abstract  
The glutamic acid residues of the peptidoglycan of Staphylococcus aureus 
and many other bacteria become amidated by an as yet unknown 
mechanism. In this communication we describe the identification, in the 
genome of S. aureus strain COL, of two co-transcribed genes, murT and 
gatD, which are responsible for peptidoglycan amidation. MurT and GatD 
have sequence similarity to substrate-binding domains in Mur ligases 
(MurT) and to the catalytic domain in CobB/CobQ-like glutamine 
amidotransferases (GatD). The amidation of glutamate residues in the stem 
peptide of S. aureus peptidoglycan takes place in a later step than the 
cytoplasmic phase – presumably the lipid phase - of the biosynthesis of the 
S. aureus cell wall precursor. Inhibition of amidation caused reduced 
growth rate, reduced resistance to beta-lactam antibiotics and increased 
sensitivity to lysozyme which inhibited culture growth and caused 
degradation of the peptidoglycan. 
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Introduction  
Peptidoglycan forms an essential stress-bearing and shape maintaining 
layer in the bacterial cell envelope. Its biosynthetic pathway is the target of 
important classes of antimicrobials such as beta-lactams and 
glycopeptides, and the polymerized cell wall is targeted by antimicrobial 
enzymes like lysozyme. The biosynthesis of peptidoglycan is a complex 
process involving several consecutive enzymatic steps that take place in 
the cytoplasm and on the inner and outer surface of the cytoplasmic 
membrane. The cytoplasmic stage of biosynthesis culminates in the 
formation of the UDP-N-acetylmuramic acid (UDP-MurNAc) covalently 
linked to a pentapeptide which is composed of L-alanine, D-iso-glutamic 
acid, L-lysine (or meso-diaminopimelic acid, DAP) and D-alanyl D-alanine. 
The assembly of this stem peptide moiety involves a superfamily of 
enzymes, the Mur ligases (22). In the next steps of biosynthesis, the UDP-
MurNAc-pentapeptide is attached to a membrane acceptor undecaprenyl 
phosphate (C55-P) followed by the addition of GlcNAc to the MurNAc 
residues yielding the structure known as lipid II. Lipid II, i.e., the 
bactoprenol linked disaccharide pentapeptide is then transported to the 
outer surface of the cytoplasmic membrane where it serves as a substrate 
for polymerization reactions catalyzed by transpeptidases and 
transglycosylases to form the polymeric cell wall peptidoglycan.  
Chemical analysis of the S. aureus peptidoglycan showed that the structure 
of these polymers differed from the structure of the cytoplasmic 
disaccharide pentapeptide cell wall precursor: some hydroxyl groups in the 
glycan chain were acetylated; and the second amino acid residue of the 
muropeptides was not isoglutamic acid but its amidated version, iso-
glutamine.  
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The mechanisms of these secondary modifications of the cell wall are not 
well understood. Enzymes and genetic determinants involved with the 
acetylation of the glycan chain and the role of this structural modification in 
the resistance of S. aureus against host lysozyme - have only been 
described recently (2).  
While amidation of the stem peptide residues at positions 2 or 3 or both is 
frequent among gram-positive bacteria, the physiological roles of this 
chemical modification have remained a matter of speculation (26) and the 
genetic determinants and enzymes responsible for the conversion of iso-
glutamic acid to iso-glutamine residues have also remained unknown.  
In this communication we describe the identification of a small operon 
composed of two genes – murT and gatD – in the genome of the beta-
lactam resistant S. aureus strain COL. Amino acid sequence of the protein 
products of these genes show similarity to murein ligases (murT) and to 
CobB/CobQlike glutamine amidotransferases (gatD). The properties of a 
conditional mutant of murT/gatD indicate that this operon is responsible for 
the conversion of isoglutamic acid to iso-glutamine residues in the 
peptidoglycan of S. aureus. 
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Materials and Methods 
Bacterial strains, plasmids, and growth conditions. Bacterial strains 
and plasmids used in this study are listed in Table 1. Staphylococcus 
aureus strains were grown at 37ºC with aeration in tryptic soy broth (TSB) 
or tryptic soy agar (TSA) (Difco Laboratories, Detroit, Mich.). Transposition 
mutant RUSA208 (19) and the conditional mutant strains 
RN4220pCadmurT-gatD and COLpCadmurT-gatD, the double mutant 
RUSA208pCadmurT-gatD, the complemented strains COLpCadmurT-
gatD+pSKmurT and COLpCadmurT-gatD+pSKgatD and the control strain 
COLpCadmurT-gatD+pSK were grown in the presence of the respective 
antibiotics (Table 1). The growth medium was supplemented with 0.2 µM of 
cadmium chloride (CdCl2; Sigma, St. Louis, MO), unless otherwise 
described. Escherichia coli strains (Table 1) were grown in Luria-Bertani 
broth (LB; Difco Laboratories) with aeration at 37ºC. Erythromycin (10 
µg/ml), neomycin sulphate (50 µg/ml), kanamycin (50 µg/ml), 
chloramphenicol (10 µg/ml) and ampicillin (100 µg/ml) from Sigma were 
used for the selection and maintenance of S. aureus and E. coli mutants. 
In silico analysis of the murT-gatD gene products. The amino acid 
sequences of ORFs SACOL1951 (MurT) and SACOL1950 (GatD) were 
retrieved from the UniProtKB database (25), and their domain architecture 
was checked using the InterProScan tool (28). The domains were aligned 
through TCoffee (18). Given the limited similarity between sequences, 
secondary structure inference was used as an independent benchmark for 
the alignment. This inference was accomplished through Psipred (4). 
Position specific annotation other than the one present in the InterPro 
documentation was collected from references (9, 22). 
DNA methods. Restriction enzymes from New England Biolabs (Beverly, 
MA) were used as recommended by the manufacturer. Routine PCR 
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amplification was performed with Tth DNA polymerase (HT Biotechnology, 
Cambridge, United Kingdom) and PCR amplification for cloning purposes 
was performed using Pfu DNA polymerase (Stratagene, Heidelberg, 
Germany). For plasmid DNA extraction High pure Plasmid Purification Kit 
(Roche, Basel, Switzerland) was used. PCR and digestion products were 
purified using High pure PCR Purification Kit (Roche). Ligation reactions 
were performed using Rapid DNA Ligation kit (Roche). 
Reverse transcription analysis. Reverse transcription (RT)-PCR was 
performed as described (24) using total RNA from strain COL as the 
template. The primers used for the reverse transcription reactions are 
described in Table S1 and the amplification conditions were: 94ºC for 2 
min; 40 cycles of 94ºC for 30 s, 53ºC for 30 s, and 72ºC for 2 min; and one 
final extension step of 72ºC for 5 min.  
Construction of pMurT’ plasmid. A 918- bp DNA fragment of murT gene 
was amplified by PCR using chromosomal DNA from strain COL as a 
template and the specific primers PmurT’-R and PmurT’-F (Table S1). The 
amplification conditions used were as follows: 94ºC for 4 min; 30 cycles, 
each consisting of 94ºC for 30 s, 50ºC for 30 s, and 72ºC for 1 min 30 s; 
and one final extension step of 72ºC for 10 min. The amplified fragment and 
the integrative plasmid pBCB20, carrying a cadmium chloride inducible 
promoter (R.G. Sobral and M.G. Pinho, unpublished) were both digested 
with SmaI and ligated, generating plasmid pMurT’. 
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Table 1. Strains and plasmids used in this study. 
Strain or plasmid  Description 
Source or 
reference 
Strains    
S. aureus  
RN4220 
 
Mc
s
; restriction negative 
 
(R. Novick) 
 
COL Homogeneous Mc
r
 (MIC, 1600 μg/ml); 
Em
s
 
Rockefeller  
University 
Collection 
RUSA208 COL with Tn551 insertion in glnR, Em
r
 (19) 
    
COLpCadmurT-gatD  COL with murT-gatD operon under Pcad 
control, Kan
r
, Neo
r
 
This study  
 
 
COLpCadmurT-gatD+ 
pSKmurT 
 
COLpCadmurT-gatD with pSK5632 
plasmid with murT gene, Kan
r
, Neo
r
, Cm
r
 
 
This study 
  
COLpCadmurT-gatD+ 
pSKgatD 
COLpCadmurT-gatD with pSK5632 
plasmid with gatD gene, Kan
r
, Neo
r
, Cm
r
 
This study 
COLpCadmurT-gatD+ 
pSK 
COLpCadmurT-gatD with pSK5632 
plasmid, Kan
r
, Neo
r
, Cm
r 
This study 
 
 
 
RUSA208pCadmurT-gatD COL with an insertion of Tn551 in glnR, 
Ery
r
 and
 
with murT-gatD operon  under  
Pcad control, Kan
r
, Neo
r
 
This study  
    
E. coli      
DH5α recA endA1 gyrA96 thi-1 hsdR17 supE44 
relA1 80 lacZM15 
Invitrogen 
Plasmids   
pBCB20  S. aureus integrative vector with Pcad 
inducible promotor, Ap
r
, Kan
r
 
R.Sobral and 
M.Pinho 
(unpublished) 
  
  
pMurT’ pBCB20 vector with murT rbs and the 
first 298 codons fused to Pcad promotor, 
Ap
r
, Kan
r
 
This study 
pSK5632 E. coli-S. aureus shuttle vector, Ap
r
,
 
Cm
r
 (10) 
pSKmurT 
 
pSK5632 vector with murT gene and 300 
bps of the immediately upstream region, 
Ap
r
, Cm
r
 
This study 
pSKgatD pSK5632 vector with gatD gene, Ap
r
, Cm
r
 This study 
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Construction of the conditional mutant. Plasmid pMurT’ was 
electroporated into competent cells of RN4220 with a Gene Pulser 
apparatus (Bio-Rad, California) under conditions described previously (15). 
Selection of the transformants was performed using kanamycin (50 µg/ml), 
neomycin sulphate (50 µg/ml) and 0.2 µM of Cadmium chloride. The correct 
insertion of pMurT’ into RN4220 chromosome was confirmed by PCR, 
using an internal murT primer chosen outside the region cloned and an 
internal pBCB20 primer (Table S1). The murT-gatD conditional mutation 
was then transduced, by phage 80α to the background of COL as 
previously described (20) and mutant COLpCadmurT-gatD was obtained. 
Construction of complemented strains. A 1673 bp DNA fragment, 
including the complete murT coding sequence and 300 bp of the immediate 
upstream region was amplified from COL genome using the primers 
PmurTSalI and PmurTBamHI (Table S1). The amplified murT fragment and 
plasmid pSK5632 (10) were digested with SalI and BamHI and ligated, 
generating the replicative plasmid pSKmurT. The same strategy was used 
for the construction of the replicative plasmid pSKgatD, in which a 1088 bp 
DNA fragment including the complete gatD gene sequence and 300 bp of 
the immediately upstream region. Plasmids pSKmurT and pSKgatD were 
separately introduced into RN4220 by electroporation and subsequently 
transferred to COLpCadmurT-gatD by transduction, generating 
COLpCadmurTgatD+pSKmurT and COLpCadmurT-gatD+pSKgatD, 
respectively. Plasmid pSK5632 was also introduced in the conditional 
mutant, providing the control strain COLpCadmurT-gatD+pSK.  
Construction of RUSA208pCadmurT-gatD double mutant. The murT-
gatD conditional mutation was transduced, using phage 80α, to the 
background of RUSA208. The obtained double mutant 
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RUSA208pCadmurT-gatD, has a transposon insertion in glnRA operon and 
the murT-gatD operon under the control of pCad promoter. 
Northern blotting analysis. Cells were grown in TSB at 37ºC to mid-
exponential phase (OD620 nm of 0.7). Prior to harvesting the cells, the 
RNA protect reagent (QIAGEN, Hilden, Germany) was added to the 
cultures. Total RNA was isolated as previously described (23). PCR 
amplified internal fragments of the murT, gatD, SACOL1949-SACOL1948, 
SACOL1952, glnA and pta genes were used as probes for hybridization 
(the primers used are listed in Table S1). The DNA probes were labeled 
with [a-32P]dCTP (Perkin Elmer, MA, USA). 
Cell wall isolation. Isolation of cell wall was performed as described (2, 6). 
Briefly, cells were harvested by centrifugation, washed twice with cold 0.9% 
NaCl, resuspended in 0.9% NaCl and boiled for 20 min. After chilling on 
ice, the suspension was centrifuged and washed twice with 0.9% NaCl. The 
cells were disrupted using 106 mm glass beads (Sigma) and FastPrep 
FP120 apparatus (Bio 101, La Jolla, Calif.), purified, washed, and boiled for 
30 min in 5% SDS, diluted in 50 mM Tris/HCl pH 7, to remove non-
covalently bound proteins. After centrifugation, the cell wall fragments were 
diluted in 0.1 M Tris-HCl (pH 6.8) and incubated with 0.5 mg/ml trypsin for 
16 h at 37ºC to degrade cell-bound proteins. Purified cell walls were 
washed with double-distilled water and lyophilized.  
Peptidoglycan purification. Lyophylised cell wall was treated with 49% of 
hydrofluoric acid for 48 hours at 4ºC in order to remove teichoic acids. The 
teichoic acid free peptidoglycan was washed with water several times to 
remove all traces of hydrofluoric acid and then lyophylised.  
Peptidoglycan analysis by RP-HPLC. Identical amounts of peptidoglycan 
were digested with mutanolysin (1 mg/ml; Sigma). The resulting 
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muropeptides were reduced with sodium borohydride and separated by 
reverse phase-high performance liquid chromatography (RP-HPLC) using a 
Hypersil ODS (Runcorn Cheshire, UK) column (3 mm particle size, 25064.6 
mm, 120 A ° pore size) and a linear gradient from 5% to 30% MeOH in 100 
mM sodium phosphate buffer pH 2.5 at a flow rate of 0.5 ml/min as 
described (7). 
Purification of monomeric muropeptides. Highly purified cell wall was 
prepared as previously described (2) and resuspended to a final 
concentration of 10 mg/ml. Cell wall material (500 µg) was digested with 
lysostaphin (300 µg) in 20 mM amonium acetate, pH 4.8, for 24 h at 37ºC 
with stirring. Subsequently, cellosyl (Hochst AG, Frankfurt, Germany) (15 
µg) was added to the reaction mixture which was incubated for 12 h at 
37ºC. Finally, additional 15 µg of cellosyl was added and the incubation 
continued for an additional 12 h. The enzymatic reaction was stopped by 
boiling the samples for 5 min and insoluble contaminants were removed by 
centrifugation. The digested cell wall was reduced with sodium borohydride 
and the resulting monomeric muropeptides were separated by RP-HPLC 
using a Prontosil (Bischoff, Leonberg, Germany) column (3 mm, particle 
size, 25064.6 mm, 120 A ° pore size), and a linear gradient from 0% to 30% 
MeOH in 10 mM sodium phosphate buffer pH 6.0 at a flow rate of 0.5 
ml/min. 
Mass spectrometry analysis of monomeric muropeptides. The eluted 
fractions corresponding to the most predominant peaks of the 
chromatograms were collected after HPLC separation, concentrated to 10–
20 µl, and acidified with 1% trifluoroacetic acid (TFA). The samples were 
then desalted and further concentrated using ZipTips (C- 18, Millipore, UK) 
according to the standard protocol recommended by the manufacturer. The 
material was eluted from the ZipTip with 3 µl of 50% acetronitrile, 0.1% TFA 
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and was sprayed directly into a Finnigan LTQ-FT mass spectrometer 
(Thermo, Bremen, Germany) operating in positive mode (Pinnacle 
Proteomics Facility, Newcastle University, UK) (5). 
Analysis of UDP-linked precursor pool. The UDP-linked peptidoglycan 
precursors from the cytoplasmic pool were isolated using a modified 
protocol (14). Briefly, vancomycin (Sigma) was added (at five times the 
minimal inhibitory concentration) to mid-exponential grown cultures and 
incubation proceeded for additional 30 minutes. The cultures were then 
chilled below 10ºC, cells were harvested, suspended in cold water and 
slowly stirred into the same volume of boiling water for 15 minutes. After 
centrifugation the supernatant was collected, lyophilized, dissolved in water 
and the pH was adjusted to 4.0 using 20% phosphoric acid. The 
suspension was again centrifuged and the pH of the supernatant adjusted 
to 2.0. The suspension was centrifuged at 4ºC for 1 h at 200000 g.  
The UDP-linked peptidoglycan precursors were separated through the 
same column used to separate the muropeptides of peptidoglycan – using 
a linear gradient from 0 to 30% of MeOH in 100 mM sodium phosphate 
buffer (pH 2.0), with a flow rate of 0.5 ml/min. Compounds to be analyzed 
by MS were isolated and desalted using the same column as before with a 
linear gradient from 0 to 30% of MeOH in 10 mM of sodium phosphate (pH 
4.3) for 25 min with a flow rate of 0.5 ml/min. Mass spectral data were 
obtained by MALDI-TOF analysis (Pinnacle Proteomics Facility, Newcastle 
University, UK). 
Growth curves. Overnight grown cultures of strains COL and 
COLpCadmurTgatD, COLpCadmurT-gatD+pSKmurT, COLpCadmurT-
gatD+pSKgatD and COLpCadmurT-gatD+pSK were diluted 1:1,000 into 
fresh TSB supplemented with the respective antibiotics (Table 1). The 
conditional mutants were grown in media containing CdCl2 concentrations 
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at 0, 0.01, 0.05 and 0.2 µM. The cultures were incubated at 37ºC with 
agitation and the OD620 nm was monitored over time. 
Determination of beta-lactam resistance. Overnight grown cultures of 
strains COL and COLpCadmurTgatD, COLpCadmurT-gatD+pSKmurT and 
COLpCadmurT-gatD+pSKgatD and COLpCadmurT-gatD+pSK were plated 
on TSA supplemented with increasing concentrations of CdCl2 (0, 0.01, 
0.05 and 0.2 µM) and incubated at 37ºC for 24 hours. Oxacillin (Sigma) 
diffusion disks (1 mg) were used to determine inhibition halos.  
Turbidometric assay of peptidoglycan hydrolysis. To analyze the 
susceptibility of peptidoglycan to lysozyme hydrolysis, a turbidometric 
assay was used as described (2, 12). Briefly, 0.5 mg of purified 
peptidoglycan from the conditional mutant, grown with and without CdCl2, 
were sonicated in 1 ml of 100 mM Sodium-Potassium phosphate buffer pH 
6.6. Human lysozyme or hen egg white lysozyme (Sigma) was added to a 
final concentration of 300 µg/ml and the reaction was incubated at 37ºC. 
The optical density was monitored at 660 nm.  
Determination of lysozyme and polymyxin resistance. The impact of 
lysozyme on exponential growth was determined as described (12). 
Overnight cultures of the conditional mutant grown with inducer were 
diluted to an OD620 nm of 0.1 in fresh TSB (with and without inducer). The 
cultures were incubated at 37ºC until an OD620 nm of 1.0. Then, each 
culture was diluted 1:10 into fresh TSB medium and lysozyme (300 µg/ml) 
was added at an OD620 nm of 1.0. The growth was monitored for several 
hours. The same procedure was done using 20 µg/ml of Polymyxin B 
(Sigma), a cationic antimicrobial peptide. 
 
Chapter II 
100 
 
Results 
The two open reading frames, SACOL1951 and SACOL1950, were 
automatically annotated in the genome of S. aureus strain COL as a 
putative Mur ligase family-like protein and a CobB/CobQ-like glutamine 
amidotransferase, respectively. The preliminary annotations of these 
genes, designated murT and gatD, respectively, suggested a role for their 
protein products in cell wall metabolism.  
murT and gatD genes are co-transcribed as a small operon. DNA 
sequence analyses of murT-gatD region suggested that murT and gatD are 
located in the same operon and might be co-transcribed from a common 
promoter: the murT stop codon and the gatD methionine codon are 
separated by 4 bp only; both genes are transcribed in the same direction 
and no promoter region sequence could be found upstream from gatD 
(Figure 1A). 
Reverse transcription-PCR (RT-PCR) was performed using total cDNA of 
strain COL with forward primers specifically binding to murT and a reverse 
primer specifically binding to gatD. The test yielded products of the 
expected size (Figure 1B, lanes C and D). No PCR product was obtained 
from the negative control using primers from the SACOL1949-1948 region, 
which was found by northern blotting not to be transcribed (Figure 1B, lane 
A). A PCR product of the expected size was obtained for the positive 
control, using primers internal to pta, a housekeeping gene. The results of 
the RT-PCR test indicated that both murT and gatD are co-transcribed from 
a common promoter. 
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Figure 1. RT-PCR amplification of the murT-gatD region. (A) S. aureus COL genome 
region encompassing murT and gatD genes and the vicinity regions. Fragments A, B, C, and 
D which were amplified by RT-PCR using primers from Table S1, are shown. (B) 
Amplification results by PCR using COL DNA and by RT-PCR using COL cDNA produced 
from a total RNA sample. A fragment from pta gene was used as a positive internal control. 
Fragment A was used as a negative control, as no transcript was detectable for SACOL1948 
and SACOL1949 by northern blotting (data not shown). 
The murT-gatD operon is a syntenic block. Analysis of genome 
sequences available showed that the murT and gatD genes occur, 
widespread among bacteria, as a syntenic block, although it is not a 
universal feature. This is in agreement with our RT-PCR results, which 
identified the two genes as a small operon. The distribution of this syntenic 
block among the prokaryotes, with emphasis on the Staphylococcaceae, is 
shown in Figure S1. 
Construction of a murT-gatD conditional mutant. In order to explore the 
functions of these uncharacterized genes we constructed a mutant strain 
containing a single chromosomal copy of murT-gatD under the control of an 
inducible promoter (pCad). A DNA fragment of murT gene which includes 
the first 298 codons and the ribosome binding site but not the promotor 
region, was cloned into the integrative plasmid pBCB20 (see Table 1). The 
recombinant plasmid was electroporated into RN4220 and the 
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chromosomal construct was transduced into the background of the MRSA 
strain COL. The only complete functional copies of murT and gatD genes 
were located immediately downstream from the pCad, generating mutant 
COLpCadmurT-gatD (Figure S2). Hence, this strain expresses the murT-
gatD genes when grown in the presence of Cd2+, and both genes are 
depleted when Cd2+ is absent from the growth medium (see below). 
Transcriptional analysis of the murT-gatD conditional mutant. Northern 
blotting assays were performed in order to confirm the specificity of 
transcription of the murT-gatD operon controlled by the CdCl2 concentration 
in the medium. The transcription of murT, gatD, SACOL1952 and 
SACOL1948-SACOL1949 genes was analyzed for COL and mutant 
COLpCadmurT-gatD grown with several concentrations of inducer. The 
level of murT and gatD transcription was found to increase with the inducer 
concentration in the medium (data not shown). No alterations were 
detected under the same conditions in the transcription level of the ORFs 
located in the immediate vicinity of the murT-gatD operon, SACOL1952 and 
SACOL1949-SACOL1948, which were found to be not transcribed even for 
strain COL (data not shown). The housekeeping gene pta was used as 
control. For strain COL, a single transcript was visualized for each gene: an 
mRNA structure of approximately 1780 nt long hybridized with murT probe 
and an mRNA structure of approximately 2300 nt long was obtained for 
hybridization with gatD probe. The size of this last transcript matches the 
size of both genes, consistent with their co-transcription. 
Abnormal peptidoglycan produced upon murT-gatD depletion. Cell 
walls of parental strain COL and of the conditional mutant, grown with and 
without Cd2+, were purified and digested with cellosyl and lysostaphin. The 
resulting monomeric muropeptides were reduced and analyzed by RP-
HPLC. The muropeptide profiles revealed that, when the transcription of 
 Identification of Genetic Determinants and Enzymes Involved with the Amidation of 
Glutamic Acid Residues in the Peptidoglycan of Staphylococcus aureus 
                                                                                   
103 
 
murT-gatD operon was inhibited, two new muropeptide structures appeared 
in the RP-HPLC profile (Figure 2A – peaks V and VI). These two 
muropeptide species showed shorter retention times than peak I, which is 
common to all the profiles. To identify the structural modifications, all peaks 
annotated in Figure 2A were isolated and analyzed by MS. The MS results 
(Table 2) indicate that the two new peaks (V and VI) observed in the profile 
of the murT/gatD depleted cells corresponded to muropeptide structures 
with D-iso-glutamate in the stem peptide replacing D-iso-glutamine. Peaks 
I, II, III and IV correspond to muropeptide structures with D-iso-glutamine 
(Figure 2B). Amidated muropeptides (Peak I) were still present when the 
transcription of murT-gatD operon was inhibited. This could be due to the 
activity of MurT and GatD expressed by residual transcription from the 
pCad promoter or to the presence of other enzymes with the same activity. 
These findings identify the protein products of murT-gatD as essential for 
the full amidation of the Dglutamic acid residues in the S. aureus 
peptidoglycan. 
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Figure 2. RP-HPLC profiles of cell walls of strains COL and the conditional mutant. (A) 
RP-HPLC profiles of cell walls prepared from strains COL and COLpCadmurT-gatD mutant 
grown with and without 0.2 µM of CdCl2. The cell walls were purified and digested with 
cellosyl and lysostaphin and the resulting muropeptides were reduced and analyzed by RP-
HPLC. Fractions eluting at 50.73 min (peak I), 52.42 min (peak II), 54.10 min (peak III), 
56.13 min (peak IV) in COL strain, and eluting at 47.00 min (peak V) and 48.33 min (peak 
VI) in COLpCadmurT-gatD, grown without the inducer, were collected and analyzed by 
mass spectrometry. (B) Proposed structures for the muropeptides corresponding to peaks I, 
II, III, IV, V and VI. Structures with different numbers of glycine residues associated with the 
D-Ala and L-Lys of the stem peptide, were identified for each peak. The mass of the 
analyzed compounds are presented in Table 2. 
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Table 2. Reduced monomeric muropeptides in HPLC fractions analyzed by LTQ-
FT mass spectrometry. 
 
Peak 
Nº 
Proposed muropeptide 
structure(s)
1
 
Theoretical 
neutral mass (Da) 
Determined 
neutral 
mass(Da) 
 
 
I
a 
Tetra(Gln)Gly3 
Tetra(Gln)Gly4 
Tetra(Gln)Gly5 
Tetra(Gln)Gly6 
Tetra(Gln)Gly7 
1067.4983 
1124.5197 
1181.5412 
1238.5626 
1295.5841 
1067.5227 
1124.5410 
1181.5290 
1238.5933 
1295.6296 
 
 
II
b 
Penta(Gln)Gly2 
Penta(Gln)Gly3 
Penta(Gln)Gly4 
1081.5139 
1138.5354 
1195.5568 
1081.5242 
1138.5427 
1195.5806 
 
III
b 
Penta(Gln)Gly3 
Penta(Gln)Gly4 
1138.5354 
1195.5568 
1138.5423 
1195.5801 
 
 
IV
b 
Penta(GlcNAc)(Gln)Gly2 
Penta(GlcNAc)(Gln)Gly3 
Penta(GlcNAc)(Gln)Gly4 
1284.5933 
1341.6147 
1398.6362 
1284.6128 
1341.6536 
1398.6787 
 
 
V
c 
Tetra(Glu)Gly3 
Tetra(Glu)Gly4 
Tetra(Glu)Gly5 
1068.4823 
1125.5037 
1182.5252 
1068.4794 
1125.5191 
1182.4912 
    
VI
c 
Penta(Glu)Gly2 
Penta(Glu)Gly3 
1082.4979 
1139.5194 
1082.5122 
1139.5170 
1
 Muropeptides with main MS intensities are in bold. 
a  
Structures found in strain COL and in COLpCadmurT grown with 0 and 0.2 µM CdCl2. 
b  
Structures found in strain COL and in COLpCadmurT grown with 0.2 µM CdCl2. 
c  
Structures found in COLpCadmurT with 0 µM CdCl2.  
 
Comparison of the peptidoglycan composition of the murT-gatD 
mutant and glnRA mutant. The cell walls of the parental strain COL and 
the conditional mutant COLpCadmurT-gatD grown with different 
concentrations of inducer were extracted, the peptidoglycan purified, 
digested with muramidase and the muropeptides analyzed by RP-HPLC 
(Figure 3A). The elution profile of the conditional mutant grown in the 
absence of CdCl2 showed longer retention times for all peaks, when 
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compared with COL. In addition, the peaks corresponding to muropeptide 
structures with higher oligomerization level (retention time over 60 min) 
were split into two or more smaller peaks eluting at very similar retention 
times. The elution profiles of the mutant grown with 0.01 µM and 0.05 µM of 
CdCl2 showed gradual re-establishment of the parental muropeptide 
pattern. For cells grown in 0.2 µM CdCl2 supplemented medium, the 
optimal inducer concentration, the peptidoglycan HPLC profile was 
indistinguishable from that of strain COL. The muropeptide elution profile of 
COLpCadmurT-gatD, grown in the absence of inducer, showed similarities 
to the elution profile of the previously characterized glnRA transposition 
mutant RUSA208 (19) (Figure 3B). In RUSA208, the transposon inserted 
into the glnR gene which codes for the repressor of the glutamine 
synthetase operon glnRA, resulting in the abolishment of glnA transcription. 
The impact of the glnRA mutation on the peptidoglycan of RUSA208 has 
been described as the substitution of the normal D-iso-glutamine residues 
by D-iso-glutamic acid at position 2 of the stem peptide (19). Substitution of 
iso-glutamine by iso-glutamic acid residues has been observed among 
muropeptide monomers (Peak 5A in Figure 3B), among dimeric 
muropeptides (Peaks 11A & 11B in Figure 3B), among the tripeptide 
structures (Peak 15B in Figure 3B) and among three of the stem peptides 
represented by peaks 15A, B & C in Figure 3B. All these structures are also 
present in the conditional mutant COLpCadmurT-gatD grown in the 
absence or at suboptimal concentrations of the inducer (see Figure 3A). 
The glnA gene sequence in COLpCadmurT-gatD was identical to that in 
strain COL, excluding the possibility that a mutation in glnA causes the 
deficiency in peptidoglycan amidation as it occurs in RUSA208 strain. Also, 
the transcription of the glnA gene did not vary with the Cd2+ concentration 
in COLpCadmurT-gatD (data not shown) discarding the hypothesis that 
murT and/or gatD may indirectly reduce glnA transcription.  
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The peptidoglycan profiles of RUSA208 and COLpCadmurTgatD grown 
with no CdCl2, showed that amidation of the muropeptides still occured 
partially. This may be due to a leaky expression of murT-gatD operon 
through pCad promoter in the absence of CdCl2. In the case of RUSA208, 
other sources of amino group, besides glutamine, may be used, although 
less efficiently. 
The peptidoglycan HPLC profile of the double mutant RUSA208pCadmurT-
gatD showed a virtually complete lack of amidated muropeptides (Figure 
3A), indicating that the gene products of these two operons are together 
needed for the amidation of the glutamic acid residue of the peptidoglycan. 
Complementation of the murT-gatD conditional mutation. The 
transcriptional analysis showed that the expression of both murT and gatD 
genes is being controlled in COLpCadmurT-gatD mutant, through the 
concentration of inducer added to the medium. For this reason we 
constructed two independent complementation mutants, COLpCadmurT-
gatD+pSKmurT and COLpCadmurT-gatD+pSKgatD, by separately 
introducing into the COLpCadmurT-gatD mutant, the replicative plasmid 
pSK5632 with either the murT or the gatD gene. Cloning of the murT-gatD 
operon into pSK5632 was also attempted, but this construct did not yield 
viable E. coli transformants. Strain COLpCadmurTgatD+pSK harboring 
pSK5632 with no cloned gene was constructed and used as control. 
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Figure 3. RP-HPLC cell wall profiles. The purified peptidoglycan was digested with 
mutanolysin, reduced and analyzed by RP-HPLC. (A) muropeptide profiles of strains COL, 
RUSA208pCadmurT-gatD, grown without CdCl2, and COLpCadmurT-gatD grown with 0, 
0.01, 0.05 and 0.2 µM of CdCl2. (B) muropetide profiles of strains COL, RUSA208. The 
muropeptide structures corresponding to peaks 5, 5A, 11, 11A, 11B, 15, 15A, 15B and 15C 
were inferred from mass spectrometric analysis (19). 
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Re-establishment of the normal peptidoglycan composition in the 
murT-gatD complementation. With the two complementation strains 
available, we obtained three distinct levels of re-establishment of the 
normal peptidoglycan: i) the in trans complementation with several copies 
of the murT gene showed a partially restored peptidoglycan with a small 
amount of muropeptides containing glutamic acid residues 
(COLpCadmurT-gatD+pSKmurT – 0 µM CdCl2, Figure S3A); ii) the in trans 
complementation with several copies of gatD gene showed no re-
establishment of the normal peptidoglycan profile (COLpCadmurT-
gatD+pSKgatD – 0 µM CdCl2, data not shown); iii) the in trans 
complementation with several copies of the murT gene and sub-optimal 
expression of the chromosomal copy of murT-gatD operon showed 
complete restoration of the peptidoglycan profile (COLpCadmurT-
gatD+pSKmurT – 0.01 µM CdCl2, Figure S3B). In the latter case (iii), the 
0.01 µM CdCl2 of added inducer is responsible for providing a sub-optimal 
number of copies of murT-gatD transcripts, adding to the already available 
copies of murT transcript provided in trans. The few copies of gatD 
provided in this condition are enough for a complete reestablishment of the 
normal peptidoglycan composition. Thus, complementation of the murT-
gatD-depletion phenotype requires the expression of murT and at least a 
basal level of gatD. 
Composition of cell wall precursor pool of COLpCadmurT-gatD 
mutant. In order to identify the biosynthetic stage at which amidation 
occurred, the cell wall precursor pool was analyzed by RP-HPLC from 
strains COL and for the murT-gatD conditional mutant grown with and 
without the inducer. The HPLC profiles were identical for the three 
conditions analyzed (Figure S4). The major peak, eluting at 38 minutes, 
was isolated from the cytoplasmic fractions of COL and of the murT-gatD 
conditional mutant grown with and without the inducer. The corresponding 
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structures were analyzed by MALDI-TOF MS. The results indicated an 
identical molecular mass of 1149.35 (neutral mass) for each of the three 
samples, consistent with the structure of the UDP-MurNAc-L-Ala-D-iGlu-L-
Lys-D-Ala-D-Ala, the last cytoplasmic precursor. The presence of D-iso-
glutamate in these three structures indicated that the conversion of 
glutamic acid to iso-glutamine residues must occur at a later stage of cell 
wall precursor biosynthesis – most likely in the lipid phase – confirming an 
earlier finding (21). 
Properties of the conditional mutant.  
Deficit in growth rate. The murT-gatD depleted cells had normal 
morphology as examined by electron microscopy (data not shown) but their 
growth rate was greatly reduced, indicating that the amidation of 
peptidoglycan is required for normal growth. COLpCadmurT-gatD was 
unable to grow on solid medium in the absence of Cd2+. In liquid medium 
the growth rate was significantly reduced in the absence of Cd2+, and it 
increased with the concentration of inducer added to the medium (Figure 
4A and 4B). The growth rate of the COLpCadmurT-gatD+pSKmurT strain in 
the absence of inducer was higher than the growth rate of the control strain 
COLpCadmurT-gatD+pSK, although a complete restoration could not be 
obtained. In contrast, the growth rate of the COLpCadmurT-gatD+pSKgatD 
strain was lower than that of the control strain COLpCadmurT-gatD+pSK 
(Figure 4C). This behavior was more obvious when the strains were grown 
in solid medium (Figure 4D). 
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Figure 4. Growth rate of the conditional mutant at different concentrations of CdCl2. 
(A) Growth curves of strains COL (black diamond), and the COLpCadmurT-gatD conditional 
mutant in TSB supplemented with (black triangle) 0 µM of CdCl2 and (white square) 0.2 µM 
of CdCl2. (B) Growth on solid medium with or without supplementation of 0.2 µM CdCl2 of 
COLpCadmurT-gatD. (C) Growth curves in liquid medium supplemented with Cm (10 µg/ml) 
of the complementation mutants COLpCadmurT-gatD+pSKmurT with 0.2 µM CdCl2 (white 
circle) or without CdCl2 (black circle), COLpCadmurTgatD+pSKgatD with 0.2 µM CdCl2 
(white triangle) or without CdCl2 (black triangle), and the control strain 
COLpCadmurTgatD+pSK with 0.2 µM CdCl2 (white line) or without CdCl2 (black line). (D) 
Growth on solid medium, with or without supplementation of 0.2 µM CdCl2, of the 
complementation strains COLpCadmurT-gatD+pSKmurT, COLpCadmurT-gatD+pSKgatD, 
and the control strain with the plasmid pSK5632, COLpCadmurT-gatD+pSK. 
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Decrease in beta-lactam resistance. The oxacillin resistance level of 
COLpCadmurT-gatD was found to depend on the inducer concentration: as 
the CdCl2 concentration was reduced, the size of the growth inhibition halos 
increased (Figure 5A). In the presence of 0.2 µM of CdCl2, the resistance 
phenotype was identical to that of COL. COLpCadmurTgatD+pSKmurT, 
grown in the absence of inducer, completely reestablished the parental 
phenotype (data not shown). 
Increased sensitivity to lysozyme. The murT-gatD depleted cells of 
COLpCadmurT-gatD grown in the absence of Cd2+ were sensitive to 
human lysozyme (Figure 5B), while the same cells grown in the presence 
of Cd2+ were lysozyme resistant, as was the parental strain COL (data not 
shown), indicating that peptidoglycan amidation is required to express 
lysozyme resistance. By contrast, murT-gatD depleted cells did not show 
diminished resistance to the cationic antimicrobial peptide polymyxin B 
(data not shown). Next, the sensitivity to lysozyme of peptidoglycan of the 
conditional mutant grown in the absence and presence of inducer were 
compared. After an incubation period of 60 minutes, lysozyme was able to 
hydrolyse 46% of peptidoglycan from the conditional mutant grown in the 
absence of inducer. For the mutant grown with inducer, less than 20% of 
peptidoglycan was hydrolysed (Figure 5C). MurT-gatD-depleted cells and 
peptidoglycan isolated from them showed also increased susceptibility to 
hen egg white lysozyme (data not shown). 
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Figure 5. Reduced antibiotic resistance and increased sensitivity to lysozyme in the 
conditional mutant. (A) Oxacillin inhibition halos (1-mg oxacillin disks) were determined for 
COL and COLpCadmurT-gatD mutant grown with 0, 0.01, 0.05 and 0.2 µM of CdCl2. At the 
right hand side of each dish is the diameter of the respective inhibition halo in mm. (B) Effect 
of human lysozyme on the growth rate of: COLpCadmurT-gatD grown with 0.2 µM of CdCl2 
(black diamond), COLpCadmurT-gatD grown with 0.2 µM of CdCl2+lysozyme (white 
diamond), COLpCadmurT-gatD grown with 0 µM of CdCl2 (black triangle), COLpCadmurT-
gatD grown with 0 µM of CdCl2+lysozyme (white triangle). Human lysozyme was added (300 
µg/ml) at an OD620 nm of 1.0 for all strains (arrow). (C) Effect of human lysozyme (300 
µg/ml) on peptidoglycan purified from COLpCadmurT-gatD grown with 0.2 µM of CdCl2 
(black diamond), or COLpCadmurT-gatD grown with 0 µM of CdCl2 (white triangle). 
Amino acid sequence analysis of MurT and GatD. MurT shares 
approximately 15% identity and 53% similarity with the sequence of the Mur 
ligases of S. aureus. Interestingly, while MurT shares the characteristic Mur 
ligase central domain (17, 22) as defined at InterPro (IPR013221), Pfam 
(PF08245) and Panther (PTHR23135) MurT lacks the flanking N- and C-
terminal domains (Figure S5A). 
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Among the conserved residues were some critical motifs required for ATP 
and Mg2+ binding and other conserved sites that may not be directly 
involved in catalysis (Figure 5A). In addition, the MurT protein has a C-
terminal domain of unknown function (Pfam: DUF1727, InterPro: 
IPR013564), which is also found at the C-terminus of more than 900 
sequences of prokaryotic proteins at UniProt, and in 5 different domain 
architectures, all of them sharing the same ORF, or in contiguous ORFs, 
with Mur central domain (PF08353). GatD shows similarity to one of the two 
domains of a cobyric acid synthetase protein: a glutamine-dependent 
amidotransferase (Gn-AT), with glutamine amide transfer (GAT) activity. Its 
architecture comprises the overlapping domain signatures of 
CobB/CobQ_GATase (InterPro: IPR017929), and GATase_3 (InterPro: 
IPR011698) domains. Through multiple sequence alignment of the N-
terminal region of three known Gn-ATs, the absence of a large fragment 
was noted in GatD (Figure S5B). This missing fragment included important 
residues for the dethiobiotin synthase activity (9) and part of the ATP 
binding motif. By placing the representation of the secondary structures 
over the sequence alignment, we can observe considerable agreement 
between the shared regions, especially near the reactive center of 
GATase_3 (Figure S5B). This domain harbored the conserved residues 
directly involved in GAT activity, according to IPR011698. GatD was also 
found to contain the unusual Triad family glutamine amidotransferase 
domain with conserved Cys and His residues (Figure S5B), but lacking the 
Glu residue of the catalytic triad, as the CobB and CobQ proteins (9). 
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Discussion 
The basic structure of S. aureus peptidoglycan is known to undergo at least 
two major secondary modifications, the O-acetylation of the free OH groups 
in the glycan strand and the amidation of the c-carboxyl group of the 
second residue of the stem peptide, D-iso-glutamate, resulting in the 
formation of D-isoglutamine. O-acetylation of the S. aureus peptidoglycan 
confers lysozyme resistance to the bacteria and its main genetic 
determinant, the oatA gene has been identified and characterized recently 
(2). 
In contrast, the mechanism of the amidation of glutamic acid residues has 
remained unknown. 
In this communication we report the identification of two genetic 
determinants – murT and gatD – in the genome of S. aureus strain COL - 
that are required and sufficient for peptidoglycan amidation. A conditional 
mutant constructed for these two genes, showed abnormal peptidoglycan 
composition, with decreased amidation of the glutamate residue. The 
characterization of a double mutant in which not only the expression of 
murT-gatD operon is inhibited but also the operon glnRA, responsible for 
providing glutamine substrate, is impaired, allowed us to infer that murT 
and gatD are the key determinants for the amidation of S. aureus 
peptidoglycan. 
Furthermore, through the analysis of the precursor pool composition of the 
mutant strain we showed that this modification step does not occur in the 
cytoplasm and most probably takes place at the membrane level, 
confirming previous observations (21). 
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Other phenotypes associated with murT-gatD mutation are decreased 
growth rate, decreased resistance to beta-lactams and to lysozyme 
hydrolysis. The strong impact on growth rate suggests that an amidated 
peptidoglycan may provide better substrates for proteins that catalyze 
peptidoglycan biosynthesis and cell division. Lack of the amide group may 
create an unbalance between the synthetic and the hydrolytic machineries 
of the cell. Electron microscopy pictures of the conditional mutant showed 
cells with normal size. However, fewer cells showed complete septa, 
suggesting slower biosynthesis of the septum (data not shown). 
The amidation of glutamic residues had already been shown to have a 
major impact on the expression of beta-lactam resistance, through the 
femC (glnRA) mutant of MRSA (11). Consistent with this result, the 
depletion of murT-gatD also shows a major decrease in the oxacillin 
resistance level. The mechanism of this effect is not well understood (8).  
However, similar effects were already described for several other genes (8) 
many of them related to peptidoglycan biosynthesis. One of the existing 
theories is that the structurally abnormal lipid II or cell wall peptides are 
poorer substrates for PBP2A. 
More unexpectedly, another feature observed in this mutant was the 
decrease of resistance to lysozyme action. Lysozyme belongs to the innate 
immune response and acts on bacteria by hydrolyzing the b-1,4 glycosidic 
bonds between the two sugar molecules of the glycan strands of 
peptidoglycan (muramidase activity). Several cell wall modifications have 
been implicated in the lysozyme resistance mechanism of S. aureus, 
namely the O-acetylation in the C-6 position in the MurNac (2) and the 
presence of wall teichoic acids (1). 
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Firstly, we observed in vivo, that the mutant cells grown in the absence of 
inducer were susceptible to lysozyme action, as the growth was impaired. 
Besides muramidase activity, lysozyme has also cationic antimicrobial 
peptide (CAMP) activity (12). The enhanced inhibitory action of lysozyme 
towards the mutant could be associated with either one of the two activities 
or both. However, we did not observe any effect of polymyxin B, a CAMP, 
on the growth rate of the mutant, indicating that glutamate amidation is 
important to prevent the muramidase activity of lysozyme. This effect could 
be a direct consequence of glutamate amidation or an indirect effect 
associated with changes in O-acetylation of the MurNac and/or in wall 
teichoic acids (WTA). For the mutant grown in the absence of inducer, the 
purified peptidoglycan, which lacks O-acetyl groups and WTA, suffered 
faster hydrolysis by lysozyme than normally amidated peptidoglycan. These 
observations allowed us to conclude that glutamate amidation is one of the 
key factors for lysozyme resistance in S. aureus. 
The role of glutamate amidation has already been described in the context 
of pathogenesis. Peptidoglycan is sensed by the human innate immune 
system via NOD1 and NOD2 (3); NOD1 recognizes as minimal structure 
the D-Glu-meso-DAP dipeptide, typical of Gram-negative bacteria, and is 
impaired by D-isoglutamine presence suggesting the involvement of this 
modification in immune evasion. However, the same was not observed for 
NOD2, whose binding activity to muropeptides is not affected by the 
amidation of glutamic acid (27). Also, this modification did not induce 
cytokine production, indicating that it is not involved in the modulation of 
pro-inflammatory capacity (16). 
Amidation of peptidoglycan glutamic acid residue is common to many 
bacterial species – not all pathogenic (Figure S1) – suggesting additional 
physiological roles for this modification. One role of amidation could be to 
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reduce the number of cell wall carboxylate groups that have recently been 
implicated together with wall teichoic acid phosphate residues to 
cooperatively bind divalent cations like Mg2+ or Mn2+ (13).  
A model for the cooperative functions of MurT and GatD. The murT-
gatD operon emerged as a syntenic block that seems to be widespread 
among bacteria. Interestingly, for the distant taxa of Actinobacteria, in some 
rare cases, the two ORFs are merged into a single one (Figure S1). 
The genome co-localization of the two determinants, together with data 
from sequence analysis, led us to suggest a model for the coordinated 
function of MurT and GatD proteins in the peptidoglycan glutamate 
amidation (Figure 6). 
Both proteins together harbor all domain functions required for amidation of 
peptidoglycan precursor: MurT may be responsible for the recognition of 
the reaction substrates, the lipid-linked peptidoglycan precursor and ATP, 
while GatD could be the catalytic subunit involved in the transfer of the 
amino group from free glutamine to the peptidoglycan precursor. The GatD 
sequence lacks an ATP binding motif which is common to all members of 
the Gn-AT family suggesting an activity that depends on the MurT protein 
which exhibits a typical Mur ligase central domain including the ATP 
binding motif (Figure 6). 
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Figure 6. Protein regions necessary for the cooperative function of MurT and GatD 
proteins. The top panel represents the general topology of Mur ligase family proteins, with 
three domains. The only domain showing homology with MurT is the central domain 
involved in nucleotide binding. The conserved motifs for ATP-binding are indicated by red 
boxes. The lower panel represents the modular structure of Gn-ATs, with a synthase domain 
and a GAT domain which has glutaminase activity motifs (yellow boxes) and ATP-binding 
motifs (red boxes). GatD only shares the glutaminase motifs. 
 
Experiments are in progress to better define the roles of MurT and GatD 
proteins in the mechanism of amidation of S. aureus peptidoglycan 
precursor. Irrespective of mechanistic details, the results with the 
conditional mutant of murT/gatD clearly indicate that the amidation of 
glutamic acid residues in the S. aureus peptidoglycan is catalyzed by the 
concerted action of these two enzymes. The murT-gatD operon appears to 
be the last missing genetic determinant to account for the structural 
variation in the S. aureus peptidoglycan. 
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Supplementary Information 
 
Supplementary Tables 
 
Table S1. Primers used in this study. 
   Primer          Sequence (5' - 3')
a
 
Source or  
reference  
Amplification of Transcripts (RT-PCR)  
P1949-R1 CTCTGAACATCGCATCAATGG This study 
P1948-R1 CGGGATCCCTAAACTACGGAGGGATGTG This study 
PmurT-D1 CTTCGGTGAAATTGATATTATGG This study 
PmurT-XR1 ATTGATCATCGCTTCTTTTCG This study 
PgatD-R1 GTGGAAGTGATAGAGAACAAGC This study 
PSK50f ACGCGTCGACGAACAATTAGAAGGCGA This study 
PmurT-D2 TATACATCAGACAATGGTCG This study 
PgatD-XR1 GCGCCTCGAGCGAGATTTCTTCTGTC This study 
   
Construction of the conditional mutant   
PmurT
'
F TCCCCCGGGCGAGTGGAAATTTGAGGAGG This study 
PmurT
'
R CGAGATCTGACCATTGTCTGATGTATACG This study 
PmurT-R1 GTTCTCTATCACTTCCACCACC This study 
PmurT-R2 GTGTTGATTGCATGATGAATGC This study 
PcadF GCACTTATTCAAGTGTATTT Novick 
PcadR GTTCAGACATTGACCTTCAC Novick 
   
Amplification of DNA probes (Northern blotting)  
PmurT-D TCCCCCGGGCGAGTGGAAATTTGAGGAGG This study 
PmurT-R CGAGATCTGACCATTGTCTGATGTATACG This study 
PgatD-D GTGGAAGTGATAGAGAACAAGC This study 
PgatD-R GAATACCCTTACGTTCACAAGC This study 
P1952-D GAATGTACGAGCGCCAAGTTC This study 
P1952-R CAATGGCAGCATACTGTGATAAAG This study 
                                                                                                    Continued in the next page. 
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Table S1. Primers used in this study (cont.). 
Primer          Sequence (5' - 3')
a
 
Source or  
reference  
FemC-D CTGGACAAGGTAAAGTTGCACG This study 
FemC-R CTAGTCCAGCTTCTAAGATTGC This study 
  
Construction of the complementation mutants  
PmurTSalI ACGCGTCGACATATGCGTGTGCTGC This study 
PmurTBamHI CGGGATCCATATTATGATTGACCTCCTTCAAAC This study 
PgatDSalI ACGCGTCGACGAACAATTAGAAGGCGA This study 
PgatDBamHI CGGGATCCAAATCCATTGATGCG This study 
a 
The restriction sites included in the primers are underlined and the putative ribosome binding site is 
indicated in boldface type. 
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Supplementary Figures 
 
 
Figure S1. Distribution of murT/gatD (red) among prokaryotes. Bacillaceae is depicted 
in magenta because only one species has the pair. In grey are the taxonomic groups for 
which no sequence information is available. Actinobacteria present three cases of fused 
ORFs. The tree representation was built with the help of iTOL (http://itol.embl.de/), and it is 
based on the structure of the NCBI Taxonomy hierarchy. It should not be considered as a 
proper phylogenetic tree. 
 
Chapter II 
126 
 
 
 
Figure S2. Construction of the murT-gatD conditional mutant. A 918 bp DNA fragment 
containing the ribosome binding site and the 5' sequence of SACOL1951 ORF was cloned 
downstream from pCad promoter. The resulting plasmid, pMurT', was introduced into S. 
aureus RN4220 by electroporation and integrated into the chromosomal SACOL1951-1950 
region by Campbell type recombination. The only complete copy of murT-gatD operon is 
under the control of the pCad promoter, in the COLpCadmurT-gatD conditional mutant. 
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Figure S3. RP-HPLC profiles of purified peptidoglycan digested with mutanolysin. (A) 
Comparison of peptidoglycan elution profiles of strains COL, mutant COLpCadmurT-gatD 
grown without inducer and the complementation strain COLpCadmurTgatD+pSKmurT grown 
without inducer. The complementation strain shows partial re-establishment of the abnormal 
amidation level. (B) Comparison of peptidoglycan elution profiles of strains COL, mutant 
COLpCadmurT-gatD grown without inducer, with sub-optimal inducer concentration (0.01 
µM of CdCl2) and the complementation strain COLpCadmurT-gatD+pSKmurT grown with 
0.01 µM of CdCl2 and with 0.2 µM of CdCl2. The complementation strain grown with sub-
optimal inducer concentration shows complete re-establishment of the abnormal amidation 
level. 
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Figure S4. RP-HPLC profiles of UDP-linked precursor pools. The UDP-linked precursor 
pools of the strain COL and COLpCadmurT-gatD grown with or without 0.2 µM of CdCl2. 
The major precursor structure (elution time of 38.0 min) was identified by mass spectrometry 
as UDP-MurNAc-L-Ala-D-iGlu-L-Lys-DAla-D-Ala. 
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Figure S5A. Structure-informed aminoacid sequence alignments. Sequence alignment 
of the central domain of Mur ligases. Residues involved with the nucleotide binding of four 
known S. aureus COL Mur ligases and MurT are labelled TP (ATP triphosphate), Mg1 and 
Mg2 (magnesium), A (adenine), and Ri (ATP ribose). The residue labelled C is the 
carbamoylated lysine residue observed in all the Mur enzymes except MurC; in this enzyme 
a glutamate residue, indicated with an asterisk (*) seems to play the same role in Mg2 
coordination. The initial alignment was performed by TCoffee (2), the secondary structure 
was inferred for all sequences through Psipred (1), and the alignment was manually edited 
according to the latter.SACOL1951-MurT; SACOL1790-MurC; SACOL1196-MurD; 
SACOL1023-MurE; SACOL2073-MurF. In the top line a-helixes (green cylinders) and b-
strands (orange arrows) were inferred for the sequences of the known Mur ligases. 
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Figure S5B. Structure-informed aminoacid sequence alignments. Sequence alignment 
of the N-terminal halves of three known GATases. The residues involved in nucleotide 
binding of S. aureus COL GatD and three known GATases are indicated with a filled red box 
and are labelled TP (ATP triphosphate). Residues in green boxes marked with DS are 
deemed important for the dethiobiotin synthetase activity. The residues in the filled box 
labelled C are annotated as being directly involved with reactive center according to the 
GATase 3 (IPR011698) domain documentation. The initial alignment was performed by 
TCoffee (2), the secondary structure was inferred for all sequences through Psipred (1), and 
the alignment was manually edited according to the latter.GatD-Q5HEN2_STAAC (S. 
aureus); COBB_BACME (Bacillus megaterium); COBB_METJA (Methanocaldococcus 
jannaschii); COBB_PSEDE (Pseudomonas denitrificans). In the top line a-helixes (green 
cylinders) and b-strands (orange arrows) were inferred for the sequences of these three 
known GATases. In the bottom line, the same information is shown for GatD. 
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Abstract 
The peptidoglycan of Staphylococcus aureus is virtually free of carboxyl 
groups due to the amidation of the α-carboxyl group of D-glutamate at 
position 2 of the stem peptide, resulting in the formation of D-isoglutamine. 
Recently, the murT-gatD operon was identified as the genetic determinant 
responsible for the amidation of D-glutamate. The MurT and GatD proteins 
have sequence similarity to the highly conserved central domain of Mur 
ligases and to the catalytic domain in CobB/CobQ-like glutamine 
amidotransferases, respectively. In the present study, we describe the co-
purification of MurT and GatD recombinant proteins from a vector 
expressing both murT and gatD genes and provide evidence indicating that 
these proteins interact, forming a stable enzymatic complex. In vitro 
analysis of lipid II amidation, using purified GatD and MurT-GatD 
recombinant proteins, demonstrated that both proteins are required for 
peptidoglycan amidation; most probably, GatD is responsible for the 
glutaminase activity and MurT is related to the ATP-dependent synthetase 
activity and substrate recognition. This second part of my Thesis also 
provided information essential for the establishment of the structure of the 
MurT-GatD protein complex. The crystal structure of the GatD protein is 
already available.  
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Introduction 
In gram-positive bacteria, the thick peptidoglycan multilayer constitutes an 
essential stress-bearing and shape-maintaining component of the bacterial 
cell envelope. The biosynthesis of peptidoglycan is a complex process, 
which requires several enzymatic reactions, and takes place in three 
distinct cellular compartments: the cytoplasm and the inner and the outer 
surface of the cytoplasmic membrane. The biosynthesis starts in the 
cytoplasm with the formation of the UDP-N-acetylmuramic acid (UDP-
MurNAc) covalently linked to a pentapeptide, which is composed of L-
alanine, D-glutamate, L-lysine and D-alanyl D-alanine. The successive 
addition of the five aminoacids is catalyzed by a set of enzymes, belonging 
to the superfamily of Mur ligases (12). The UDP-MurNAc-pentapeptide is 
next attached to a membrane acceptor, undecaprenyl phosphate (C55-P), 
by the translocase MraY, producing a structure known as lipid I. In the 
subsequent steps of biosynthesis, the enzyme MurG links UDP-GlcNAc to 
lipid I, resulting in the formation of lipid II (3, 14), which is transported to the 
outer surface of the cytoplasmic membrane, where it serves as a substrate 
for polymerization reactions catalyzed by transpeptidases and 
transglycosylases to form the polymeric cell wall peptidoglycan (9, 15). 
Chemical analysis of S. aureus peptidoglycan showed that the molecular 
composition of this polymer differs from the molecular composition of the 
cytoplasmic disaccharide pentapeptide cell wall precursor, namely some 
hydroxyl groups of the glycan chain were O-acetylated (1, 2) and the 
second amino acid residue of the pentapeptide was not glutamic acid but 
its amidated version, D-iso-glutamine (10). 
In search for genes and enzymes responsible for the amidation of glutamic 
acid carboxyl residues, we identified in S. aureus strain COL a small 
operon composed of two genes, murT and gatD. The two genes were 
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encoding enzymes responsible for the conversion of glutamic acid residues 
to iso-glutamine of peptidoglycan. This secondary modification of the S. 
aureus peptidoglycan was shown to be important for bacterial growth and 
resistance to beta-lactam antibiotics and lysozyme (5). Furthermore, a 
substantial reduction of peptidoglycan crosslinking was also observed in a 
mutant (femC), unable to synthesize glutamine, the amino group donor, 
suggesting that non-amidated cell wall precursors are poor substrates for 
transpeptidases. Thus, glutamate amidation also plays an important role in 
proper transpeptidation of neighboring stem peptides (4, 13).  
In this study, we document the physical interaction between the MurT and 
GatD proteins and provide evidence for the importance of this interaction in 
the amidation of peptidoglycan. In addition, we also demonstrate that the 
amidation of glutamic acid residues occurs at the lipid II stage of 
peptidoglycan biosynthesis.    
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Materials and Methods 
Bacterial strains, plasmids, and growth conditions. Bacterial strains 
and plasmids used in this study are listed in Table 1. Escherichia coli 
strains were grown at 37ºC in Luria-Bertani broth (LB, Difco Laboratories) 
or in LB agar (LA, Difco Laboratories), in the presence of the respective 
antibiotics (Table 1), ampicillin 100 g/ml (Sigma), kanamycin 30 g/ml 
(Sigma) and chloranfenicol 50 g/ml (Sigma). For protein expression, a 
final concentration of 1mM of IPTG inducer (Sigma) was used. Growth in 
liquid medium was monitored by measuring the optical density of E. coli 
cultures at 578 nm.  
Construction of S. aureus GatD as an His6-tag N-terminal fusion.  The 
gatD gene of S. aureus strain COL was amplified using primers PGatD-
NdeI-d1 and PGatD-NotI-r1 (Table 2) and ligated into pET28a vector using 
T4 DNA ligase (New England Biolabs) and NdeI (Fermentas) and NotI 
(Fermentas) restrictions sites to generate a N-terminal His6-fusion protein. 
E. coli DH5 host was transformed with the ligation mixture and positive 
transformants were screened by PCR and sequenced. The correct 
recombinant plasmid was designated pET28a-His6-gatD. 
Over-expression and purification of S. aureus His6-GatD. E. coli 
BL21(DE3) CodonPlus RIPL cells transformed with the pET28a-His6-gatD  
were grown at 37ºC in LB medium supplemented with the appropriate 
antibiotics. In order to optimize the expression and solubility, several 
conditions were tested: different induction periods (3h versus overnight), 
induction temperatures (37ºC, 30ºC, 28ºC) and salt concentrations (100 
mM versus 500 mM NaCl). The final induction conditions were the 
following: at an optical density at 578 nm (OD578nm) of 0.6, 1mM IPTG 
inducer was added and the culture was grown at 30ºC, to induce 
expression of the recombinant protein. After 3 h, cells were centrifuged at 
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6000 g for 15 min at 4ºC, resuspended in extraction buffer (20 mM Tris-HCl 
pH 8.2, 500 mM NaCl, 10 mM MgCl2, 1 mM PMSF, 0.1 mg/ml of DNaseI 
(Sigma)) and incubated on ice, for 10 min. The cell suspension was 
sonicated, with 30% of intensity for 10 min (Branson S450D), and the cell 
debris were spun down. After addition of Imidazole (Sigma) to a final 
concentration of 10 mM, the supernatant was mixed with Ni-NTA beads 
(Qiagen) and incubated at 4ºC for 16 h, with stirring. This mixture was then 
loaded onto a gravity column. In order to remove the weakly bound 
material, the column was washed with 10 column bead volumes of 
extraction buffer containing 10 mM Imidazole. The His-tagged recombinant 
protein was eluted with extraction buffer containing 200 mM of Imidazole. 
The purity of each elution was controlled by SDS-PAGE. Imidazole was 
dialyzed out against 20 mM Tris-HCl pH 8.2, 200 mM NaCl, 10 mM MgCl2 
and 10% of glycerol. Then, the suspension was diluted to a final 
concentration of NaCl of 100 mM and purified by anion exchange 
chromatography using a Q-HP-5 ml column (GE Healthcare) with a 
gradient of 30 ml from 100 mM to 1 M of NaCl in 20 mM Tris-HCl, pH 8.2, 
10 mM MgCl2, 10% of glycerol and at a flow rate of 0.5 ml/min. Elutions of 1 
ml were collected and their purity was analyzed by SDS-PAGE. The elution 
fractions of interest were concentrated using Vivaspin centrifugal 
concentrators (Sartorius) and purified by size exclusion chromatography 
using a Superdex 7510/300 Gl column (GE Healthcare) and 20 mM Tris-
HCl, pH 8.2, 500 mM NaCl, 10 mM MgCl2 at a flow rate of 0.5 ml/min. 
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Table 1. Strains and plasmids used in this study. 
Strain or plasmid  Description
a Source or 
reference 
Strains    
S. aureus   
COL Homogeneous Mc
r 
The Rockefeller 
Univ. Collection 
E. coli 
DH5α recA endA1 gyrA96 thi-1 hsdR17 supE44 
relA1 F80 DlacZDM15 
Invitrogen 
 
BL21-CodonPlus(DE3)-RIPL B F
- 
ompT hsdS(rB
-
  mB
-
) dcm
+ 
Tet
r 
gal λ 
(DE3) endA Hte [argU proLCm
r
]
 
[argU ileY 
leuW Strep/Spec
r
] 
   Stratagene 
   
BL21-His6-gatD BL21-CodonPlus(DE3)-RIPL strain with 
pET28a-His6-gatD 
This study 
   
BL21-murT-gatD-His6 BL21-CodonPlus(DE3)-RIPL strain with 
pET28a-murT-gatD-His6 
This study 
Plasmids 
 
pET28a Expression vector with T7/lac promoter,  
N-terminal His tag, thrombin cleavage site, 
C-terminal His tag; Kan
r
 
Invitrogen 
pET28a-His6-gatD pET28a expressing His6-GatD This study 
pET28a-murT-gatD-His6 pET28a expressing MurT-GatD-His6 This study 
a)
 Mc
r
,
 
methicillin resistant; Cm
r
, chloramphenicol resistant; Spec
r
, spectinomycin resistant; Kan
r
, 
kanamicin resistant.  
Construction of S. aureus MurT-GatD as a His6-tag C-terminal fusion. 
The murT-gatD operon of S. aureus strain COL was amplified using the 
primers P1951-NcoI-d1 and P1950-XhoI-r1 (Table 2) and cloned in pET28a 
vector using NcoI (Fermentas) and XhoI (Fermentas) restrictions sites to 
generate a C-terminal GatD-His6 fusion protein. E. coli DH5 host was 
transformed with the ligation mixture and positive transformants were 
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screened by PCR and sequenced. The correct recombinant plasmid was 
designated pET28a-murT-gatD-His6. 
Table 2. Primers used in this study. 
Primer  Sequence (5' - 3')a Reference 
GatD-NdeI-d1 GCGCCATATGCATGAATTGACTATTTATC This study 
GatD-NotI-r1 GCGCGCGGCCGCTTAACGAGATTTCTTCTGTC This study 
P1951-NcoI-d1 CATGCCATGGGAAGACAGTGGACGGCAATC This study 
P1950-XhoI-r1 GCGCCTCGAGACGAGATTTCTTCTGTCTATTTG This study 
a 
Restrictions sites are underlined. 
Co-expression and purification of MurT-GatD enzyme complex. The 
pET28a-murT-gatD-His6 plasmid was introduced into E. coli BL21(DE3) 
CodonPlus RIPL and over-expression was performed as described for His6-
GatD purification, with the following modifications. Briefly, after the 
induction of expression of recombinant proteins, cells were resuspended in 
extraction buffer (20 mM Tris-HCl, pH 8.2, 1 M NaCl, 10 mM MgCl2, 1 mM 
PMSF, 0.1 mg/ml of DNaseI), sonicated and the cell debris were spun 
down. After the addition of Imidazole, to a final concentration of 20 mM, the 
supernatant was mixed to Ni NTA beads and incubated at 4ºC for 16 h, with 
stirring. The elution was performed as described for His6-GatD purification, 
with modifications. After loading the mixture onto a gravity column, the 
column was washed with 10 column bead volumes of extraction buffer 
containing 40 mM Imidazole followed by elution with extraction buffer 
containing 400 mM of Imidazole. Imidazole was dialyzed out as described 
above. The suspension was purified by cation exchange chromatography, 
using a HP-S-5 ml column (GE Healthcare), with a gradient of 30 ml from 
100 mM to 1 M of NaCl in 20 mM Tris-HCl, pH 8.2, 10 mM MgCl2, 10% of 
glycerol, at a flow rate of 0.5 ml/min. Protein elutions of 1 ml were collected 
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and their purity was analysed by SDS-PAGE. The eluted fractions of 
interest were concentrated as mentioned before and purified by size 
exclusion chromatography using a Superdex 7510/300 GI column (GE 
Healthcare) and 20 mM Tris-HCl, pH 8.2, 1 M NaCl, 10 mM MgCl2 at a flow 
rate of 0.5 ml/min. 
In vitro synthesis of amidated lipid II. The assays for synthesis of 
amidated lipid II were performed in a total volume of 30 µl containing 2 mg 
of purified His6-GatD or MurT-GatD-His6. Different reaction conditions were 
tested and the ones that yielded the best results were described in Munch 
et al (7). Briefly, 0.5 mM of lipid II 
(http://www2.warwick.ac.uk/efac/sci/lfesci/people/droper/bacwan/) were 
incubated with 160 mM Tris-HCl, 0.7 % or 0.2 % Triton X-100, 5 mM KCl, 
40 mM MgCl2, pH 7.5, 6 mM ATP and 7 mM glutamine, for 4 h at 30ºC. To 
extract the synthesis products, the reaction mixtures were incubated with 
the same volume of n-butanol/pyridine acetate, pH 4.2. After centrifugation, 
the upper phase, containing the lipid products, was analyzed by Thin Layer 
Chromatography (TLC) using the mobile phase (butanol, acetic acid, water, 
pyridine, 15:3:12:10) and aluminum foil sheets coated with silica gel 
adsorbent with a pore size of 60 Å (Sigma), as the stationary phase. Lipid 
spots were visualized using iodine vapor. 
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Results 
In order to explore the enzymatic mechanism of the two enzymes and their 
contribution to the amidation reaction, active recombinant proteins were 
constructed: i) a MurT-GatD co-expression system was constructed in 
order to test the physical interaction between the two proteins; ii) MurT and 
GatD proteins were purified for enzymatic studies and structure 
determination.  
MurT and GatD proteins interact physically. Previously, murT and gatD 
genes were shown to be co-transcribed from the same promoter, organized 
as a small operon.  Moreover, analysis of available genome sequences 
showed that the murT and gatD genes occur, widespread among Gram-
positive bacteria, as a syntenic block, suggesting that the protein products 
interact functionally. The full in vivo complementation of the murT-gatD 
depletion phenotype, confirmed the functional cooperative action of the two 
proteins (5).  
The experimental evidence for a functional interaction between GatD and 
MurT proteins suggested that the two proteins interact physically and form 
an enzymatic complex.  
To test this hypothesis we designed a co-purification assay for MurT and 
GatD proteins using a vector expressing both murT and gatD genes. The 
murT-gatD operon amplified from strain COL was cloned into the E. coli 
expression vector pET28a, fusing the operon sequence with the C-terminal 
His6-tag. Such construction allowed the expression of both proteins, MurT 
and GatD-His6. The conditions used to over-express both MurT and GatD 
were the following: E. coli expressing MurT-GatD-His6, was induced with 1 
mM of IPTG for 3h at 30ºC. The optimal salt concentration for the elution 
procedure was 1 M.  
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Through affinity chromatography, the recombinant GatD-His6 was 
recovered from the supernatant and MurT was pulled down along, strongly 
suggesting that the two proteins are able to form an enzymatic complex 
(Figure 1). Moreover, the fact that both proteins co-eluted at high ionic 
conditions (1M NaCl) in the absence of substrate molecules, suggests a 
strong physical interaction between GatD and MurT. 
 
 
 
Figure 1. Co-elution of MurT and GatD-His6 proteins using Ni-NTA beads. Samples of 
the co-expression and co-purification procedure were resolved by 12%-SDS-PAGE and 
stained with coomassie blue G-250 (Bio-rad). Lane 1: PageRuler prestained protein ladder 
(Fermentas); Lane 2: protein sample before be applied to the column; Lane 3: flow through; 
Lane 4: washing step 1; Lane 5: washing step 10; Lane 6: elution 1; Lane 7: elution 2; Lane 
8: elution 3; Lane 9: elution 4; Lane 10: elution 5. Numbers on the left side represent the 
molecular weights of the protein ladder. 
Enzymatic activity of MurT and GatD proteins. To determine in vitro the 
amidation activity of MurT and GatD, independent His-tagged proteins were 
constructed. However, while the His6-GatD fusion was successfully 
expressed, the His6-MurT fusion was not obtained in sufficient amounts for 
activity assays. The amidation assays were performed with the purified 
MurT-GatD complex and with GatD protein alone. 
Purification of the MurT-GatD-His6 complex. To determine in vitro the 
enzymatic activity of MurT-GatD, the enzymatic complex was purified. 
Elution fractions 1 to 5 (Figure 1) were purified by cation exchange 
chromatography, using a salt concentration gradient from 100 mM to 1 M 
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NaCl (Figure 2). Elutions 14 to 18 (Figure 2) were concentrated and purified 
by size exclusion chromatography (Figure 3). 
 
 
Figure 2. Purification of MurT-GatD-His6 by cation exchange chromatography. 
Samples of some steps of the purification procedure were resolved by 12% SDS-PAGE and 
stained with coomassie blue G-250 (Bio-rad). Lane 1, 4 and 21: PageRuler prestained 
protein ladder (Fermentas); Lane 2: protein sample before application to the column; Lane 3: 
flow through; Lane 5: elution 5; Lane 6: elution 6; Lane 7: elution 7; Lane 8: elution 8; Lane 
9: elution 9; Lane 10: elution 10; Lane 11: elution 11; Lane 12: elution 12; Lane 13: elution 
13; Lane 14: elution 14; Lane 15: elution 15; Lane 16: elution 16; Lane 17: elution 17; Lane 
18: elution 18; Lane 19: elution 19; Lane 20: elution 20. Numbers on the left side represent 
the molecular weights of the protein ladder. 
 
Figure 3. Purification of MurT-GatD-His6 by size exclusion chromatography. Samples 
of some steps of the purification procedure were resolved by 12%-SDS-PAGE and stained 
with coomassie blue G-250 (Bio-rad). (A) MurT-GatD-His6 elutions purified by size exclusion 
chromatography. Lane 1 and 11: PageRuler prestained protein ladder (Fermentas); Lane 2: 
protein sample before be applied to the column; Lane 3: elution 6; Lane 4: elution 7; Lane 5: 
elution 8; Lane 6: elution 9; Lane 7: elution 10; Lane 8: elution 11; Lane 9: elution 12; Lane 
10: elution 13. (B) MurT-GatD-His6 protein after concentration, as described in materials and 
methods, from elutions 9 and 10 from painel A.  Lane 1: PageRuler prestained protein 
ladder; Lane 2: MurT-GatD-His6 protein. Numbers on the left side represent the molecular 
weights of the PageRuler prestained protein ladder. 
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Expression and purification of GatD recombinant protein. To further 
investigate the role of GatD in glutamate amidation, GatD was purified as a 
His-tag fusion protein. The conditions used to over express His6-GatD were 
the following: induction was performed with 1 mM of IPTG for 3h at 30ºC. 
The capture of His6-GatD was performed with Ni-NTA beads and 10 mM 
imidazole. A step of 200 mM imidazole was used to remove the weakly 
bound material and to elute His6-GatD (Figure 4). Elutions 1 to 7 (Figure 4) 
were further purified by anion exchange chromatography using a 
concentration gradient from 100 mM to 1 M of NaCl (Figure 5). Due to the 
concentration ratio between His6-GatD and contaminant proteins, elutions 
11 to 15 (Figure 5) were further purified by size exclusion chromatography 
(Figure 6). 
 
Figure 4. Affinity purification of His6-GatD protein using Ni-NTA beads. Samples of 
each phase of the purification procedure were resolved by 12% SDS-PAGE and stained with 
coomassie blue G-250 (Bio-Rad). Elutions were performed with 200 mM of Imidazole. Lane 
1: PageRuler prestained protein ladder (Fermentas): Lane 2: flow-through; Lane 3: washing 
step 1; Lane 4: washing step 10; Lane 5: elution 1; Lane 6: elution 2; Lane 7:  elution 3; 
Lane 8: elution 4: Lane 9: elution 5; Lane 10: elution 6; Lane 11: elution 7. Numbers on the 
left side represent the molecular weights of the protein ladder. 
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Figure 5. Purification of His6-GatD protein by anion exchange chromatography. 
Samples of some steps of the purification procedure were resolved by 12% SDS-PAGE and 
stained with coomassie blue G-250 (Bio-rad). Lane 1 and 4: PageRuler prestained protein 
ladder (Fermentas); Lane 2: Protein sample before be applied to the column; Lane 3: flow 
through; Lane 5: elution 7; Lane 6: elution 8; Lane 7: elution 9; Lane 8: elution 10; Lane 9: 
elution 11; Lane 10: elution 12; Lane 11: elution 13; Lane 12; elution 14; Lane 13: elution 15; 
Lane 14: elution 16; Lane 15: elution 17. Numbers on the left side represent the molecular 
weights of the protein ladder. 
 
Figure 6. Purification of His6-GatD protein by size exclusion chromatography. Samples 
of some steps of the purification procedure were resolved by 12%-SDS-PAGE and stained 
with coomassie blue G-250 (Bio-rad). (A) His6-GatD elutions purified by size exclusion 
chromatography. Lane 1 and 7: PageRuler prestained protein ladder (Fermentas); Lane 2: 
Protein sample before be applied to the column; Lane 3: elution 7; Lane 4: elution 8; Lane 5: 
elution 9; Lane 6: elution 10; Lane 8: elution 11; Lane 9: elution 12; Lane 10: elution 13; 
Lane 11: elution 14; Lane 12: elution 15; Lane 13: elution 16; Lane 14: elution 17. (B) His6-
GatD protein after concentration, as described in materials and methods, from elutions 13, 
14 and 15 (pannel A).  Lane 1: PageRuler prestained protein ladder; Lane 2: His6-GatD 
protein. Numbers on the left side represent the molecular weights of the protein ladder. 
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Enzymatic activity assays. Siewert and Strominger observed that after 
addition of ATP and NH4Cl or glutamine, amidated Lipid I or lipid II could be 
detected in membranes of S. aureus (11). In fact, S. aureus cytoplasmic 
precursors are not amidated, while the cell wall fraction shows prevalence 
of amidated muropeptides, suggesting that the amidation reaction takes 
place at the membrane level (5). For these reasons, lipid II was chosen as 
substrate for the activity assays. 
To assess the enzymatic activity of the MurT-GatD complex and GatD 
alone, lipid II intermediate was incubated with the previously purified 
recombinant proteins, ATP and glutamine. Different reaction conditions 
were tested and the ones that yielded the best results were described in 
Munch et al (7). 
Separation of the reaction products by TLC showed an additional lipid II 
band, that migrates slightly faster than unmodified lipid II (Figure 7A, lane 
1), which indicates that both lipid structures differ in their polarity. Analysis 
of the product band was performed by ESI-TOF-Mass Spectrometry, which 
allowed us to identify the compound as amidated lipid II (7). Therefore, lipid 
II is a substrate for peptidoglycan amidation, which confirms previous data 
(11). When the reaction occurs in the presence of purified GatD (Figure 7, 
lane 2), or in the absence of MurT-GatD (Figure 7A, lane 3), only non-
amidated lipid II is observed, indicating that the occurrence of glutamic acid 
amidation is dependent on the presence of MurT-GatD complex. In 
addition, this modification is also dependent of glutamine and ATP, since in 
the absence of these components, only non-amidated lipid II is observed 
(Figure 7B). 
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Figure 7. Migration behavior of lipid II and amidated lipid II on TLC. (A) TLC of Lipid II 
incubated with 0.2% of Triton-X-100. Lane 1:  Lipid II incubated with MurT-GatD purified 
complex; Lane 2: Lipid II incubated with GatD; Lane 3: Lipid II incubated in the absence of 
MurT-GatD purified complex. (B) TLC of Lipid II incubated with 0.7% of Triton-X-100. Lane 
1: Lipid II incubated in the absence of MurT-GatD purified complex; Lane 2: Lipid II 
incubated with MurT-GatD purified complex; Lane 3: Lipid II incubated with GatD; Lane 4: 
Lipid II incubated in the absence of ATP: Lane 5: Lipid II incubated in the absence of L-
glutamine.  
Structure determination of GatD protein. X-ray structure determination of 
the enzymatic complex MurT-GatD should provide mechanistic insights into 
the amidation reaction of peptidoglycan in S. aureus. With this aim, the 
recombinant proteins for GatD and MurT described above were 
constructed. As previously stated, MurT expression was unsuccessful. 
Regarding GatD, in collaboration with J. Trincão (Diamond Light Source, 
Harwell Oxford, Didcot, UK), preliminary crystal growth attempts were 
unsuccessful as the expression yield was not enough for crystalization 
purposes. Optimization of the expression and purification strategies were 
pursued and the native and selenomethionine derivatives of substrate-free 
GatD were crystallized. For this purpose, the protein was produced using 
the expression vector pOPINF in E. Coli Lemo21pLysS(DE3) expression 
+
 M
u
rT
-G
a
tD
+
 G
a
tD
N
o
 e
n
z
y
m
e
s
Amidated Lipid II
Non-amidated Lipid II
Lipid II
1                          2                             3
Lipid II
N
o
 e
n
z
y
m
e
s
+
 M
u
rT
-G
a
tD
+
 G
a
tD
+
 M
u
rT
-g
a
tD
N
o
 A
T
P
+
 M
u
rT
-G
a
tD
N
o
 L
-g
lu
ta
m
in
e
1                     2                  3                       4                    5      
A
B
Amidated Lipid II
Non-amidated Lipid II
Chapter III 
150 
 
strain. These results are described in Appendix I (Vieira, D., T. A. 
Figueiredo, A. Verma, R. G. Sobral, A. M. Ludovice, H. de Lencastre, and 
J. Trincao. 2014. Purification, crystallization and preliminary X-ray 
diffraction analysis of GatD, a glutamine amidotransferase-like protein from 
Staphylococcus aureus peptidoglycan. Acta Crystallogr. F Struct. Biol. 
Commun. 70: 632-635.) 
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Discussion 
The peptidoglycan of S. aureus is a highly dynamic molecule that 
undergoes several secondary modifications to its primary structure during 
its biosynthesis.  Amidation of the -carboxyl group of the D-glutamate 
residues is one of such modifications and studies described in this Thesis 
have led to the identification of the murT-gatD operon as the genetic 
determinant involved in this step. MurT shares approximately 15% identity 
and 53% similarity with the sequence of the Mur ligases of S. aureus, while 
GatD shows similarity to one of the two domains of a cobyric acid 
synthetase protein: a glutamine amidotransferase, with glutamine amide 
transfer activity (5).  
The glutamine amidotransferases (GATases) are involved in a variety of 
biological reactions such as biosynthesis of nucleotides, amino acids, 
aminated sugars, coenzymes and antibiotics. These proteins are modular 
enzymes, since they are organized in two distinct catalytic domains: the 
glutaminase domain responsible for glutamine hydrolysis and for the amide 
nitrogen transfer from glutamine to its acceptor substrates; and the 
synthetase domain involved with the recognition and binding of the amino 
group acceptor substrate. The nitrogen transfer requires synchronization of 
both reactions and a close interaction between the two catalytic domains.  
This may be achieved by several – alternative – ways: the catalytic 
domains may be located on the same polypeptide; on two distinct subunits 
in heterodimeric GATase; or they can be positioned on subunits from 
different enzymes, forming an enzymatic complex (6).  
In the present study we used co-purification of MurT and GatD to 
demonstrate that the two proteins interact physically.  Furthermore, using in 
vitro activity assays, we showed that lipid II amidation needs the presence 
of both enzymes, demonstrating that MurT and GatD form a glutamine 
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amidotransferase bi-enzymatic complex. We infer that GatD is responsible 
for the glutaminase activity, while the role of MurT is related to the ATP-
dependent synthetase activity. Our results demonstrate that lipid II is an 
efficient amino acceptor molecule and that glutamine is an efficient amino 
donor. 
While obtaining the data described in this Thesis chapter, similar results 
were obtained by Munch and colleagues (7). In the study of Munch and 
colleagues, the nature of the nitrogen donor substrate and of the acceptor 
substrate was further explored. While the majority of GATases seem to be 
highly specific for using glutamine as an amide nitrogen donor, they can 
also accept exogenous ammonia as nitrogen source (16). Munch et al, (7) 
demonstrated that at optimal conditions for the ammonia-dependent activity 
(pH 8.5), the MurT-GatD complex is able to use free ammonia, as nitrogen 
donor substrate. However, taking into account the neutral pH within the 
cytoplasm and the fact that the peptidoglycan composition of a glnRA 
transposition mutant (8), unable to synthesize glutamine, is identical to the 
one of the murT-gatD depletion mutant (5), it is most likely that MurT-GatD 
enzymatic complex, normally, uses glutamine as nitrogen donor. Moreover, 
the peptidoglycan HPLC profile of a glnRA and murT-gatD depletion double 
mutant, showed a complete lack of amidated muropeptides (5), which 
indicates that the gene products of these two operons are together 
essential for the lipid II amidation and highlight that this modification is 
glutamine-dependent. 
Regarding the acceptor molecule, Munch et al (7) tested the in vitro 
amidation of several structures, namely lipid I, lipid II and lipid II-Gly5, in the 
presence of MurT-GatD, glutamine and ATP. The authors concluded that 
the most efficient substrate was lipid II, although amidation of lipid I and 
lipid II-Gly5 also occurred. The presence of a 10 fold excess of MurNAc-
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pentapetide did not interfere with the amidation of lipid II, indicating that the 
cytoplasmic precursors are not substrates for MurT-GatD dependent 
amidation reaction. 
The glutamine amido transfer domains are highly conserved among the 
GATases family, whereas the synthetase domains are all different, since 
they bind to different nitrogen acceptor substrates in different biological 
reactions (6). Regarding MurT-GatD complex, MurT shares high level of 
similarity with the sequence of the four Mur ligases of S. aureus (5) that 
catalyze the synthesis of UDP-MurNAc-pentapeptide through the stepwise 
addition of five aminoacids. Munch et al showed that, despite the sequence 
similarity, all S. aureus Mur Ligases were not able to replace in vitro the 
activity of MurT protein. It has been shown that the amidation reaction itself 
doesn’t require the presence of ATP, however, some GATases are 
dependent of ATP to activate the nitrogen acceptor substrate (6). Our 
results indicate that the amidation reaction requires the presence of ATP.  
The absence of amidated lipid II when only GatD is present in the in vitro 
reaction, together with the fact that the in trans complementation with 
several copies of gatD gene showed no re-establishment of the normal 
peptidoglycan profile (5), demonstrate that MurT is essential for 
peptidoglycan amidation. 
Taking into account the frequent presence of MurT-GatD in gram-positive 
bacterial pathogens; the essentiality of these proteins in S. aureus; and 
their involvement in the resistance to -lactam antibiotics and to lysozyme – 
the amidation step in peptidoglycan biosynthesis offers a new target for the 
development of inhibitors as mono therapeutics and/or as combination 
agents for existing β-lactam antibiotics. 
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All the experimental work described in this chapter was performed by T. A. 
Figueiredo. 
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Abstract  
The enzymes responsible for peptidoglycan amidation in Staphylococcus 
aureus, MurT and GatD, were recently identified and shown to be required 
for optimal expression of resistance to β-lactams, bacterial growth, and 
resistance to lysozyme. In this study, we analyzed the impact of 
peptidoglycan amidation in representative strains of the most widespread 
clones of methicillin resistant S. aureus (MRSA). The inhibition of the 
expression of murT-gatD operon resulted in different phenotypes of 
resistance to β-lactams and lysozyme according to the different genetic 
backgrounds. Further, clonal lineages CC1 and CC398 (community-
acquired MRSA [CA-MRSA]) showed a stronger dependency on MurT-
GatD for resistance to β-lactams, when compared to the impact of the 
impairment of the cell wall step catalyzed by MurF. In the remaining 
backgrounds similar phenotypes of β-lactam resistance were observed 
upon the impairment of both cell-wall-related genes. Therefore, for CA-
related backgrounds, the predominant β-lactam resistance mechanism 
seems to involve genes associated with secondary modifications of 
peptidoglycan. On the other hand, the lack of glutamic acid amidation had a 
more substantial impact on lysozyme resistance for cells of CA-MRSA 
backgrounds, than for hospital-acquired MRSA (HA-MRSA). However, no 
significant differences were found in the resistance level of the respective 
peptidoglycan structure, suggesting that the lysozyme resistance 
mechanism involves other factors. Taken together, these results suggested 
that the different genetic lineages of MRSA were able to develop different 
molecular strategies to overcome the selective pressures experienced 
during evolution. 
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Introduction  
Methicillin resistant Staphylococcus aureus (MRSA) are a major cause of 
nosocomial infections worldwide (15, 18, 24, 27) and most cases of 
hospital-acquired MRSA (HA-MRSA) infections are caused by a few 
successful multidrug-resistant epidemic clones (38).  
In the last two decades, the emergence of community-acquired MRSA (CA-
MRSA), causing infections among healthy individuals, has been a subject 
of growing concern (6, 7, 20, 33). Nevertheless, nowadays, the recent 
changes in the epidemiology of CA-MRSA suggest that the boundaries 
between the hospital and community are blurring (21, 29, 30, 50).  
Several studies have demonstrated that genetic backgrounds associated 
with CA-MRSA have a number of features that distinguish them from HA-
MRSA. CA-MRSA typically have increased virulence and carry the smaller 
and easier to transfer staphylococcal chromosomal cassette (SCCmec) 
type IV and V (12). Interestingly, the largest SCCmec type II, usually found 
in HA-MRSA, has a significant fitness cost for the bacteria, resulting in a 
decrease in the growth rate, and in a reduction of toxin expression levels 
(9, 10). The balance between the virulence and antibiotic resistance costs 
may explain why MRSA with SCCmec type II are found mainly in hospital 
environments where high antibiotic pressure, immunocompromised 
individuals, and vector-mediated transmission are present (10). Moreover, 
for CA-MRSA strains, in contrast to HA-MRSA, mecA was suggested not to 
be the primary determinant of methicillin resistance, being the expression of 
pbp4 the main determinant of resistance (32).  
Recently, a small operon, encoding the enzymatic complex MurT-GatD, 
was identified to be responsible for a secondary modification of 
peptidoglycan in S. aureus, the amidation of glutamic acid in the stem 
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peptides (17, 34). Inhibition of amidation caused reduced growth rate; 
reduced resistance to β-lactam antibiotics, shown previously to be affected 
by auxiliary genes (14); and increased sensitivity to lysozyme in HA-MRSA 
strain COL (17). 
In this communication we report that peptidoglycan amidation has different 
impacts in the expression of resistance to β-lactams and to lysozyme, 
depending on the genetic background of the particular strain. These 
observations suggest that S. aureus, from different genetic lineages, 
include different elements from their core genomes in the strategies of 
resistance to β-lactam and lysozyme adopted. 
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Materials and Methods 
Bacterial strains and growth conditions. The 11 MRSA strains analyzed 
in this study are listed in Table 1. The respective mutants with murT-gatD 
and murF conditional mutations are listed in Table 2. S. aureus strains were 
grown at 37ºC with aeration in tryptic soy broth (TSB; Difco Laboratories) or 
tryptic soy agar (TSA; Difco Laboratories). The strains with murT-gatD and 
murF conditional mutations were grown in the presence of kanamycin (50 
µg/ml; Sigma) and neomycin sulfate (50 µg/ml; Sigma). Growth medium 
was supplemented with the appropriate concentration of cadmium chloride 
(CdCl2; Sigma), unless otherwise described. 
Construction of murT-gatD conditional mutants. The murT-gatD 
conditional mutation (17) was transduced, by phage 80α into the recipient 
strains (Table 1), as previously described (41) generating the murT-gatD 
conditional mutants in different backgrounds (Table 2). 
Construction of murF conditional mutants. A 768-bp DNA fragment of 
the 5’ end of murF gene, including the ribosome binding site but not the 
promoter sequence, was amplified using chromosomal DNA from strain 
COL as template and the specific primers PmurF’-R and PmurF’-F (Table 
S1). The amplified murF fragment and plasmid pBCB20 (R.G. Sobral and 
M.G. Pinho, unpublished data), carrying a CdCl2 inducible promoter, were 
digested with SmaI (New England Biolabs) and ligated, generating plasmid 
pMurF’. Plasmid pMurF’ was electroporated into competent cells of 
RN4220 with a Gene Pulser apparatus (Bio-Rad). The correct insertion of 
pMurF’ into RN4220 chromosome was confirmed by polymerase chain 
reaction, using an internal murF primer chosen downstream of the cloned 
region (PmurFdn) and an internal primer to pCad conditional promoter 
(Pcad-F) (Table S1). The murF conditional mutation was then transduced, 
by phage 80α into the recipient strains (Table 1), as previously described 
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(41) generating the murF conditional mutants in different backgrounds 
(Table 2). 
Pulsed-field gel electrophoresis. The correct insertion of murT–gatD and 
murF conditional mutations into the chromosome of the recipient strains 
was performed by comparing the pulsed-field gel electrophoresis (PFGE) 
profiles of the parental strains and the respective transductants. DNA 
agarose disks of the parental strain and the respective mutant were 
prepared, digested with SmaI, and separated as described (8). 
Southern blot analysis. SmaI chromosomal fragments, from the parental 
strain and the respective murF and murT-gatD mutants, were transferred to 
nylon membranes (Hybond N+; GE Healthcare) that were subsequently 
hybridized with specific DNA probes labeled with the ECL direct labeling 
system (GE Healthcare). The DNA probes used for murT-gatD and murF 
genes were amplified with primer pairs PmurT-D1+PmurTR1 and PmurF’-R 
+PmurF’-F, respectively (Table S1). 
Population analysis profile. Overnight-grown cultures of the parental 
strains and the respective murT-gatD and murF conditional strains were 
plated at various dilutions on TSA plates, with increasing concentrations of 
oxacillin (0, 0.75, 1.5, 3, 6.25, 12.5, 25, 50, 100, 200, 400, and 800 µg/ml), 
and colonies were counted after incubation at 30ºC for 48 hours, as 
previously described (13). 
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Peptidoglycan isolation for lysozyme lytic assays. Isolation of cell wall 
was performed as described previously (3). Briefly, cells were harvested by 
centrifugation, washed twice with cold 0.9% NaCl, and boiled for 20 
minutes. After chilling, the cells were washed twice and disrupted using 
106-mm glass beads (Sigma) and FastPrep FP120 apparatus (Bio 101). 
The suspension was then washed, and boiled for 30 minutes in 5% sodium 
dodecyl sulfate and 50mM Tris-HCl (pH 7), to remove noncovalently bound 
proteins. After centrifugation, the cell wall fragments were diluted in 0.1M 
Tris-HCl (pH 6.8) and incubated with 0.5 mg/ml trypsin for 16 hours at 37ºC 
to degrade cell bound proteins. Purified cell walls were washed with water 
and lyophilized and treated with 49% hydrofluoric acid for 48 hours at 4ºC, 
to remove teichoic acids. The purified peptidoglycan was washed with 
water and lyophilized. 
Turbidometric assay of peptidoglycan hydrolysis. To analyze the 
susceptibility of peptidoglycan to lysozyme hydrolysis, a turbidometric 
assay was performed as described previously (3, 17, 19). Briefly, purified 
peptidoglycan was sonicated in 100mM sodium-potassium phosphate 
buffer (pH 6.6). Egg white lysozyme (Sigma) was added (300 µg/ml) and 
the reaction was incubated at 37ºC. The optical density was monitored at 
595 nm in 96-well microplates (pure grade, Brand) using a microplate 
reader (Infinite F200 Pro; Tecan).  
Determination of lysozyme resistance of S. aureus growing cells. The 
impact of lysozyme on exponentially growing cultures was determined as 
described previously (17, 19). Overnight cultures of the conditional mutants, 
grown with inducer, were inoculated into fresh TSB, with and without 
inducer. The cultures were incubated at 37ºC to an OD620nm of 1.0. Then, 
each culture was diluted 1:10 into fresh TSB, with and without inducer, and 
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lysozyme (300 µg/ml) was added as the OD620nm reached 1.0. The growth 
was monitored for several hours. 
Statistical analysis. A two-tailed Student’s t test with Welch correction was 
used to determine the significance of differences in lysozyme digestion 
within groups of CA-MRSA and HA-MRSA. Differences were considered 
statistically significant when p was < 0.005. The Graph Pad Prism 5.0 
package was used. 
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Results 
The impact of the impairment of peptidoglycan amidation on oxacillin 
resistance was previously demonstrated by the construction and 
characterization of the murT-gatD conditional mutation in strain COL. This 
mutation was shown to impact not only β-lactam resistance, but also growth 
rate and lysozyme resistance (17). In this study, we first observed that the 
effects of murT-gatD inhibition in the resistance level of strain COL and 
strain MW2 were clearly distinct, as observed through oxacillin inhibition 
halos (1-mg disc) (Figure S1). The decrease in the resistance level of the 
strain was significantly more pronounced for MW2pCadmurT-gatD, 
showing a twofold wider inhibition halo. To test that this behavior was the 
result of different genetic backgrounds and not a strain-specific trait, the 
mutation was transferred to another strain of the same clone USA400 and a 
similar resistance profile was obtained (Figure 1A). These results led to the 
hypothesis that murT-gatD expression and/or the enzymatic step catalyzed 
by the MurTGatD complex could have different physiological consequences 
depending on the genetic background.  
To address this hypothesis, the murT-gatD conditional mutation was 
transduced to representative strains of the most widespread MRSA clones, 
among both HA-MRSA and CA-MRSA (Table 1).  
The correct transfer of the mutation was determined by comparing the 
SmaI PFGE profiles of the parental strains and the respective transductants 
(Figure S2). In addition, Southern blot analysis using specific probes for 
murT-gatD genes confirmed the correct insertion of the conditional 
mutation. 
Impact of murT-gatD conditional mutation on resistance to β-lactam 
antibiotics in different MRSA genetic backgrounds. The impact of 
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murT-gatD conditional mutation on the β-lactam resistance level of the 
different MRSA strains was evaluated by performing oxacillin population 
analysis profiles.  
The most striking observation was that MW2/USA400, ST398, and WIS 
CA-MRSA murT-gatD conditional mutants (Figure 1A) grown in the 
absence of inducer were overall less resistant to oxacillin, when compared 
with the HA-MRSA mutant strains (Figure 1B). A first early drop in the 
number of cfu/ml, occurring at 0.75 µg/ml, was common to all analyzed 
mutant strains, followed by a high frequency of resistant subpopulations, 
able to grow on higher concentrations of antibiotic. Strikingly, while for the 
HA-MRSA (COL, HUR75, and HDES57) the subpopulations of the mutants 
were able to grow on antibiotic concentrations near the MIC (minimal 
inhibitory concentration) of the parental strain (from 50 to 800 µg/ml, Figure 
1B), for the CA-MRSA (MW2, USA400, ST398, and WIS), the mutants’ 
subpopulations only grew at low antibiotic concentrations (from 0.75 to 6.25 
µg/ml, Figure. 1A). Consequently, complete growth inhibition occurred at 
much lower antibiotic concentrations for murT-gatD mutants of CA-MRSA 
backgrounds (Figure 1A).  
Within the CA-MRSA strains, C377pCadmurT-gatD and 
DEN2294pCadmurT-gatD showed a less striking decrease in resistance to 
oxacillin (Figure 2A), with subpopulations that were able to grow up to 100 
µg/ml. In fact, C377pCadmurTgatD showed an overall resistance profile 
similar to HUR75pcadmurT-gatD (Figures 2A and 1B, respectively). The 
similarities between these resistance profiles were consistent with the fact 
that HUR75 and C377 are genetically related, belonging to the same clonal 
complex (CC8). 
Likewise, DEN2294 (ST30-IV, Southwest Pacific clone) is genetically 
related to the HA-MRSA ST36-MRSA-II (EMRSA-16) as they are 
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descendants from the common ancestral ST30-MSSA (45). A conditional 
murT-gatD mutant was not constructed in the ST36-MRSA-II background, 
as all the strains available were resistant to the selectable marker of the 
pMurT’ integrative plasmid (kanamycin). 
Regarding the Pediatric and New York/Japan clones (HDE288 and 
HUC599, respectively) the parental strains exhibited, together with a high 
frequency of resistant subpopulations, lower MIC values (0.75 µg/ml) than 
the previously analyzed HA-MRSA strains (50–800 µg/ml, Figure 2B). 
Consistently, for these strains, the murT-gatD mutation had a complete 
inhibitory impact at lower antibiotic concentrations (6.25 and 100 µg/ml for 
HDE288 and HUC599 mutants, respectively, Figure 2B), than the 
remaining HA-MRSA mutants.  
To explore whether this behavior is associated with distinct steps of 
peptidoglycan biosynthesis, the impact of a murF conditional mutation was 
also studied in the same genetic backgrounds. 
Impact of murF conditional mutation on resistance to β-lactam 
antibiotics in different MRSA genetic backgrounds. A conditional 
mutation for murF gene ( pCadmurF) was constructed using the same 
pCad inducible promoter, transduced from RN4220pCadmurF to the strains 
listed in Table 1, and oxacillin population analysis profiles were performed 
(Figures 1 and 2). In the absence of inducer, the murF conditional mutants 
were impaired in the last biosynthetic cytoplasmic step, catalyzed by MurF 
protein, the addition of the D-alanyl-D-alanine terminus to the stem peptide 
(49). For most clonal lineages the level of resistance to oxacillin was similar 
for murT-gatD and murF mutants (Figures 1B and 2B). However, for 
MW2/USA400 and ST398 CA-MRSA strains, all CA-MRSA strains, the 
inhibition of murT-gatD transcription caused a more pronounced effect on 
oxacillin resistance, than inhibition of murF transcription (Figure 1A).  
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Figure 1. Impact of murT-gatD and murF conditional mutations on the oxacillin 
resistance profiles of MW2, USA400, WIS, ST398, COL, HUR75, and HDES57 strains. 
Overnight cultures of the parental strains and conditional mutants grown with CdCl2 inducer 
were plated on TSA containing increasing concentrations of oxacillin. Plates were incubated 
for 48 hours at 30ºC. (■) Oxacillin population analysis profile of parental strains; (○) oxacillin 
population analysis profile of murT-gatD conditional mutants; ( ) oxacillin population 
analysis profile of murF conditional mutants. Oxacillin population analysis profile of (A) CA-
MRSA strains and (B) HA-MRSA strains. CA-MRSA, community-acquired methicillin 
resistant Staphylococcus aureus; CdCl2, cadmium chloride; HA-MRSA, hospital-acquired 
MRSA; TSA, tryptic soy agar. 
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Figure 2. Impact of murT-gatD and murF conditional mutations on the oxacillin 
resistance profiles of C377, DEN2294, HUC599, and HDE288 strains. Overnight cultures 
of the parental strains and conditional mutants, grown with CdCl2 inducer, were plated on 
TSA containing increasing concentrations of oxacillin. Plates were incubated for 48 hours at 
30ºC. (■) Oxacillin population analysis profile of parental strains; (○) oxacillin population 
analysis profile of murT-gatD conditional mutants; () oxacillin population analysis profile of 
murF conditional mutants. Oxacillin population analysis profile of (A) CA-MRSA strains and 
(B) HA-MRSA strains. 
Impact of murT-gatD and murF conditional mutations on β-lactam 
resistance in a mecA-negative strain resistant to methicillin. The 
pCadmurT-gatD and pCadmurF conditional mutations were transduced to 
the M100 strain (Table 2), a laboratory step mutant selected for methicillin 
resistance (51) which encodes a modified PBP3 (43) and does not contain 
mecA. The inhibition of murF transcription, in the background of M100 
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strain, resulted in a decrease in cell viability, shown by a drop in the 
number of cfu/ml from 108 to 106 (Figure 3). However, no effect was 
observed in the oxacillin resistance level. In contrast, the impairment of 
murTgatD caused, besides the same decrease in viability, a four fold 
decrease in oxacillin resistance; the conditional mutant, grown in the 
absence of inducer, showed complete growth inhibition at 2 µg/ml of 
oxacillin, in contrast to the parental strain (8 µg/ml) (Figure 3). 
 
Figure 3. Impact of murT-gatD and murF conditional mutations on the oxacillin 
resistance profile of mecA-negative M100 strain. Overnight cultures of the parental strain 
and conditional mutants, grown with CdCl2 inducer, were plated on TSA containing 
increasing concentrations of oxacillin. Plates were incubated for 48 hours at 30ºC. (■) 
Oxacillin population analysis profile of M100 parental strain; (○) oxacillin population analysis 
profile of murT-gatD conditional mutant; () oxacillin population analysis profile of murF 
conditional mutant. 
Impact of murT-gatD conditional mutation on lysozyme resistance in 
different MRSA genetic backgrounds. 
Lysozyme resistance assays in living cells. To evaluate the impact of 
murT-gatD conditional mutation on S. aureus intrinsic lysozyme resistance, 
in the several genetic backgrounds, the murT-gatD conditional mutants 
were grown, in the absence and in the presence of inducer, and treated 
with muramidase during the exponential phase. The cell density of the 
cultures was then monitored for several hours. 
1,00E+00
1,00E+01
1,00E+02
1,00E+03
1,00E+04
1,00E+05
1,00E+06
1,00E+07
1,00E+08
1,00E+09
0 0,25 0,5 1 2 4 8 16 32 64 128
C
F
U
/m
l
Oxa (µg/ml)
M100
Chapter IV 
176 
 
The parental strains, as the conditional mutants grown with inducer, 
showed no growth alteration upon addition of lysozyme to the medium 
(shown for HDES57, HDE288, MW2, and C377 strains and for the 
respective mutants, grown without inducer, Figure 4; data not shown for the 
remaining strains), confirming that all these strains are resistant. 
To address the effects of the impairment of murT-gatD transcription on 
lysozyme resistance level, the cell density values of each mutant culture, 
grown with and without lysozyme, were compared at 90 minutes after the 
addition of muramidase (Figure 5A). 
Overall, murT-gatD mutants constructed in CA-MRSA backgrounds were 
more sensitive to lysozyme, when compared with mutants constructed in 
HA-MRSA backgrounds. In fact, while all CA-MRSA mutants showed a 
decrease in optical density above 70% (mean value of 86.1% – 9.6%) when 
grown in the presence of lysozyme, in HA-MRSA the decrease was much 
more variable, ranging between 23.1% and 90.6% (Figure 5A). The 
difference in the mean lysozyme digestion level, between groups of CA-
MRSA and HA-MRSA, was statistically significant (p < 0.005, Student’s t 
test). Interestingly, mutants DEN2294pCadmurT-gatD and C377pCadmurT-
gatD were more resistant to lysozyme, than the remaining CA-MRSA 
strains, showing again a different behavior, as previously observed for the 
oxacillin resistance profiles (Figures 5A and 2A). 
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Figure 4. Impact of murT-gatD conditional mutation on lysozyme resistance in 
HDES57, HDE288, MW2, and C377 strains and the respective mutants, grown without 
inducer. Overnight cultures were diluted to OD620nm 0.1 and were incubated at 37ºC to 
OD620nm of 1.0. Then, each culture was diluted into fresh medium and lysozyme (300 µg/ml) 
was added at OD620nm 1.0, as indicated by the dashed line. Conditional mutant grown 
without inducer, in the presence (∆) and in the absence of lysozyme (▲); parental strain 
grown in the presence (□) and in the absence of lysozyme (■). 
Lysozyme resistance assays with purified peptidoglycan. To determine 
whether the mutant phenotypes, observed in vivo, were directly associated 
with the lack of amidation of peptidoglycan, or whether they were 
associated with other strain specificities, the peptidoglycan of the parental 
strains and the respective mutant, grown without inducer, was isolated and 
purified. The peptidoglycan concentration was adjusted and after addition 
of lysozyme, the optical density was monitored to assess the amount of 
peptidoglycan digested. The results of the lytic assays showed no 
statistically significant differences (Student’s t test) between the lysozyme 
resistance of the purified peptidoglycan of the different mutant strains 
(Figure 5B). The comparison between the susceptibility to lysozyme of 
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murT-gatD mutants’ living cells and their respective purified peptidoglycan 
(Figure 5A, B) showed no correlation. In fact, while cells from CA-MRSA 
mutants were more susceptible to lysozyme than cells from HA-MRSA 
mutants, their respective purified peptidoglycan showed no significant 
variability between the resistance levels. 
 
Figure 5. Impact of murT-gatD conditional mutation on lysozyme resistance. (A) Effect 
of lysozyme (300 µg/ml) on the growth rate of the conditional mutants grown without inducer. 
The impact of lysozyme is represented as the ratio between the optical density of the culture 
of the mutant grown with lysozyme ( + lys) and without lysozyme ( - lys), 90 minutes after 
addition of the muramidase. (B) Effect of lysozyme (300 µg/ml) on purified PG from the 
conditional mutants grown without inducer. The impact of lysozyme is represented as the 
percentage of undigested peptidoglycan, 40 minutes after addition of the muramidase. 
Dashed bars, conditional mutants of CA-MRSA strains; solid bars, conditional mutants of 
HA-MRSA strains. Also represented are the mean and standard deviation of triplicate 
experiments. PG, peptidoglycan. 
 
 
 
 
 
 
Contribution of Peptidoglycan Amidation to β-Lactam and Lysozyme Resistance in Different 
Genetic Lineages of Staphylococcus aureus 
 
179 
 
Discussion 
In the last half-century, the cell wall biosynthetic pathway has been 
extensively studied, namely, for its role as an antimicrobial target. However, 
the enzymes responsible for the amidation of D-glutamic acid of 
staphylococcal peptidoglycan were described only recently. Figueiredo et 
al. (17) identified, in MRSA strain COL, the murT-gatD operon whose 
protein products catalyze the amidation of peptidoglycan and showed that 
this cell wall modification is important for optimal growth, β-lactam 
resistance, and sensitivity to the host defense factor lysozyme. Munch et al. 
(34) demonstrated that both enzymes, MurT and GatD, are essential for 
survival and interact as a glutamine amidotransferase bi-enzymatic 
complex.  
Several genes of the peptidoglycan biosynthetic pathway, among other 
housekeeping genes, are involved in the β-lactam resistance mechanism. 
In fact, the mechanism of resistance of MRSA strains is not simply mecA-
dependent, but also needs the optimal expression of the so-called auxiliary 
genes (4, 14, 25, 35) among which are essential cell-wall related 
determinants, such as murE (28) murF (48); pbp2 (44); pbp1 (42); femABX 
(5); and murT-gatD operon (17). However, the impact of different steps of 
peptidoglycan synthesis in β-lactam resistance of MRSA strains from 
different genetic backgrounds, was only assessed for PBP4 (32). 
Previously, Katayama et al. (23) showed that impairment of pbp4 does not 
affect the β-lactam resistance level of MRSA, being not classified as an 
auxiliary gene. Later, Memmi et al. (32) showed that pbp4 is an auxiliary 
gene in CA-MRSA, being the key player in the resistance mechanism of 
these specific strains. 
In this communication, the murT-gatD conditional mutation was studied in 
the background of the major contemporary MRSA clones. Different impacts 
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in the oxacillin resistance profile were observed for murT-gatD depletion in 
several MRSA genetic backgrounds, with a more pronounced effect on CA-
MRSA-related backgrounds, when compared with HA-MRSA. The 
conditional mutants of MW2/USA400, ST398, and WIS strains showed 
complete growth inhibition at antibiotic concentrations *100-fold lower than 
HA-MRSA mutants. However, this effect was not shared by all CA-MRSA 
strains; the conditional mutants of C377 and DEN2294, belonging to 
lineages highly disseminated in community settings (USA300 and 
Southwest Pacific clones, respectively), showed a less striking decrease in 
resistance to oxacillin. In the case of C377, this behavior could be 
explained by the fact that this strain is genetically related with the HA-
MRSA HUR75 strain, as they belong to the same clonal complex (CC8). 
Likewise, DEN2294 CAMRSA (ST30-IV, Southwest Pacific clone) has a 
genetic background related to the hospital-acquired ST36-MRSA-II 
(EMRSA-16) as DEN2294 and ST36-MRSA-II have a common ancestral, 
ST30-MSSA (22, 45).  
Although the differences in oxacillin resistance decrease observed between 
the CA- and HA-related strains are clear, the molecular mechanism behind 
these different phenotypes is probably directly associated rather with the 
strains’ clonal complexes, and therefore, with their genetic background.  
An association between the strains’ genetic background and their capacity 
to acquire and maintain a recombinant plasmid expressing mecA was 
previously observed (22).  Strains from clonal complexes CC1 and CC5 
were, among the major MRSA lineages tested, the ones that were less 
efficiently transformed. However, CC5 lineage has been recently described 
to be well adapted to the hospital environment through the efficient 
acquisition of resistance to new antibiotics (26), suggesting that strains 
belonging to CC5 are able to easily acquire mecA, but not able to efficiently 
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maintain it. Therefore, the CC5 lineage seems to be less dependent on the 
presence of mecA than other major lineages, for the efficient expression of 
resistance to β-lactams. One hypothesis is that in strains of CC5 β-lactam 
resistance relies on the presence of specific housekeeping genes, namely, 
murT-gatD, although the presence of mecA would still be essential. 
Coincidently, strains belonging to CC1 (MW2/USA400) typically associated 
with the community onset, and CC5 (HDE288 and HUC599), which 
includes hospital-related strains, were among the ones that showed higher 
impact from murT-gatD impairment. The other strains that showed the 
same level of impact were WIS and ST398 (CC59 and CC398, 
respectively), which harbor the small SCCmec type V, suggesting that their 
genetic background would also not favor the stability of mecA expression. 
In this line of thought, the clonal complexes CC8, CC22, and CC30, which 
showed higher efficiency of transformation with mecA and stability of mecA 
expression (22) were, in our study, represented by the strains showing less 
impact of murT-gatD impairment (COL, HUR75, C377, HDES57, and 
DEN2294). Taken together, these observations suggest that the genetic 
backgrounds less prone to receiving mecA gene recruited preferentially 
specific housekeeping genes, such as murT-gatD, for their β-lactam 
resistance strategy. To address the importance of mecA presence in this 
alternative resistance strategy, murT-gatD mutation was transferred into a 
mecA-independent resistant strain, M100, with a truncated PBP3. The 
murT-gatD impairment resulted in a decrease in the level of resistance of 
the M100 strain, indicating that peptidoglycan amidation is essential for a 
mecA-independent resistant strategy. 
To assess the importance of different steps of peptidoglycan biosynthesis 
in this alternative strategy of mecA associated resistance, murF gene was 
chosen for further testing. On one hand, MurF catalyzes a crucial step of 
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the primary pathway of peptidoglycan biosynthesis; on the other hand, it is 
a well-documented auxiliary gene for COL background (48). While for most 
genetic backgrounds the impact of murF impairment in the resistance 
profile was comparable to the one of murT-gatD, for MW2/USA400 and 
ST398 strains, murT-gatD conditional mutation showed a drastic and 
unique effect. Further, the inhibition of murF transcription did not affect the 
level of resistance in the mecA-negative strain M100, suggesting that the 
contribution of murF auxiliary gene for β-lactam resistance is related to the 
presence of mecA.  
Therefore, the alternative strategy for β-lactam resistance seems to rely on 
genes involved in peptidoglycan secondary modifications, as secondary 
cross-linking (pbp4) and amidation (murT-gatD) (32). Recently, Zapun et al. 
(52) showed that in Streptococcus pneumoniae, peptidoglycan amidation 
catalyzed by MurT-GatD complex is necessary for efficient cross-linking by 
PBP2a, PBP2b, and PBP2X. PBP1a retained some activity for 
nonamidated lipid precursors. Although the substrate preferences of S. 
aureus PBPs regarding the amidation status of the precursor molecule are 
not known, it seems reasonable to speculate that PBP4 and/or PBP2 also 
require amidated precursors to perform transpeptidation, as these two 
proteins appear to be involved in the alternative mechanism of resistance to 
β-lactams (32). 
Moreover, besides being essential for optimal β-lactam resistance, the 
murT-gatD operon is also needed for optimal lysozyme resistance, 
evidencing its role in virulence. We also observed that the impairment of 
murT-gatD operon had a strong impact on lysozyme resistance in CA-
MRSA backgrounds. For the HA backgrounds, the impact of this mutation 
is more variable, according to the genetic background. However, the 
lysozyme resistance levels of purified peptidoglycan were similar for strains 
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from both CA and HA settings. This observation indicates that specific 
factors, intrinsic to the strain genetic background, contribute to the final 
lysozyme resistance level, although dependent on the amidation status of 
the cell wall.  
The results reported in this communication suggest that peptidoglycan 
amidation is involved through different mechanistic links in the β-lactam 
resistance strategies of strains from distinct backgrounds, evidencing in this 
way the existence of more than one physiological approach for survival to 
antibiotic stress. 
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Supplementary Information 
 
Supplementary Tables  
Table S1. Primers used in this study. 
Primer Sequence 5'-3' 
a
 
Source or 
reference 
PmurF’-R  CCCGGGCATTATCAGTAGCAACACCA This study 
PmurF’-F  CCCGGGCTGAGGTTGTTATTATGATT This study 
PmurFdn TGCTTTTTCGACATGTTGC (3) 
Pcad-R GTTCAGACATTGACCTTCAC (1) 
PmurT-D1 CTTCGGTGAAATTGATATTATGG (2) 
PmurT-R1 GTTCTCTATCACTTCCACCACC (2) 
a)
 The  restriction sequences included in the primers are underlined and the putative ribosome-binding 
site is indicated in boldface type. 
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Supplementary Figures 
 
Figure S1.  Effect of murT-gatD conditional expression on β-lactam resistance 
phenotype in COL and MW2 strains. Oxacillin inhibition halos (1-mg disks) were 
determined for COL, COLpCadmurT-gatD, MW2 and MW2pCadmurT-gatD grown under 
CdCl2 concentrations of 0 and 0.2 μΜ.  
 
Figure S2. PFGE profiles of strains, listed in table 1, and of their respective murT-gatD 
conditional mutants. The boxes highlight the fragments where murT-gatD operon is 
located in the chromosome. The identification of these fragments was performed by the 
analysis of SmaI PFGE profile of the parental strain and the respective murT-gatD 
conditional mutant and through Southern blotting. Numbers on the left side indicate the size 
(Kb) of the molecular marker (M).  
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Discussion 
The peptidoglycan of Staphylococcus aureus is a highly dynamic molecule 
that undergoes several secondary modifications to its primary structure. 
One of these modifications is the amidation of the -carboxyl group of the 
second residue of the stem peptide, D-glutamate, resulting in the formation 
of D-iso-glutamine. My doctoral Thesis describes identification of two genes 
- murT and gatD - in the genome of S. aureus strain COL, the new protein 
products of which are responsible for the amidation of the peptidoglycan. 
These determinants were unknown at the beginning of my work. My Thesis 
work also provided evidence for the existence of a physical interaction 
between the MurT and GatD proteins, resulting in the formation of a 
glutamine amidotransferase bi-enzymatic complex.  
The findings reported in my Thesis allows one to conclude that amidation of 
S. aureus peptidoglycan requires the cooperative action of the MurT and 
GatD proteins, and to draw a functional model in which MurT is associated 
with the ATP-dependent synthetase activity, responsible for the recognition 
of the substrate and ATP, while GatD provides the glutaminase domain, 
involved in glutamine hydrolysis and in the subsequent amide nitrogen 
transfer from free glutamine to the peptidoglycan precursor.  
Importantly, the availability of a murT-gatD conditional mutant allowed to 
demonstrate that amidation of peptidoglycan is important for bacterial 
growth, and is associated with the mechanism of resistance to β -lactams 
and lysozyme in S. aureus. Finally, the evaluation of the impact of 
peptidoglycan amidation on β-lactam and lysozyme resistance in different 
lineages of methicillin resistant S. aureus (MRSA) led to the suggestion that 
MRSA strains are able to develop different molecular mechanisms to 
overcome antibiotic pressure and to evade the host immune system during 
the infection process.   
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The amidation of S. aureus peptidoglycan is dependent on the activity 
of MurT-GatD enzymatic complex. In Chapter II of this Thesis, it is 
described a conditional mutant constructed for murT-gatD operon in the 
background of strain COL, COLpCadmurT-gatD, which showed abnormal 
peptidoglycan composition with decreased amidation of the D-glutamate 
residues, when grown in the absence of the promoter inducer. This 
provided direct evidence for the involvement of both genes in peptidoglycan 
amidation in S. aureus (8). Observations, described in Chapter II of this 
Thesis, raised the hypothesis that the protein products of murT and gatD 
genes interact functionally in order to amidate the peptidoglycan: i) murT 
and gatD genes are co-transcribed from the same promoter, and are 
organized as a small operon; ii) murT and gatD genes are present in most 
Gram-positive bacteria, as a syntenic block; and iii) the murT-gatD 
depletion phenotype is fully complemented, only when both murT and gatD 
are expressed extra-chromosomally (8).  
The co-purification of MurT and GatD recombinant proteins from a vector 
expressing both murT and gatD genes, described in the chapter III, clearly 
indicating that the two proteins interact physically. Furthermore, the in vitro 
activity assays, with purified MurT-GatD and GatD proteins, showed that 
peptidoglycan amidation is dependent on both MurT and GatD activities, 
which is in agreement with the findings of Munch and colleagues (24).     
The in vivo complementation assays, described in the Chapter II of this 
Thesis, constituted the first experimental evidence for the requirement of 
both MurT and GatD proteins in the peptidoglycan amidation reaction. 
These results indicated that MurT enzyme is essential and highly specific 
for the peptidoglycan amidation reaction, since the in trans 
complementation of the murT-gatD conditional mutant with several copies 
of gatD gene revealed no re-establishment of the normal peptidoglycan 
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composition (8). The specificity of MurT for S. aureus peptidoglycan 
amidation reported in this Thesis is in agreement with the findings of Munch 
and colleagues. Despite the fact that MurT shared high similarity with the 
sequence of S. aureus Mur ligases, MurT activity could not be replaced by 
purified MurC, D, E, and F proteins, in the lipid II amidation reaction in vitro 
(24). Regarding GatD specificity, S. aureus may contain other glutamine 
amidotransferases, besides GatD, able to catalyse the glutamine hydrolysis 
and the amino group transfer to peptidoglycan, as the in trans 
complementation with several copies of the murT gene was enough to 
obtain a partial amidated peptidoglycan. Nevertheless, the 
complementation assays showed that full expression of murT, together with 
a sub-optimal expression of gatD, are the minimal conditions to produce 
peptidoglycan fully amidated. Taking together, these results were not 
unexpected as the glutaminase domains of glutamine amidotransferases 
(GATases) have been described as highly conserved all through the entire 
GAT-family, while the synthetase domains tend to be more heterogeneous, 
since they are specific for the different nitrogen acceptor substrates in 
different biological reactions (22). In conclusion, the complete re-
establishment of the murT-gatD-depletion phenotype requires the 
expression of murT, which is essential and highly specific for the 
recognition of peptidoglycan precursor, and at least a basal level of gatD, 
suggesting that S. aureus contains other glutamine amidotransferases that 
are able to partially replace GatD activity.  
MurT amino acid sequence shares approximately 15% identity and 53% 
similarity with the sequence of the Mur ligases of S. aureus, which are 
responsible for the sequential addition of the five aminoacids to the cell wall 
precursor UDP-MurNAc, resulting in the formation of UDP-MurNAc–
pentapeptide (30). The Mur ligases share the same type of enzymatic 
mechanism, consisting in the activation of the carboxyl group of the UDP 
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precursor by ATP, generating an acyl phosphate intermediate and ADP (1). 
Whereas several GATases do not need ATP for the amidation reaction, for 
some subtypes the ATP-hydrolysis is essential for the activation of the 
acceptor substrate (22).  
The in vitro amidation assays, described in Chapter III, revealed that the 
MurT-GatD catalyzed reaction requires the presence of ATP, which allowed 
to infer mechanistically, that this reaction includes the activation of the 
substrate acceptor, resulting in the formation of an acyl phosphate 
intermediate. The phosphate group is then displaced by the incoming 
nitrogen group. Through similar in vitro amidation assays, Munch and 
colleagues also concluded that amidation of peptidoglycan is an ATP-
dependent reaction (24). Interestingly, these authors reported that MurT 
could replace, in vitro, the MurE activity, suggesting that MurT is able to 
recognized UDP-MurNAc-dipeptide, bind L-lysine and activate the D-Glu 
carboxylate by phosphorylation. However, it is improbable that, in vivo, 
MurT can substitute MurE activity, as both genes are considered essential 
(16, 34).  
The 243 amino acid GatD protein shows sequence similarities with the 
glutaminase domain of GATases. Also, S. aureus GatD harbored the 
conserved cysteine and histidine residues, commonly found in this family of 
proteins, but the third catalytic triad residue, glutamine, is missing (8). It 
was suggested by Munch and colleagues that the highly conserved glycine 
present in GatD aminoacid sequence, could be the third residue of its 
catalytic triad (24). The cysteine residue from the active site of the 
GATases is essential for glutaminase activity (22, 32, 37), since its 
nucleophilic sulfhydryl side chain initiates the amide transfer by the 
formation of a thioester with the substrate glutamine. Therefore, Munch and 
colleagues explored the importance of the cysteine residue in the catalytic 
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activity of GatD by site-directed mutagenesis. The inability of the GatD 
mutant, wherein the canonical cysteine of the proposed active site was 
replaced by glycine, to use glutamine and consequently to amidate the 
peptidoglycan precursor allowed to confirm the active site of the enzyme 
and provided clear evidence for the function of GatD as a glutaminase (24). 
The analysis of MurT-GatD amino acid sequence and the experimental 
data allowed to propose that both proteins together contain the domains 
required for the amidation of S. aureus peptidoglycan to occur. Therefore, 
considering the modular organization of the GATases, the peptidoglycan 
amidation should require the synchronization of MurT and GatD activities: 
MurT acting as the synthetase domain, responsible for the recognition of 
the acceptor substrate and ATP, while GatD acting as the glutaminase 
domain, responsible for the hydrolysis of glutamine and the transfer of the 
resultant amino group to the peptidoglycan precursor (Figure 1).  
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Figure 1. Protein regions necessary for the cooperative function of MurT and GatD proteins. 
The top panel illustrates the topology of Mur ligase family proteins. The MurT protein shows 
similarities only with the central domain, including the conserved motifs for ATP binding, 
which are indicated by red boxes.The lower panel illustrates the modular structure of 
glutamine-dependent amidotransferases, which includes a synthetase domain and a 
glutamine amide transfer domain, containing the glutaminase activity motifs (yellow boxes) 
and ATP-binding motifs (red boxes). GatD only shows similarities with the glutaminase 
domain, namely with the conserved residues important for glutaminase activity. 
(Reproduced from reference 8). 
 
The peptidoglycan lipid-linked intermediates are acceptor substrates 
of the peptidoglycan amidation reaction. It was previously described by 
Siewert and Strominger that, upon addition of ATP and NH4Cl or glutamine, 
amidated lipid I or lipid II could be detected in membranes of S. aureus. 
The composition of the peptidoglycan precursor pool of the murT-gatD 
conditional mutant and the respective parental strain, described in Chapter 
II of this Thesis, showed that S. aureus cytoplasmic precursors are not 
amidated (8). Hence, probably the D-glutamic acid amidation occurs at the 
membrane stage, confirming the previous findings described above (29).  
The in vitro amidation of lipid II in the presence of MurT-GatD, glutamine 
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and ATP, described in Chapter III, supports the proposal that this step 
occurs at the membrane stage of peptidoglycan biosynthesis and shows 
that lipid II is an acceptor substrate of the reaction catalyzed by the MurT-
GatD enzyme complex. In order to identify the primary acceptor substrate, 
Munch and colleagues also included purified lipid I and lipid II-Gly5 in the in 
vitro amidation assay, and concluded that the both lipid intermediates can 
serve as acceptor substrates for the MurT-GatD enzymatic complex (24). 
On the other hand, the presence of a 10 fold excess of MurNAc-
pentapeptide did not interfere with the amidation of lipid II, indicating that 
the cytoplasmic precursors are not substrates for MurT-GatD dependent 
amidation. Furthermore, these authors also clarified that this reaction does 
not occur during MurC-F catalyzed stem peptide formation, highlighting 
once again that the soluble cell wall precursor UDP-MurNac-pentapeptide 
does not serve as a substrate for the amidation reaction (24).     
Glutamine is the nitrogen donor substrate of the peptidoglycan 
amidation reaction. The abnormal peptidoglycan composition of murT-
gatD depletion mutant had already been observed for glnRA transposition 
mutant RUSA208 (27). In RUSA208, the transposon insertion occurred in 
the glutamine synthetase repressor gene (glnR), resulting in a polar effect 
on the transcription of the glutamine synthetase gene (glnA). The inhibition 
of the glnRA operon produced a decrease in the glutamine synthetase 
activity and most probably, a reduction in the availability of glutamine in the 
cells, which explains the decrease of the amount of amidated D-glutamate 
in the mutant strain RUSA208 peptidoglycan. In the present study, the fully 
non amidated peptidoglycan of the construct RUSA208pCadmurT-gatD, in 
which both expression of murT-gatD and glnRA are inhibited, allowed us to 
conclude that their protein products are together essential for the amidation 
of the glutamic acid residue of S. aureus peptidoglycan, indicating that 
MurT-GatD enzymatic complex uses glutamine as the nitrogen source (8).  
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The analysis of the peptidoglycan composition of RUSA208 strain revealed 
that amidation of the muropeptides still occurred partially (27), suggesting 
that other sources of nitrogen, besides glutamine, may be used, although 
less efficiently. In fact, although most GATases seem to be highly specific 
for glutamine utilization as an amide nitrogen donor, they can also accept 
exogenous ammonia as nitrogen source (36). Munch and colleagues 
demonstrated that only at optimal conditions for the ammonia-dependent 
activity at pH 8.5, is the MurT-GatD complex able to use free ammonia, as 
nitrogen donor substrate (24). Taking into account the neutral pH within the 
cytoplasm and the fact that the peptidoglycan composition of a glnRA 
transposition mutant, unable to synthesize glutamine, is identical to that of 
the murT-gatD depletion mutant (8), it is most likely that MurT-GatD 
enzymatic complex uses preferentially glutamine as nitrogen donor 
substrate. Additionally, the complete absence of amidated muropeptides in 
the peptidoglycan of glnRA and murT-gatD depletion mutant highlight that 
D-glutamate amidation is dependent of the presence of glutamine, as the 
source of the amino group, and no other nitrogen donor is accepted by 
MurT-GatD enzymatic complex.  
Peptidoglycan amidation is required for bacterial growth, and for 
optimal expression of β-lactam and lysozyme resistance in S. aureus. 
The growth rate of murT-gatD depleted cells was greatly reduced in the 
conditional mutant, indicating that amidation of peptidoglycan is required, 
but not essential, for normal growth (8), which contrasts with the findings of 
Munch and colleagues who found the murT-gatD genes essential for S. 
aureus growth (24). The residual growth and the partial amidation of the 
peptidoglycan of the conditional mutant, grown with no CdCl2, can be 
explained by the leaky expression of murT-gatD operon through the pCad 
promoter in the absence of CdCl2. However, the viability of the glnRA and 
murT-gatD depleted mutant, the peptidoglycan of which is totally 
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deamidated, suggests that D-glutamic acid amidation is not essential for 
bacterial survival (8). The different genetic strategies used in the two 
studies can account for the divergent results regarding the essentiality of 
murT-gatD in S. aureus. In the study of Munch and collaborators, murT and 
gatD were recognized as essential genes for S. aureus, through the 
transformation of the MRSA COL strain with a plasmid containing a xylose 
inducible antisense interference fragment, specifically targeting murT and 
gatD genes (9, 21). Upon addition of xylose, the antisence expression 
targets the complementary mRNA which totally blocks the transcription and 
translation of both proteins. In contrast, the murT-gatD conditional mutant 
used in our work, wherein the murT-gatD operon was placed under the 
control of an inducible promoter, showed a residual level of transcription in 
the absence of inducer, which probably is the cause for the observed 
residual growth.  
The impact of peptidoglycan amidation on growth rate is consistent with 
previous results, which suggested that non-amidated lipid II is an inefficient 
substrate for one or more transpeptidases, as crosslinking of two adjacent 
stem peptides requires that at least one of them is amidated (26, 31). On 
the other hand, considering that the cell viability depends on the close 
coordination between the peptidoglycan precursor translocation, 
transglycosylation and transpeptidation reactions, MurT-GatD dependent 
amidation may function as a check-point signal, and could regulate, 
spatially and temporally, these biochemical events. In Streptococcus 
pneumoniae, it was recently demonstrated that the efficient peptidoglycan 
crosslinking, catalyzed by penicillin binding proteins 2a, 2b, and 2x, is 
dependent on the presence of D-iso-glutamine in lipid II structure (38). 
Curiously, the PBP2x and PBP2b are the two essentials PBPs of S. 
pneumoniae (18), which are also the main targets of β-lactams, and PBP2a 
seems to be the main transglycosylase, since the mutant affected in pbp2a 
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gene showed a higher sensitivity to moenomycin, a inhibitor of the 
transglycosylase activity in Escherichia coli PBP1b (14, 28). Therefore, it 
appears that amidation of peptidoglycan is involved in the growth of S. 
pneumoniae, by interfering with the activity of essentials proteins in cell wall 
biosynthesis.   
It is possible that lack of the amide group may create an unbalance 
between the biosynthetic and the hydrolytic machineries of the cell. 
Interestingly, the structure of the amidase catalytic domain of the autolysin 
Atl of Staphylococcus epidermidis, referred to as AmiE, revealed the 
existence of extended contacts between the D-iso-glutamine residue of the 
cell wall muropeptide and conserved residues in the putative ligand-binding 
groove of AmiE, which suggested an essential role for the D-iso-glutamine 
in substrate recognition (39). This data raised the hypothesis that cell wall 
degradation during cell division, required for splitting the equatorial septum 
between two dividing daughter cells (13, 35), can be regulated by the 
presence of D-iso-glutamine in the stem peptide. However, the morphology 
of the murT-gatD depleted cells did not show significant abnormalities, 
which suggests that the cell division process is not affected by the 
presence of D-glutamate in the stem peptide of peptidoglycan. Interestingly, 
these findings can lead to new insights into S. aureus cell division 
mechanism, as Atl can be replaced by the activity of Sle1, the other S. 
aureus hydrolase responsible for daughter cells separation during cell 
division. 
The impact of amidation on oxacillin resistance level observed in murT-
gatD depleted cells, is consistent with previously results described for 
glnRA mutant (RUSA208) (12). It has been shown that several genes (the 
so called auxiliary genes), many of them cell wall related, are linked to the 
optimal expression of methicillin resistance (7). However, the mechanism 
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by which these genes contribute to the expression of methicillin resistance 
is not well understood. One of the existing theories is that the inactivation of 
genes involved in cell wall biosynthesis leads to the production of 
structurally abnormal muropeptides, which are poorer substrates for 
PBP2A. Consequently, due to the lack of effective muropeptide 
competitors, methicillin molecules would bind more frequently to the active 
site of PBP2A, resulting in a decrease of methicillin resistance levels (6).  
In S. aureus, several modifications of cell wall structure, namely the O-
acetylation of MurNac and the D-alanylation of wall teichoic acids (WTA), 
are involved in lysozyme resistance (3). In this Thesis, glutamate amidation 
was also found to contribute to S. aureus lysozyme resistance, since 
purified non-amidated peptidoglycan was more susceptible to the 
muramidase activity of this enzyme (8). However, it appears that the lack of 
amidation in the stem peptide of peptidoglycan does not affect the cationic 
antimicrobial peptide activity of lysozyme, which was an unexpected result, 
as the presence of D-glutamate leads to a more negatively charged cell 
wall. These observations suggest that the negative charge induced by the 
presence of glutamic acid may be neutralized by same other factor, such as 
the level of D-alanylation of WTAs.  
The impact of peptidoglycan amidation on lysozyme resistance of the cell 
wall may play a role in bacterial pathogenesis, as it may encumber bacterial 
clearance by the host’s immune system. The impact of peptidoglycan 
structure on pathogenesis has been studied extensively. The products of 
peptidoglycan degradation, the muropeptides, are recognized by receptors 
from the human innate immune system, namely by NOD1, that senses the 
minimal structure D-Glu-meso-diaminopimelic acid (DAP) dipeptide, 
commonly found in Gram-negative bacteria (5, 10), and NOD2, which 
detects the muramyl dipeptide and the lysine-containing muramyl tripeptide 
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(11, 15). It was reported that the presence of D-isoglutamine hampered 
recognition of peptidoglycan via NOD1, while the binding activity of NOD2 
was not impaired (33). On the other hand, it appears that this peptidoglycan 
modification is unrelated with pro-inflamatory activity, as amidated S. 
aureus peptidoglycan did not affect the production of cytokines (20). 
Despite the clear evidences, suggesting a direct involvement of amidation 
of peptidoglycan glutamic acid residue in bacterial pathogenesis, other 
physiological roles must also be attributed to this cell wall modification, as it 
is commonly found in many no pathogenic bacterial species.  
The impact of peptidoglycan amidation on β-lactam and lysozyme 
resistance is determined by the genetic background of the strain. As 
mentioned above, despite mecA gene being the main determinant of 
methicillin resistance in MRSA strains, other genes are required for the 
optimal expression of methicillin resistance (4, 7, 19, 25).  
Chapter IV of this Thesis describes that lack of amidation can generate 
different levels of decrease in oxacillin resistance in the most important 
MRSA clones, including community acquired MRSA (CA-MRSA) and 
hospital acquired MRSA (HA-MRSA). Overall, the impairment of murT-gatD 
caused a higher decrease of oxacillin resistance in CA-MRSA or related 
strains, than in HA-MRSA. Actually, this differential impact in oxacillin 
resistance can be correlated with the genetic background of each strain. 
Therefore, according to the ability of each genetic background to receive 
and maintain mecA (17), these results seem to suggest that the 
backgrounds less fit to receiving mecA gene need to recruit preferentially 
specific housekeeping genes, such as murT-gatD, for their -lactam 
resistance mechanism. Thus, the absence of murT-gatD expression would, 
in these strains, produce a higher decrease of oxacillin resistance. 
Interestingly, the impairment of murT-gatD also caused a decrease of β-
Discussion and Future Perspectives 
207 
 
lactam resistance in a mecA-independent resistant strain, suggesting that 
peptidoglycan amidation is important for expression of β-lactam resistance, 
even in the absence of mecA gene.  
Furthermore, the impairment of murT-gatD and murF caused different 
levels of oxacillin resistance in some CA-MRSA clones. In these strains, it 
appears that murT-gatD is more important for the optimal expression of 
methicillin resistance, than the murF gene, suggesting that various auxiliary 
genes may be involved in methicillin resistance through different 
mechanisms. 
Overall, these results allowed us to speculate that MRSA strains are able to 
develop different strategies, in which different auxiliary genes are recruited, 
in order to overcome the antibiotic selective pressure.  
In this line of thought, and considering that PBP4 is a major player for 
methicillin resistance specifically in CA-MRSA (23), a strategy for -lactam 
resistance that relies on peptidoglycan secondary modifications, such as 
secondary cross-linking (pbp4) and amidation (murT-gatD), may also exist.  
Despite the lack of evidence indicating a dependence of S. aureus PBPs 
catalytic “efficiency” on the amidation status of the substrate molecule, the 
results reported in this Thesis allows one to speculate that PBP4 and/or 
PBP2 may also require amidated muropeptides to perform optimal 
transpeptidation, both proteins being involved in methicillin resistance 
although through different mechanisms.   
The impairment of murT-gatD operon produced a strong impact on 
lysozyme resistance in CA-MRSA backgrounds. For the HA backgrounds, 
the impact of this mutation was more variable, depending on the genetic 
background. However, the lysozyme resistance levels of purified 
Chapter V 
208 
 
peptidoglycan were similar for strains from both CA and HA settings. We 
propose that additional factor(s) conferring lysozyme resistance that are 
triggered/controlled by peptidoglycan amidation, may exist in the CA-MRSA 
strains analyzed.  
 
Future perspectives 
The studies performed in this Thesis led to the conclusion that amidation of 
the -carboxyl group of the D-glutamate of the stem peptide of the S. 
aureus peptidoglycan is important for the rate of bacterial growth and also 
for several other physiologically important properties. However, the exact 
mechanism through which peptidoglycan amidation influences growth 
remains unknown. To explore if deaminated peptidoglycan is a poor 
substrate for S. aureus autolysins, we plan to perform zymogram, using cell 
walls from the murT-gatD depleted mutant. This approach should clarify if 
peptidoglycan amidation is required for the proper cell wall degradation by 
the action of autolysins during cell division. In addition, this strategy may 
also provide insights regarding the role of the major staphylococcal 
autolysins in cell division, as this event is not affected by peptidoglycan 
amidation.   
It is clear that lipid-linked intermediates of peptidoglycan synthesis are the 
acceptor substrates for the reaction catalyzed by the MurT-GatD enzymatic 
complex. However, it is not yet understood if amidation of D-glutamate 
takes place in the cytoplasm, or in the outer side of the cytoplasmic 
membrane, where the polymerization of peptidoglycan occurs. The 
determination of the intra- or extra-cellular presence of MurT-GatD complex 
by chemical cross-linking followed by immunoprecipitation should allow one 
to determine the precise location of amidation reaction. The 
immunoprecipitation assays would also provide evidence for the existence 
of other partners able to interact with MurT and GatD proteins.   
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Considering the frequent presence of MurT-GatD among gram-positive 
bacterial pathogens, the importance of these proteins in S. aureus, and 
their involvement in the resistance to -lactams and lysozyme, the 
amidation step offers a new target for the development of inhibitors as 
monotherapeutics and/or as combination agents for existing β-lactam 
antibiotics, thereby boosting and/or restoring their activity against MRSA. 
The identification of the specific region responsible for the interaction 
between MurT and GatD is essential for the design of the proper inhibitor of 
peptidoglycan amidation. The C-terminal domain of unknown function 
(DUF1727) present in the MurT structure constitutes a likely candidate for 
the region responsible of MurT-GatD interaction. The construction of a 
MurT-GatD-His6 co-expression system, in which expression of DUF1727 is 
blocked by the insertion of a stop codon in the 3’ end of murT, would clarify 
the role of the N-terminal domain of MurT in the assembly of MurT-GatD 
enzymatic complex. This strategy would test if DUF1727 is required for the 
co-purification of GatD-His6 and MurT, by affinity chromatography. 
Furthermore, the construction of a His6-DUF-GatD co-expression system, 
wherein the duf-gatD sequence is fused with the N-terminal His6-tag, 
would also provide some clues regarding the role of DUF1727 in the 
interaction between MurT and GatD proteins. The co-purification of His6-
DUF1727 with GatD, through affinity chromatography, would indicate that 
the N-terminal domain of MurT (DUF1727) is able to interact with GatD and 
therefore is important for the interaction between MurT and GatD. 
Additionally, the performance of “Bacterial two-hybrid system”, using GatD 
and different versions of MurT, should clarify and confirm the results 
obtained by affinity chromatography, described above. On the other hand, 
in a more detailed approach, the performance of Isothermal Titration 
Calorimetry assays would define not only the requirement of DUF1727 for 
MurT-GatD interaction, but also would identify the forces that stabilize the 
interaction. 
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Since peptidoglycan amidation is directly involved in the intrinsic resistance 
of S. aureus to lysozyme, it is expected that this structural modification 
provides protection against macrophage killing and may limit host cytokine 
responses, promoting bacterial survival in the infected host, similarly to 
OatA acetyltransferase in Listeria monocytogenes (2). The evaluation of the 
impact S. aureus MurT-GatD inhibition on the stimulation of an 
inflammatory response by macrophages, (using murine infection models 
and animal cells lines), should begin to explore the role of glutamate 
amidation of peptidoglycan in host evasion. The effect of reduced 
peptidoglycan amidation on lysozyme resistance was clearly distinct 
between CA and HA MRSA backgrounds, with a more pronounced effect 
on MRSA strains predominant in the community. For this reason exploring 
the impact of the murT-gatD mutation should be done in S. aureus genetic 
backgrounds, representing both hospital derived as well as community 
strains of MRSA.  
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Abstract  
Amidation of peptidoglycan is an essential feature in Staphylococcus 
aureus that is necessary for resistance to β-lactams and lysozyme. GatD, a 
27 kDa type I glutamine amidotransferase-like protein, together with MurT 
ligase, catalyses the amidation reaction of the glutamic acid residues of the 
peptidoglycan of S. aureus. The native and the selenomethionine-derivative 
proteins were crystallized using the sitting-drop vapour-diffusion method 
with polyethylene glycol, sodium acetate and calcium acetate. The crystals 
obtained diffracted beyond 1.85 and 2.25 A°, respectively, and belonged to 
space group P212121. X-ray diffraction data sets were collected at 
Diamond Light Source (on beamlines I02 and I04) and were used to obtain 
initial phases. 
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Introduction 
Peptidoglycan, the major component of the Gram-positive bacterial cell 
wall, is a polymer composed of glycan chains cross-linked by short 
peptides and is responsible for cell-shape maintenance and for 
counterbalancing turgor pressure (5). The importance of peptidoglycan for 
cell survival and its exclusivity to the bacterial kingdom renders most 
enzymatic steps involved in its biosynthesis excellent targets for 
antimicrobial therapy. 
Staphylococcus aureus, an opportunistic bacterium responsible for a wide 
range of infections (2, 6) owes its success as a human pathogen mainly to 
its capacity to acquire antibiotic-resistance traits. Most genes involved in 
the peptidoglycan biosynthesis pathway are intimately related to the 
mechanism of β-lactam resistance, enhancing their potential as targets for 
antimicrobial therapy (3).  
The main biosynthesis of peptidoglycan is well understood (9, 12).  
Additional steps are responsible for secondary modifications to the main 
structure (13). In S. aureus, one such modification is the amidation of the γ-
carboxyl group of the second residue of the stem peptide, d-isoglutamate, 
resulting in the formation of d-isoglutamine (10). Recently, the murT-gatD 
operon was identified as the genetic determinant of peptidoglycan 
amidation in S. aureus, which is found to be widespread among bacteria as 
a syntenic block, almost exclusively in Gram-positives. The impaired 
expression of this operon impacts bacterial growth, β-lactam resistance and 
intrinsic lysozyme resistance (4). Moreover, the two proteins physically 
interact and form a glutamine amidotransferase bienzymatic complex (8). 
We have cloned and expressed the GatD protein in Escherichia coli and 
purified and crystallized it. X-ray diffraction data were collected both from 
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native as well as SeMet-containing protein and were used to obtain 
preliminary phases of the model. 
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 Materials and methods 
 
Cloning, overexpression and purification of GatD. The coding sequence 
of the gatD gene was amplified from S. aureus and cloned into the vector 
pOPINF using the In-Fusion method to generate the construct OPPF12143 
(1). The protein was produced in E. coli using the auto-induction method 
(11). Macromolecule production information is given in Table 1. 
Table 1. Macromolecule-production information. 
Source organism S. aureus COL 
DNA source S. aureus COL 
Forward primer AAGTTCTGTTTCAGGGCCCGCATGAATTGACTATTTATCAT 
TTTATGTCAG 
Reverse primer ATGGTCTAGAAAGCTTTAACGAGATTTCTTCTGTCTATTTG- 
CTC 
Cloning vector pOPINF 
Expression vector pOPINF 
Expression host E. coli strain Lemo21(DE3) 
UniProt accession code Q5HEN2 
Complete amino-acid 
sequence of the construct 
produced 
GPHELTIYHFMSDKLNLYSDIGNIIALRQRAKKRNIKVNVVEINE
TEGITFDECDIFFIGGGSDREQALATKELSKIKTPLKEAIEDGMP
GLTICGGYQFLGKKYITPDGTELEGLGILDFYTESKTNRLTGDI
VIESDTFGTIVGFENHGGRTYHDFGTLGHVTFGYGNNDEDKK
EGIHYKNLLGTYLHGPILPKNYEITDYLLEKACERKGIPFEPKEI
DNEAEIQAKQVLIDRANRQKKSR 
 
After 20 h of incubation, the cells were harvested and resuspended in lysis 
buffer: 50 mM Tris–HCl pH 7.5, 500 mM NaCl, 20 mM imidazole and 0.2% 
Tween 20 supplemented with protease inhibitors (Sigma) and 400 U/ml 
DNAse type I. The cells were lysed using a Basic-Z cell disruptor at 207 
MPa and clarified by centrifugation at 30 000g for 30 min at 4ºC. The 
supernatant was loaded onto a 5 ml HisTrap FF column (GE Healthcare) 
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equilibrated with wash buffer (50 mM Tris–HCl pH 7.5, 500 mM NaCl, 20 
mM imidazole), extensively washed with this buffer and eluted with elution 
buffer (50 mM Tris–HCl pH 7.5, 500 mM NaCl, 500 mM imidazole). The 
sample was subsequently loaded onto a Superdex 200 HiLoad 16/60 
column (GE Healthcare) equilibrated with gel-filtration buffer (20 mM Tris–
HCl pH 7.5, 200 mM NaCl, 1 mM TCEP). Fractions containing GatD protein 
were pooled and the N-terminal hexahistidine tag was removed by 
cleavage with 3C protease. The mixture was then purified by reverse Ni-
affinity chromatography. The protein was concentrated to 10, 20 and 45 
mg/ml in gel-filtration buffer for crystallization. The expressed protein differs 
from the native in its N-terminus, where the original M is substituted by GP. 
A selenomethionine derivative was expressed using the Seleno-Methionine 
Expression Media kit (Molecular Dimensions) and the purification protocol 
was followed as described above. 
 
Crystallization. Crystallization screens were performed at the Oxford 
Protein Production Facility (OPPF-UK) using a Cartesian instrument 
(Digilab MicroSys liquid-handling system). 100 nl GatD sample was mixed 
with 100 nl crystallization solution and equilibrated over 90 ml reservoir 
solution (see Table 2 for details). Crystals appeared in several conditions 
from the Emerald Wizard 1 and 2 crystallization screen (Rigaku Reagents). 
The best crystals (native and SeMet derivative) grew after 48 h (Fig. 1). 
The crystals were cryoprotected in 50%(v/v) PEG 400 and flash-cooled in 
liquid nitrogen prior to data collection. 
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Table 2. Crystallization. 
Method Sitting-drop vapour diffusion 
Plate type Greiner Bio-One 
Temperature (K) 294 
Protein concentration (mg ml
-1
) 45 
Buffer composition of protein solution 20 mM Tris–HCl pH 7.5, 200 mM NaCl, 1mM 
TCEP 
Composition of reservoir solution 30%(w/v) PEG 400, 100 mM sodium acetate/ 
acetic acid pH 4.5, 200 mM calcium acetate 
Volume and ratio of drop 200 nl; 1:1 
Volume of reservoir (ml) 90 
 
Figure 1. GatD crystals obtained using the crystallization robot (native, left; SeMet 
derivative, right). The dimensions of the best crystal were 250x30x30 mm. 
 
Data collection and processing. Data were collected on beamlines I02 
(on a Pilatus 6M detector) and I04 (on an ADSC Quantum Q315r detector) 
at the Diamond Light Source (DLS). Crystals of the native protein diffracted 
beyond 1.9 A° resolution and those of the SeMet-derivatized protein 
diffracted beyond 2.3 A° resolution (Fig. 2). The data were automatically 
processed using xia2 (14). Data-collection and processing statistics are 
given in Table 3. 
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Initial phases were obtained by single-wavelength anomalous diffraction 
(SAD) using data collected from SeMet derivative at the Se edge peak. 
 
Figure 2. Representative diffraction patterns of the crystals (native, left; SeMet derivative, 
right). The resolution at the edge of the detector is 2.1 and 2.5 A°, respectively. 
 
Table 3. Data collection and processing. Values in parentheses are for the 
outer shell. 
 SAD Native 
Diffraction source I04, DLS I02, DLS 
Wavelenght (Å) 0.9796 1.0000 
Temperature (K) 100 100 
Detector ADSC Q315r Pilatus 6M 
Crystal-to-detector distance 
(mm) 
375 407.4 
Rotation range per image (º) 1.0 0.5 
Total rotation range (º) 360 1200 
Exposure time per image (s) 0.5 0.04 
Space group P212121 P212121 
a, b, c (Å ) 48.28, 93.00, 109.30 48.61, 93.92, 110.08 
α, β, γ (Å) 90, 90, 90  90, 90, 90 
Mosaicity (º) 0.387 0.141 
Resolution range (Å) 47.12-2.25 36.43-1.85 
Total No. of reflection 301512 839410 
No. of unique reflection 24020 42987 
Completeness (%) 98.7 (89.2) 97.9 (83.7) 
Multiplicity 12.6 (6.7) 19.5 (10.1) 
I/σ(I) 16.5 (2.2) 20.7 (2.2) 
Rp.i.m. 0.078 (0.477) 0.028 (0.313) 
Overall B factor from Wilson 
plot (Å
2
) 
9.429 15.237 
Anomalous completeness 
(%) 
98.7 (89.2)  
Anomalous multiplicity 6.7 (3.4)  
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Results and discussion 
The recently identified MurT–GatD enzymatic complex represents an 
unexplored step as a potential antimicrobial target. MurT shares 
considerable similarity with the sequence of the Mur ligases of S. aureus, 
which are cytoplasmic enzymes that are responsible for the sequential 
addition of amino-acid residues to the growing muropeptide stem. GatD 
shows similarity to the glutamine amidotransferases (GATases), with 
glutamine amide-transfer activity to a wide variety of substrates (7). 
Typically, GATases catalyze two distinct reactions: the glutaminase 
reaction, in which glutamine is converted into ammonia and glutamate, and 
the synthase reaction, in which ammonia is transferred to an acceptor 
substrate. These two reactions occur at distinct active sites, which may sit 
on the same polypeptide chain or on independent protein subunits. GatD 
protein corresponds to a glutaminase subunit, most probably being 
responsible for the production of ammonia from glutamine. 
In order to determine the structure of S. aureus GatD protein, the encoding 
region of the gatD gene was cloned into pOPINF plasmid and expressed in 
E. coli Lemo21(DE3) as an N-terminal His-tag fusion. The purity of the 
recombinant protein was estimated by SDS–PAGE, which showed a single 
band corresponding to a molecular weight of 27 kDa. 
The crystallization trials were performed at a high-throughput crystallization 
facility. Several crystallization hits were obtained using the Emerald Wizard 
1 and 2 screens from Rigaku Reagents. 
Diffraction data were collected on I02 and I04 at DLS to a resolution 
beyond 1.9 A°. Initial phases were obtained by single-wavelength 
anomalous diffraction (SAD) using data collected from SeMet derivatives at 
the Se edge peak.  
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The crystals belonged to space group P212121, with unit-cell parameters a 
= 48.29, b = 93.00, c = 109.31 A°. The structure of GatD, together with 
complete biochemical studies, will provide important insights into the 
molecular basis of the mechanism responsible for the amidation of the 
glutamic acid residues of the peptidoglycan of S. aureus. 
The authors would like to thank the Oxford Protein Production Facility, 
Research Complex at Harwell, Didcot, England for access to all the high-
throughput facilities and for assistance during expression, purification and 
crystallization and the beamline staff at I02 and I04 for assistance during 
data collection at Diamond Light Source, Didcot, England. DV and TAF 
were supported by fellowships SFRH/BD/62415/2009 and 
SFRH/BD/36843/2007 from Fundação para a Ciência e Tecnologia, 
Ministério da Ciência e Tecnologia, Portugal, respectively. This work was 
supported by project PTDC/BIA-MIC/3195/2012 from the Fundação para a 
Ciência e Tecnologia, Ministério da Ciência e Tecnologia, Portugal. We 
also acknowledge support from FCT (Portugal) through grants PEst-
OE/EQB/LA0004/2011 (ITQB) and PEst-OE/BIA/UI0457/2011 (CREM). 
 
 
 
 
 
 
 
Appendix I 
226 
 
References 
1.  Bird, L. E. 2011. High throughput construction and small scale expression 
screening of multi-tag vectors in Escherichia coli. Methods. 55: 29-37. 
2.  Boucher, H. W., G. H. Talbot, J. S. Bradley, J. E. Edwards, D. Gilbert, 
L. B. Rice, M. Scheld, B. Spellberg and J. Bartlett. 2009. Bad bugs, no 
drugs: no ESKAPE! An update from the Infectious Diseases Society of 
America. Clin. Infect. Dis. 48: 1-12. 
3.  de Lencastre, H., S. W. Wu, M. G. Pinho, A. M. Ludovice, S. Filipe, S. 
Gardete, R. Sobral, S. Gill, M. Chung, and A. Tomasz. 1999. Antibiotic 
resistance as a stress response: complete sequencing of a large number of 
chromosomal loci in Staphylococcus aureus strain COL that impact on the 
expression of resistance to methicillin. Microb. Drug Resist. 5: 163-175. 
4.  Figueiredo, T. A., R. G. Sobral, A. M. Ludovice, J. M. Almeida, N. K. 
Bui, W. Vollmer, H. de Lencastre, and A. Tomasz. 2012. Identification of 
genetic determinants and enzymes involved with the amidation of glutamic 
acid residues in the peptidoglycan of Staphylococcus aureus. PLoS 
Pathog. 8:e1002508. 
5.  Holtje, J. V. 1998. Growth of the stress-bearing and shape-maintaining 
murein sacculus of Escherichia coli. Microbiol. Mol. Biol. Rev. 62:
 181-203. 
6.  Klevens, R. M., M. A. Morrison, J. Nadle, S. Petit, K. Gershman, S. Ray, 
L. H. Harrison, R. Lynfield, G. Dumyati, J. M. Townes, A. S. Craig, E. R. 
Zell, G. E. Fosheim, L. K. McDougal, R. B. Carey, S. K. Fridkin. 2007. 
Invasive methicillin-resistant Staphylococcus aureus infections in the 
United States. J.A.M.A. 298: 1763-1771. 
7.  Massiere, F., and M. A. Badet-Denisot. 1998. The mechanism of 
glutamine-dependent amidotransferases. Cell Mol. Life Sci. 54: 205-222. 
8.  Munch, D., T. Roemer, S. H. Lee, M. Engeser, S. H. Sahl, and T. 
Schneider. 2012. Identification and in vitro analysis of the GatD/MurT 
enzyme-complex catalyzing lipid II amidation in Staphylococcus aureus. 
PLoS Pathog. 8: e1002509. 
9.  Scheffers, D. J., and M. G. Pinho. 2005 Bacterial cell wall synthesis: new 
insights from localization studies. Microbiol. Mol. Biol. Rev. 69: 585-607. 
10.  Siewert, G., and J. L. Strominger. 1968. Biosynthesis of the 
peptidoglycan of bacterial cell walls. XI. Formation of the isoglutamine 
amide group in the cell walls of Staphylococcus aureus. J. Biol. Chem. 243: 
783-790. 
11.  Studier, F. W. 2005. Protein production by auto-induction in high density 
shaking cultures. Protein Expr. Purif. 41: 207-234. 
12.  Veiga, P., M. Erkelenz, E. Bernard, P. Courtin, S. Kulakauskas and M. 
P. Chapot-Chartier. 2009. Identification of the asparagine synthase 
responsible for D-Asp amidation in the Lactococcus lactis peptidoglycan 
interpeptide crossbridge. J. Bacteriol. 191: 3752-3757. 
13.  Vollmer, W. 2008. Structural variation in the glycan strands of bacterial 
peptidoglycan. FEMS Microbiol. Rev. 32: 287-306. 
14.  Winter, G., S. Dokel, A. K. Jones, P. Scheerer, N. Krauss, W. Hohne 
and B. Friedrich. 2010. Crystallization and preliminary X-ray 
Purification, crystallization and preliminary X-ray diffraction analysis of GatD, a glutamine 
amidotransferase-like protein from Staphylococcus aureus peptidoglycan 
 
227 
 
crystallographic analysis of the [NiFe]-hydrogenase maturation factor 
HypF1 from Ralstonia eutropha H16. Acta Crystallogr. Sect. F Struct. Biol. 
Cryst. Commun. 66: 452-455. 
 
 
 
 
 
 
 
 
 
 
 
 
